Synthesis of Sulfotyrosine Bearing Peptides and Analogues by Ali, Ahmed Magdy Ahmed Mohamed
Synthesis of Sulfotyrosine Bearing 











presented to the University of Waterloo 
in fulfillment of the 
thesis requirement for the degree of 






Waterloo, Ontario, Canada, 2010 
 





I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any 
required final revisions, as accepted by my examiners. 
 





 Sulfation of tyrosine residues is a post-translational modification that occurs on many 
secretory as well as transmembrane proteins.  This modification is believed to be essential for 
numerous biological processes.  However, one of the factors hindering the study of the 
significance of sulfotyrosine (sTyr) within a protein is the absence of a general method that 
enables the synthesis of sTyr peptides in satisfactory yields and purity. 
 A general approach to the synthesis of sTyr-bearing peptides was developed in which 
the sTyr residue is incorporated into the peptides with the sulfate group protected.  For the 
implementation of this general approach a new protecting group for sulfates, namely, the 
dichlorovinyl (DCV) group was developed.  This was accomplished by conducting a careful 
analysis of the reaction of a trichloroethyl (TCE)-protected sulfate ester with piperidine and 
2-methylpiperidine (2-MP).  A unique sulfuryl imidazolium reagent, compound 2.22, was 
also developed that enabled the ready synthesis of DCV-protected sulfates.  This reagent was 
used to prepare the amino acid building block FmocTyr(SO3DCV)OH (2.23).  An alternative 
and more economical synthesis of FmocTyr(SO3DCV)OH (2.23)  was also developed that 
did not require reagent 2.22.  Fmoc-based solid phase peptide synthesis (SPPS) was used to 
incorporate 2.23 into peptides using 2-MP for Fmoc removal.  After cleavage of the peptide 
from the support, the DCV group was removed by hydrogenolysis to give sTyr peptides in 
good yield and purity.  Using this approach a variety of sTyr peptides were prepared 
including a tetrasulfated 20-mer corresponding to residues 14-33 in chemokine receptor D6 
and a disulfated 35-mer corresponding to residues 8-42 of the N-terminus region of the 
chemokine receptor DARC and this is the largest multisulfated sTyr–bearing peptide made to 
 
 iv 
date.  It was also demonstrated that the incorporation of an important non-hydrolyzable sTyr 
analog, 4-(sulfonomethyl)phenylalanine (Smp), into peptides can be accomplished in good 
yield by protecting the sulfonate residue with a TCE group during SPPS. This approach was 
shown to be superior to the previously reported method where the sulfonate group is 
unprotected. Finally, a number of sulfotyrosine bearing peptides were synthesized and tested 
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1,2-DMI 1,2-Dimethylimidazole  
DMS Dimethylsulfide 
DNA Deoxyribonucleic acid 
DNP 2,4-Dinitrophenol  
EDT Ethanedithiol 
ESMS electrospray mass spectrometry 












HIV Human immunodeficiency virus 





HPLC High performance liquid chromatography 
IL  Interleukin 
IR Insuline receptor 
IRS Insuline receptor substrate 
MCP-1 (CCL2) Monocyte chemotactic protein-1 







PAP (3’,5’-ADP) Adenosine 3’,5’-diphosphate 
PAPS Adenosine 3’-phosphate 5’-phosphosulfate 
PAS Pyridinium acetylsulfate 
Pbf Pentamethyl-dihydrobenzofuran-5-sulfonyl 
PhA Phenoxyacetyl 
PTKs protein tyrosine kinases 
PTPs protein tyrosine phosphatases  
PTP-1B protein tyrosine phosphatase-1B  
PSGL-1 P-Selectin Glycoprotein Ligand-1 
PTM Post-translation modification 
pTyr Phospho-tyrosine  
PvDBP Plasmodium vivax Duffy Binding Protein 
RANTES (CCL-5) Regulated upon Activation, Normal T-cell Expressed, and Secreted 
RV Rotary evaporator 




SPPS Solid phase peptide synthesis 
sTyr Sulfo-tyrosine  
TCE 2,2,2-Trichloroethyl  
TBAF tetra-n-butylammonium fluoride  
TBAI tetra-n-butylammonium iodide 
TFA Trifluoroacetic acid 
TFE Trifluoroethanol 
THF Tetrahydrofuran 
TIPS (TIS) Triisopropylsilane  
Tos Tosyl 
Tmb 2,4,6-Trimethoxybenzyl  
TNF Tumor necrosis factor 
TPSTs Tyrosylprotein sulfotransferases 
Troc 2,2,2-Trichloroethoxycarbonyl  
WSCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl 
Z (CBz) Benzyloxycarbonyl 
























Tyrosine Sulfation as a Post-Translational Modification and the Synthesis 
of Sulfotyrosine-Bearing Peptides 
1.1  Tyrosine sulfation as a post translational modification. 
Living cells can produce a wide variety of peptides and proteins.  The amino acid 
composition, number and sequence of a peptide or protein are initially determined by the 
genomic sequences of DNA.  However, cells can broaden the diversity of the synthesized 
protein via modifications which target the fully assembled protein or peptide chains in a 
process known as post-translation modification (PTM).1, 2 In PTMs the assembled protein is 
varied either by cleaving or splicing the protein amide bond at certain position(s) or by 
adding new organic or inorganic moieties to one or more amino acids on the protein chain.1  
Perhaps the most famous example of a PTM involving a cleavage process is insulin which is 
first translated as a single chain prohormone but is then converted to a disulfide bridged two-
chain active form by the aid of specific proteases.3  The number of PTMs involving the 
covalent addition of organic or inorganic moieties is vast.  PTMs such as glycosylation, 
phosphorylation, sulfation, acetylation, methylation, ubiquitination, and hydroxylation are 
the most common PTMs of this type.  This thesis is concerned with sulfation as a PTM.   
Although phosphorylation is perhaps the most studied PTM, modification by adding a 
sulfate group instead of a phosphate group has not been as extensively studied. Throughout 
the rest of this chapter we will discuss in detail how sulfotyrosine (sTyr or sY) containing 
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peptides/proteins are synthesized in vivo, the biological significance of these peptides/protein 
and, finally, we will describe in detail the available methods to obtain these peptides/proteins 
synthetically.  
O-Sulfation of tyrosine residues in proteins is a PTM that is believed to occur in all 
eukaryotes on secreted and membrane-spanning proteins.4 It has been suggested that up to 
1% of all tyrosine residues of the overall protein content in an organism are sulfated which 
makes tyrosine sulfation an important post-translation modification.5  Tyrosine sulfation is 
catalyzed by members of the sulfotransferase family of enzymes called tyrosylprotein 
sulfotransferases (TPSTs).  TPSTs catalyze the transfer of a sulfate group from the sulfate 
donor adenosine 3’-phosphate 5’-phosphosulfate (PAPS) to the phenolic group of a tyrosine 
residue(s) within the fully assembled peptide or protein to generate the sulfotyrosine bearing 
peptide along with adenosine 3’,5’-diphosphate (PAP) (Figure 1.1).6 
To date two TPST isozymes have been identified, namely TPST-1 and TPST-2.6-9 
The two isozymes show 63% sequence identity with each other but there is considerably 
higher sequence identity (> 90%) for each of these isozymes between mammalian species.6  
This high degree of sequence conservation between mammalian species suggests the 
functional importance of these differences between the two isozymes.10 In vitro studies have 
shown that the two isozymes have overlapping but not identical substrate specificities.8 The 












































Figure 1.1.  TPST catalyzed protein tyrosine sulfation. 
 
Protein sulfation occurs in the trans-Golgi network. The TPSTs are transmembrane 
proteins with a short N-terminal cytoplasmic domain, a single transmembrane domain and a 
luminal catalytic domain.  Such architecture requires both unsulfated substrate together with 
PAPS to be presented in the lumen of the trans-Golgi network.6 
PAPS is synthesized in the cytosol by a bifunctional enzyme called PAPS synthase 
which has a sulfurylase domain and a kinase domain.  It uses two molecules of ATP and one 
molecule of inorganic sulfate which enters the cells via a sulfate transporter.  One molecule 
of ATP reacts with inorganic sulfate to form adenosine 5’-phosphosulfate (APS) at the ATP 
sulfurylase domain.  3’-phosphorylation of APS using the second ATP molecule to give 




Figure 1.2.  Schematic representation of process of tyrosine sulfation in trans-Golgi network 
(adapted from Moore6)   
 
There does not appear to be a specific sequence that determines which tyrosyl residue 
within a protein transiting the secretory compartment is to be sulfated.  However, studies 
conducted on synthetic peptides have shown that the presence of the acidic residues aspartate 
or glutamate in the vicinity of the sulfated tyrosine is required.11-13 Besides acidic residues, 
small amino acid residues are usually located 1-2 residue(s) upstream of the tyrosyl moiety 
which is believed to facilitate binding of substrates to TPSTs.11, 14  For the same reason, 
sulfation sites are usually well separated from both disulfide bonds and N-linked 
glycosylation sites.13  
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1.2  Biological significance of tyrosine sulfation. 
 It is now believed that the main role of tyrosine sulfation is to modulate protein-
protein interactions.15-17Although many proteins are tyrosine sulfated, how essential the sTyr 
residue(s) to the biological function of these proteins is, in most cases, not known.  
Nevertheless, the role of tyrosine sulfation in some proteins has been elucidated to some 
degree.  In the following pages we will discuss some of these proteins as well as proteins that 
have been shown to contain sTyr but the function of the sTyr residue is unknown. 
1.2.1  Tyrosine sulfation of P-Selectin Glycoprotein Ligand-1 (PSGL-1). 
One of the most important steps in the process of inflammation is the recruitment of 
leukocytes into the site of inflammation which is derived by an intercellular communication 
cascade between cell adhesion molecules extended from the cell membranes of both 
endothelium cells of various blood vessels and leukocytes (Figure 1.3).15  
 
Figure 1.3.  Schematic representation of process of leukocytes rolling, adhesion and 
transmigration into the site of inflammation. 
 
At the site of inflammation, chemokines are produced as signalling molecules by 
different cells in response to different inflammatory stimuli like bacterial/virus infections 
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and/or physical damage.  Chemokines stimulate endothelial cells of venules at this particular 
site to express P-selectin and E-selectin on their luminal surface.15 The natural ligand of P-
selectin is P-selectin glycoprotein ligand-1 (PSGL-1) which is expressed on the surface of 
leukocytes as disulfide-linked homodimers and post-translationally modified by O-
glycosylation and tyrosine sulfation.18  Studies have shown that only the first 19 amino acid 
residues within the N-terminal region, which has an O-glycan attached to threonine 16 and 
has three sulfotyrosine residues at positions 5, 7 and 10, are required for optimum binding to 
P-selectin.19 In fact, it has been demonstrated that just this N-terminal portion (1.1, Figure 
1.4), in its glycosylated and sulfated form, binds as efficiently to P-Selectin as the fully 
dimeric PSGL-1.20 Furthermore, inhibition of sulfation at these particular sites using chlorate, 
an inhibitor of tyrosine sulfation, or site directed mutagenesis of tyrosine residues into 
phenylalanine dramatically affects the binding affinity to P-selectin. 21, 22 All three sTyr 
residues contribute to high affinity binding to P-selectin.20, 23 From all the above one can 
conclude that finding an efficient method for the synthesis of the truncated PSGL-1 or its 
analogs and elucidating the details of its binding to P-selectin will pave the way for the 
discovery of novel anti-inflammatory drugs.  
 
1.1 
Figure 1.4.  The N-terminal domain (residues 1-19) of mature PSGL-1 showing the sulfation 
sites at 5, 7 and 10 residues as well as glycosylation site at residue 16 (indicated by arrow).   
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1.2.2  Tyrosine sulfation of chemokine receptors.  
Chemokines are a group of functionally related, small, soluble proteins (~ 8-14 kDa). 
They are named chemokines because of chemoattractant properties. There are about 40 
chemokines currently known.  A considerable number of basic amino acids as well as several 
cysteine residues (usually four) are characteristic features of these proteins.  Chemokines 
have a high expression level and so they are produced in large amounts in order to create a 
concentration gradient to attract the migrating cells (chemotactic cytokines).24,25  
Chemokines are classified into four chemokine subfamilies according to the number and 
spacing of the conserved cysteine residues. The two largest subfamilies are the CC 
chemokines (for example CCL5), where the first two cysteines appear consecutively and, the 
CXC chemokines (for example CXCL16) where the first two cysteines are intervened by 
another amino acid residue X (where X is any amino acid residue except proline).  The other 
two subfamilies, which are relatively new and small compared to the first two subfamilies, 
are the XC subfamily, which contains only one conserved cysteine (for example XCL1) and 
the CX3C chemokines (for example CX3CL1) which contains three amino acids spacing the 
first two conserved cysteines.  Each subfamiliy contains many members and the members 
within one subfamily resemble each other more than the members of other families.24  
Functionally, chemokines can be divided into two types; “homeostatic chemokines” which 
manage leukocyte homing and lymphocyte recirculation under normal conditions and 
“inflammatory chemokines” which are produced in response to inflammatory stimuli like 
TNF (tumor necrosis factor) and responsible for recruitment of leukocytes to sites of 
inflammation.26  During the last few years chemokines have earned more attention due to 
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several findings showing that chemokines are involved in diseases such as autoimmune 
diseases and infectious diseases (e.g. HIV/AIDS).24   
Chemokines bind to a group of G-protein coupled receptors named chemokine 
receptors. There are 19 known chemokine receptors.  Typically the same receptor binds 
multiple chemokines in a subfamily restricted manner.25 Chemokine receptors are usually 
classified and named according to the classification of their ligands.  For example CCR5 is 
the receptor for CCL5 chemokines.27 Chemokine receptors are seven transmembrane domain 
receptors with an acidic N-terminal extracellular domain and a serine/threonine-rich 
intracellular C-terminal domain.  The N-terminal domain is linked through disulfide bonds to 
a second loop while the first and third loops are connected through another one.  Chemokine 
receptors are mainly expressed on the surface of leukocytes and their binding to their ligand 
induces the expression of other surface receptors called integrins. The latter receptors bind 
firmly to endothelial cells and such binding promotes morphological changes in leukocytes 
which induces the migration of leukocytes through endothelial cells into the underlying 
tissue.10  Interestingly, the N-terminal of all known chemokines receptors contain sTyr 
residues as confirmed by experiment or as predicted through bioinformatic analyses.10  In the 
following pages we will discuss some of these sulfated chemokine receptors and we will 
emphasize the importance of the presence of the sulfate group(s) for proper functioning of 





1.2.2.1 CCR5 and CXCR4 
Although the main role of chemokines receptors is to facilitate leukocyte trafficking 
some chemokine receptors can themselves facilitate infection.  Examples of such receptors 
are CCR5 and CXCR4.  It has been reported that CCR5 and CXCR4 are crucial for the entry 
of HIV-1 into the target cells in that the HIV-1 gp120 envelope glycoprotein uses CCR5 and 
CXCR4 as co-receptors besides CD4 to mediate the virus-membrane fusion and hence virus 
entry. 28, 29  To emphasize the importance of CCR5 to the process of viral entry it was found 
that certain chemokine proteins, CCR5 inhibitors and anti-CCR5 antibodies inhibit HIV-1 
infections.30 Indeed, Maraviroc®, which is a CCR5 antagonist, has been approved for clinical 




Figure 1.5.  Amino acid sequence (residue 1-20) of the N-terminal region of CCR5.  
Sulfation sites are in bold. 
 
The N-terminal region and the second extracellular loop are the domains of CCR5 
that are responsible for binding of CCR5 with gp120.  The N-terminal of CCR5 (1.2, Figure 
1.5) has four tyrosine residues at positions 3, 10, 14 and 15 which are vulnerable to sulfation. 
To underscore the importance of the presence of these sulfate groups it was found that 
chlorate decreases the binding affinity of CCR5 to the gp120/CD4 complex without affecting 
the rate of expression in cells transfected with CCR5.32  Furthermore, site directed 
mutagenesis of the sTyr moieties to phenylalanine greatly reduces the binding efficiency and 
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hence the entry ability of HIV.32 Last but not least, the presence of the sTyr residues are 
critical for binding to the gp120/CD4 complex in vitro.33  Interestingly, Siebert et al. showed 
that the in vitro sulfation of peptide sequences corresponding to the N-terminal of CCR5 
using TPST-1 and TPST-2 enzymes occurs in a nonrandom and sequential manner.34  The 
authors demonstrated that the sulfation of tyrosine residues at position 14 or 15 occurs first 
followed by position 10 then finally at position 3.  Moreover, there is more than one report 
showing that sulfation at positions 10 and 14 is sufficient to induce the binding between 
CCR5 and gp120/CD4 complex and absence of a sulfate group at these positions greatly 





Figure 1.6.  Amino acid sequence (residue 1-27) of N-terminal region of CXCR4. Possible 
sulfation sites are in bold. 
 
Surprisingly, although the N-terminal domain of the CXCR4 (1.3, Figure 1.6) 
contains at least three possible sites for sulfation the presence of a sulfate group(s) does not 
seem to play a major role of binding of CXCR4 to gp120/CD4 complex.36  The role of 
tyrosine sulfation in CXCR4 is not yet known. 
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1.2.2.2 Chemokine Decoy receptors (D6 and DARC). 
Chemokine decoy receptors are an atypical family of chemokine receptors differing 
from other signaling chemokine receptors in that they bind to a wide range of chemokines 
and more importantly, such binding does not induce any further signaling machinery.37 The 
lack of signaling ability is due to the absence of a DRYLAIV motif (or simply DRY motif) in 
the second intracellular loop of these atypical chemokine receptors. The DRY motif is 
responsible for coupling chemokine binding to the triggering of intracellular events.  Because 
this unique class of chemokine receptors lacks such a motif they bind their cognate ligands 
without triggering any biological response (Figure 1.7).37, 38 When a chemokine binds to 
these receptors, it is either transported through the cytoplasm and expelled from the other 
side of the cell in a process known as transcytosis or it is degraded in the cytoplasm.25 It is 
believed that the main biological role of these “silent” receptors is to compete with signaling 
receptors for excess chemokines and thus act as negative modulators of inflammation.25 The 
decoy receptor family includes DARC (Duffy Antigen Receptor for chemokines), D6, CCX 
and CKR receptors.25  We will discuss the first two receptors in detail. 
DARC is a promiscuous decoy receptor that binds to 11 pro-inflammatory 
chemokines from CC and CXC family but not with homeostatic chemokines.39, 40 DARC is 
expressed under normal conditions in erythrocytes and endothelial cell of postcapillary 
venules and veins of lymph nodes, skin, kidney, lung, brain, thyroid and spleen.41 It was 
reported that there is high rate of DARC expression in the inflamed tissues such as the 
rheumatoid joint synovium, psoriatic skin and pathological conditions involving skin and 




Figure 1.7.  Typical (A) and atypical chemokine receptors (B) signaling cascades. 
 
It is believed that the presence of DARC on erythrocytes regulates the concentration 
of circulating chemokines by acting as sink or reservoir for chemokines.  This belief is 
confirmed by the observation that DARC-null mice rapidly eliminate the chemokines from 
circulation. 39, 43  On the other hand, in the venular endothelial cells DARC acts as negative 
modulator of inflammatory process through scavenging the excess chemokines by binding to 
them.44    
In addition to its chemokine-binding ability, DARC receptor can serve as erythrocyte 
receptor for the malaria parasite Plasmodium vivax.45 It was found that the erythrocyte 
invading stage of Plasmodium vivax expresses an erythrocyte-binding antigen called 
Plasmodium vivax Duffy Binding Protein (PvDBP).  The N-terminal of PvDBP contains a 
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highly-conserved cysteine-rich domain called the Duffy-Binding Like (DBL) domain.46, 47 
The first interaction between DARC and DBL is a crucial step in erythrocyte invasion by the 
parasite and failure to complete such interaction retards the invasion.  In order to demonstrate 
the importance of such interaction in the consequence of parasite invasion, Chaudhuri et al. 
showed that a 35-mer N-terminal peptide of DARC (non-sulfated) or even smaller peptides 
can prevent DBL binding to Duffy positive red blood cell.  Moreover, antibodies against N-
terminus of DARC interfere with the erythrocyte invasion by DARC-dependent Plasmodium 
yoelii. 48 All these results highlight the importance of DARC-DBL interaction for parasite 




Figure 1.8.  Amino acid sequence (residue 8-42) of N-terminal region of DARC. Sulfation 
sites are in bold. 
 
The N-terminal region of human DARC (1.4, Figure 1.8) contains two sTyr residues 
at positions 30 and 41.49  sTyr-41 plays a crucial role in promoting DARC-DBL interactions 
as indicated by total loss of binding ability on mutating Tyr-41 to Phe.49  Interestingly, the 
binding affinity to different chemokines depends on the sulfation pattern of the DARC N-
terminus.  Where alteration of Tyr-41 to Phe-41 interferes with binding of chemokines MCP-
1, RANTES and MGSA with DARC, such alteration does not affect the IL8 chemokine. On 
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the other hand, the Y30F modification affected IL8 chemokine binding to DARC but not the 
binding of other chemokines.49 Thus, it seems that both tyrosine moieties should be sulfated 
for full activity. However, the full significance of the sulfate moieties and their effect on 
binding to different chemokines and/or PvDBL has yet to be fully elucidated.  
Most often the role of sTyr in chemokine receptors is not known.  An example of this 
is D6.  D6 is a chemokine decoy receptor which binds a broad range of inflammatory CC 
chemokines but does not recognize homeostatic CC chemokines or any other chemokine 
subfamilies such as CXC chemokines.50 D6 is expressed at low levels by the circulating 
leukocytes but it is selectively expressed in the high levels at endothelial cells of the skin, 
gut, lungs and placenta.51 As a member of decoy chemokine receptors, D6 does not facilitate 
any conventional intracellular signaling and is not involved in transcytosis.  It is generally 
believed that D6 competes with the typical chemokine receptors for inflammatory CC 
chemokines.  After binding chemokines, the ligand-receptor vesicle is mobilized 
intracellularly, the chemokines are rapidly dissociated and degraded during vesicle 
acidification leaving D6 for recycling.52-54 Furthermore, the in vivo studies using D6-
deficient mice support the chemokine scavenging role of D6 where the D6 deficient mice 
showed an exacerbated inflammatory response.  The exacerbated effect was due to a high 
level of chemokine aggregation which could be prevented by the pretreatment with 
inflammatory CC chemokine-antibodies.55, 56 The chemokine scavenging action of D6 was 
demonstrated in placenta where D6 functions to reduce the amount of inflammatory CC 
chemokines passed to the fetus as shown by an increase in inflammation-induced fetal loss in 
D6-deficient pregnant mice.57  Besides its action as a chemokine scavenger, Neil et al. 
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demonstrated that D6 is expressed on primary astrocytes and is used by gp120 of dual tropic 
isolate of HIV-1 and HIV-2 as a coreceptor in a manner similar to CCR5 and CXCR4.58 
 
H-Asp14-Ala-Asp-Ser-Glu-Asn-Ser-Ser-Phe-Tyr23-Tyr24-Tyr25-Asp-Tyr27
HO-Phe33-Ala-Val-Glu-Asp-Leu   
1.5 
Figure 1.9.  Amino acid sequence (residue 14-33) of N-terminal region of D6.  Possible 
sulfation sites are in bold. 
 
The N-terminal domain of D6 has been shown to be sulfated as demonstrated by a 
metabolic labeling experiment.59  This region (1.5, Figure 1.9) contains four Tyr residues all 
of which are possible sulfation sites.  However, it is not known which Tyr residues are 
sulfated and how important sTyr is for chemokine binding and for HIV entry.59  Clearly the 
role of sulfation of D6 merits further investigation. 
1.2.2.3 CXCR6 
Another example where the role of sTyr in a chemokine receptors is not known is 
CXCR6.  CXCR6 is a member of CXC family of chemokine receptors which has a unique 
character of being one of the few chemokine receptors which binds only one ligand, namely 
CXCL16.25  CXCL16 itself is an unusual chemokine being expressed in soluble as well as 
membrane bound forms where the latter can act as a receptor itself for scavenging oxidized 
lipoproteins and bacteria besides facilitating the tight adhesion of cells expressing CXCR6 
such as T cells.  On the other hand, soluble CXCL16 acts as a chemoattractant for CXCR6+ T 
cells.60-62  Both CXCR6 and its ligand are coexpressed within the atherosclerotic lesion and 
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they are believed to be involved in the pathogenesis of atherosclerosis.63 Furthermore, it was 
found that CXCR6 also plays a role as co-receptor for the entry of HIV-1 onto macrophages 
and T-cells.64  
H-Met1-Ala-Glu-His-Asp-Tyr6-His-Glu-Asp-Tyr10-Gly-Phe-Ser-Ser-Phe
HO-Gln-Ser-Ser-Asp-Asn   
1.6 
Figure 1.10.  Amino acid sequence (residue 1-20) of N-terminal region of CXCR6.  
Sulfation sites are in bold. 
 
As with most chemokine receptors the N-terminal region of CXCR6 (1.6, Figure 
1.10) is post-translationally modified through tyrosine sulfation and glycosylation.  But 
interestingly, Petite et al. showed that the presence of acidic residues in general is not crucial 
for binding of CXCL16 to its receptor. Instead, they proposed a model for binding of soluble 
as well as membrane-bound forms of CXCL16 to CXCR6 which is completely different from 
the established model of chemokine-receptor binding where sTyr plays crucial role.65  Such a 
model opens up a wide array of questions about why these tyrosine residues are sulfated and 
why CXCR6 has a binding profile which differs from its chemokines mates. 
1.2.3  Tyrosine sulfation of other G-protein coupled receptors. 
Besides chemokine receptors there are a number of other GPCRs for which the 
presence of a sTyr residue(s) is crucial for its functions.  For example, C5a-anaphylatoxin 
chemotactic receptor (C5aR), C3a-anaphylatoxin chemotactic receptor (C3aR), Type 1 
Sphingosine 1-phosphate receptor (S1P1R), Follicle-stimulating hormone receptor (FSHR), 
Luteinising hormone receptor (LHR)/Chorionic gonadotropin receptor (CGR) and Thyroid-
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stimulating hormone receptor (TSHR) are GPCRs in which the extracellular domain contains 
sulfotyrosine residues as demonstrated by 35S-sulfate metabolic labeling experiments.10  The 
presence of these residues creates a negative charge on the N-terminal domain of these 
receptors which is crucial for the initial docking of theirs hormonal ligands.  Not surprising, 
mutagenesis of these particular sites results in decreased binding affinity.  Of this class of 
receptors, C5aR and its ligand C5a have received a lot of attention because their involvement 
in numerous inflammatory diseases.10  
C5a is one of the most potent inflammatory peptides producing a wide-range of 
effects depending on the cell type it acts upon like, phagocytosis, degranulation, H2O2 
production, granule enzyme release, delay or enhancement of apoptosis, chemokine and 
cytokine production and chemotaxis.66  C5aR and C5L2 are the natural receptors of C5a.  
The binding of C5a to the former is believed to be fundamental for the development of 
several disease states for example, rheumatoid arthritis, psoriasis and acute respiratory 
distress syndrome.66 The N-terminal domain of C5aR contains two sTyr residues (residues 11 
and 14) as indicated by labeling experiments.67  The presence of these sulfated residues is 
crucial for the binding of C5aR to its ligand as indicated by site directed mutagenesis 
experiment.67 On the other hand, sulfated peptide sequence corresponding to residues 7-28 









Figure 1.11.  Amino acid sequence (residue 7-28) of the N-terminal region of C5aR.  
Sulfation sites are in bold. 
 
Recently, Soliris® (eculizumab) a monoclonal antibody targeting C5a was approved 
by the FDA (USA) for treating paroxysmal nocturnal hemoglobinuria (PNH) and so prevent 
hemolysis.68 Moreover, due to the widespread involvement of C5a-C5aR in many 
inflammatory conditions it has been suggested that C5aR is a potential target for developing 
anti-inflammatory drugs for treating conditions such as rheumatoid arthritis.66    
1.3  Synthesis of sulfotyrosine containing peptides. 
1.3.1  Peptide synthesis and the chemistry of sulfate monoesters 
The study of biological systems has been greatly enhanced by the ready availability 
of synthetic peptides.  Synthetic peptides are also very important in the pharmaceutical 
industry.  This is mainly because many pharmaceutical targets are receptors and enzymes 
whose ligands are peptides or other proteins.  Synthetic peptides corresponding to sequences 
within the bound peptides or proteins are used as lead structures for drug development.  
Peptides themselves are also used as drugs though this is less common due to bioavailability 
issues with peptidyl drugs.69  Since many enzymes and receptors specifically recognize a 
sequence within peptides or proteins that has been post-translationally modified, the 
synthesis of peptides bearing modified amino acids is also very important.  For some PTMs, 
such as tyrosine phosphorylation, the corresponding synthetic peptides (peptides bearing 
phosphotyrosine) are readily prepared.  However, sometimes the synthesis of peptides 
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bearing modified amino acids can be very challenging.  This has been the case for sTyr-
bearing peptides.  Indeed, one of the factors that has, to a certain extent, limited the study of 
tyrosine sulfation in proteins has been the lack of a general and effective method for readily 
preparing sTyr-bearing peptides in quantities necessary for detailed studies.  It is this issue, 
the synthesis of sTyr-bearing peptides, that is the primary focus of this thesis. 
In order to explain why the synthesis of sTyr peptides has been difficult some 
background on the synthesis of peptides in general and the chemistry of sulfate monoesters is 
required.  Peptides can be prepared “in solution” using standard synthetic organic chemistry 
techniques or they can be prepared using a process known as solid phase peptide synthesis 
(SPPS). We will focus our attention on SPPS since the vast majority of peptides today are 
prepared using that approach.70, 71 SPPS is based on the sequential addition of protected 
amino acids (α-amino group and side chains are protected) to the N-terminus of a side chain-
protected peptide that has been attached to an insoluble polymer (such as cross-linked 
polystyrene) via its C-terminus carboxyl group (Scheme 1.1).  There are two types of SPPS:  
Boc/Bn SPPS, where the acid [usually trifluoroacetic acid (TFA)]-labile Boc (tert-
butoxycarbonyl) group is used for temporary Nα-protection and most of side chains are 
protected with HF-labile groups [such as benzyl (Bn) or other HF-labile groups], or 
Fmoc/tBu SPPS, where the base-labile Fmoc (Fluorenylmethyloxycarbonyl) group is used for 
temporary Nα-protection and most of side chains are protected as tert-butyl ethers or esters or 
some other group that is removed using TFA (Scheme 1.1).  After removing the temporary 
Nα-protecting group, using TFA in case of Boc SPPS, or piperidine in case of Fmoc SPPS, 
the incoming amino acid is coupled to the growing peptide chain using one of a variety of 
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coupling agents or a preactivated amino acid is used (Scheme 1.2).  After each step the 
excess reagents are removed by filtration.  At the end of the synthesis, all the side chain 
protecting groups are removed and the peptide is detached from the resin in one step through 
treatment with HF when using Boc chemistry or TFA when using Fmoc chemistry.  During 
side chain deprotection and cleavage of the peptide from the support it is common to add 
reagents, such as thiols, to the HF or TFA which can scavenge reactive cations that are 
generated during this process.  The crude peptide is obtained by filtration and then purified 
using HPLC.  Fmoc-based SPPS, as opposed to Boc-based SPPS, is by far the more common 
approach since it does not require the need for repeated treatment with TFA and, most 
importantly, does not require treatment with hazardous HF, which requires specialized 
equipment and training, to cleave the peptide from the resin.  Solution phase synthesis of 
peptides is carried out in a similar manner except the peptides are not built on a polymer 
support and the C-terminus is protected usually as a benzyl ester.  Unlike the synthesis of 
peptides in solution, SPPS does not require the purification of intermediates since the amino 
acids and reagents are added in excess to drive the reactions to as to close to 100% 
completion as possible and the excess reagents are removed by filtration.  SPPS has also been 
automated.  The 1984 Nobel Prize in chemistry was awarded to Bruce Merrifield for his 




Scheme 1.1.  Schematic representation of SPPS.  tPG = temporary protecting group (Fmoc or 

















Scheme 1.2.  Common coupling agents used in SPPS. 
Sulfate monophenylesters are acid labile.  Several studies have suggested that they 
hydrolyze in acid via an A-1 type mechanism as shown in Scheme 1.3.72-75   Dissociation of 



































It is the acid lability of sulfate monoesters that makes the synthesis of sTyr peptides a 
considerable challenge since acid treatment of the peptide, either during chain elongation 
(when using Boc chemistry either in solution or during solid phase synthesis) or during 
cleave of the peptide from the support (using Boc or Fmoc chemistry) is a necessary 
component of peptide synthesis.  Consequently, unless special precautions are taken, loss of 
the sulfate group will occur during the synthesis of sTyr bearing peptides.  In the following 
section we will outline the various approaches that have appeared in the literature previous to 
our studies for constructing sTyr-bearing peptides.   
1.3.2   The global sulfation approach to the synthesis of sTyr peptides. 
In the global sulfation approach the fully extended peptide chain is assembled first 
using solution or solid phase methods then the tyrosine moieties are sulfated using a sulfating 
agent. Any protecting groups on the side chains of the other amino acids are then removed 
and the peptide is cleaved from the support (if doing SPPS).  Several considerations should 
be taken into account on applying the global sulfation approach.  First, the sulfating agent 
should be of appropriate sulfating power to give the intended tyrosine sulfated compound in 
good yield without any other side reactions occurring on the tyrosyl moiety itself or other 
amino acid side chains.  Second, the side chain protecting groups on the other amino acids 
must withstand the synthesis and sulfating conditions yet are removed under conditions 
which will not affect the sTyr residue.  Third, if using SPPS, then the conditions for removal 
of the peptide from the support must not result in desulfation. 
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A variety of sulfating agents have been used in the global sulfation strategy.  Simple 
neat concentrated sulfuric acid was among the first.  When using sulfuric acid the hydroxyl 
and thiol groups of other amino acids should be protected otherwise they will be 
quantitatively sulfated and the reaction should be run at low temperature (-5 oC) and for short 
period of time otherwise an appreciable degree of 3-sulfonation of tyrosyl moieties occurs. 
On the other hand, running the reaction under these attenuated conditions usually gives low 
yields. For example Ondetti et al. used concentrated sulfuric acid to sulfate CCK-
(cholecystokinin) octapeptide 1.8 after constructing it using Boc/Bn solution phase chemistry 
(Scheme 1.4).76 Although, the reaction was conducted at -5 oC for 15 min a considerable 
degree of tyrosine sulfonation took place and the yield of the sulfation step to give peptide 
1.9 was only 24%.  In order to enhance the sulfation reaction using sulfuric acid, a mixture of 
DCC and [S35]-sulfuric acid was used to effect the radiolabelling of unprotected CCK-8; 
however the labeled CCK-8 was obtained in a moderate yield (40 % for the sulfation step 
only) even in presence of four-fold molar excess of sulfuric acid and 40-fold molar excess of 
DCC.  Moreover, other side chains were found to have reacted with the sulfating agent.77 
 
Scheme 1.4.  Sulfation of CCK-8 using concentrated sulfuric acid. 
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Sulfur trioxide complexes with pyridine, dimethylformamide or triethylamine are 
reported to effectively react with tyrosine residues to give sTyr without any appreciable 
sulfonation even at high temperatures.78 On using these sulfating agents, full protection 
strategies are required since sulfation of hydroxyl groups, thiol groups, amino, guanidine and 
primary amido occurs besides sulfation of phenol groups.78 Furthermore, methionine residues 
may be harmed when exposed to these sulfating agents for long periods of time as found by 
Beacham et al. during the solution phase synthesis of a decapeptide derived from human 
gastrin and using sulfur trioxide/pyridine in aqueous medium as sulfating agent.79  Since 
homoserine was detected amongst the products it is believed that the sulfur of methionine 
reacted with sulfur trioxide/pyridine to form the corresponding sulfonium derivative which 
decomposed to give homoserine.79  This was further supported by the fact that replacing 
methionine residues in CCK-heptapeptide for norleucine (Nle) resulted in a dramatic increase 
in the obtained yield under almost identical reaction conditions (Scheme 1.5).80, 81 
 
Scheme 1.5.  Sulfation of CCK-heptapeptide and  its norleucine analogue.  
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 Tryptophan residues may also be modified upon exposure to sulfur trioxide/pyridine 
through 2-sulfonation (Scheme 1.6).82 Fortunately, this side reaction can be prevented by 
protecting the indole ring with a formyl group which in turn can removed with short 



















Scheme 1.6.  Sulfonation of tryptophan residues upon treatment with sulfur trioxide/pyridine. 
Epimerization (up to 20% occurred) at the C-terminal residue can also occur when 
using sulfur trioxide/pyridine and using pyridine/DMF 1:1 as solvent for peptide sulfation but 
only if the C-terminus is left unprotected.  The epimerization is proposed to occur through 
oxazol-5(4H)-one formation as shown in Scheme 1.7.  Luckily, such racemization is greatly 
inhibited by shifting to sulfur trioxide/DMF and using DMF as solvent.83   
 




Sulfur trioxide/DMF complex is a stronger sulfating agent than sulfur 
trioxide/pyridine complex.84  Furthermore, Futaki and his coworkers reported that using 
sulfur trioxide/DMF complex eases the purification of the final product since the water 
solubility of sulfur trioxide/DMF complex is better than that of the pyridine complex.84 Sulfur 
trioxide/Et3N has also been used but is less reactive than sulfur trioxide/DMF.85 Pyridinium 
acetylsulfate (PAS) has also been used as a sulfating agent for sTyr peptide synthesis. As the 
sulfation reaction is conducted in acidic medium, AcOH or TFA, sulfation of amino, 
guanidino, imidazole, indole groups is suppressed.  Serine residues must be protected.  On 
the other hand, under these conditions, sulfonation of tyrosine moieties can occur, albeit to a 
small extent. The main drawback of pyridinium acetylsulfate is its reduced reactivity and so 
sometimes quantitative sulfation is hard to obtain even with using a large excess of sulfating 
agent and long reaction times.86  
As mentioned earlier, one of the problems with the global sulfation approach is 
selectivity.  Sulfation often occurs at other residues and so these residues must be protected 
and their protecting groups must be removed at the end of the synthesis without affecting the 
sTyr residue.  One way of getting around this problem is to use protecting groups on the side 
chains that can be cleaved with non-acidic reagents and performing the synthesis in solution 
or, when using SPPS, employing a linker to the resin that is extremely acid labile.  Futaki et 
al. employed side chain protecting groups that were removed by hydrogenolysis for the 




Scheme 1.8.  Synthesis of Leu-enkephalin sulfate 1.16. 
Rosamond et al. used PAM resin to construct appropriately protected CCK-8 
following Fmoc-SPPS.87 After on-resin sulfation using sulfur trioxide/pyridine, the acid 
labile side chain protecting groups were removed under attenuated acidic conditions without 
affecting the peptide benzyl linkage to the PAM resin. The linkage was cleaved upon 
ammonolysis for 3 days to give the desired compound in 23% yield (Scheme 1.9).87 
 




An interesting example of the global sulfation approach that employs an 
unconventional side chain protecting group has been reported by Kurano and coworkers for 
the synthesis of CCK-33 as outlined in Scheme 1.10.88  Four segments were constructed and 
then coupled together to assemble the final peptide using solution phase Boc chemistry and 
applying water soluble-carbodiimide WSCI/HOBT and WSCI/ Hydroxy- 3,4-dihydro-4-oxo-
1,2,3-benzotriazine (HOOBt) for coupling.  All of the serine residues were protected with 
phenoxyacetyl (PhA) groups which are stable to hydrogen fluoride.  After constructing the 
full length peptide chain, all of the protecting groups within the peptide chain were removed 
using HF except the PhA groups and the formyl group of tryptophan. The tyrosine residue 
was sulfated with PAS.  Deprotection of the serine residues and deformylation of tryptophan 
under basic conditions gave the final product in 5% yield. The low yield was attributed to 




Scheme 1.10.  Synthesis of CCK-3. WSCI-HOBT method used as coupling agent. a, 
catalytic hydrogenolysis; b, TFA; c, Zn-acetic acid; d, phenoxyacetic anhydride; e, WSCI-
HOBT; f, WSCI-HOOBT. Pac= phenacyl 
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Another interesting example of the global sulfation approach that employs an 
unconventional side chain protecting group has been reported by Futaki et al. (Scheme 1.11).  
These workers used the acid stable P-(methylsulfinyl)benzyl (Msib) group to protect 
hydroxyl groups and P-(methylsulfinyl)benzyloxy carbonyl (Msz) to protect the amino 
groups.89  These protecting groups allowed them to apply Fmoc SPPS using the usual TFA-
labile protecting groups for the other amino acid side chains.  After deprotection and 
cleavage of the peptide from the support under acidic conditions, sulfation was conducted 
using SO3/DMF-ethanedithiol (EDT) which caused concomitant reduction of both Msib and 
Msz to acid labile Mtb and Mtz, respectively (Scheme 1.11).89   Mtb and Mtz were 
subsequently removed under mild acidic conditions to yield the sulfated peptides.  
Unfortunately, the overall yield was only 7% and furthermore, this approach is generally 




Scheme 1.11.  Synthesis of CCK-12 using Msib and Msz protecting groups 
Young and Kiessling have used non acid-labile protecting groups and the global 
sulfation strategy to construct sTyr peptides.91 The azidomethyl group (Azm) was used to 
protect the tyrosine residues that would ultimately be sulfated and benzyl protecting groups 
were used for the side chains of other amino acids (Scheme 1.12A).  The Azm-protected 
tyrosine moiety was incorporated into the growing peptide chain using regular Fmoc-SPPS 
and using the highly acid labile chlorotrityl resin (Scheme 1.12B).  Tin chloride was used to 
remove the Azm groups followed by on-resin sulfation.  Cleavage of the peptide from the 
resin was achieved using trifluoroethanol (TFE)-acetic acid (AcOH) to yield the sulfated 
peptides and then the rest of the protecting groups on the side chain of the other amino acids 
were removed by hydrogenolysis.  Unfortunately, the application of this method to the 
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synthesis of trisulfated octapeptide 1.38 which corresponds to residues 5-12 of PSGL-1 and 
its monosulfated analogue 1.39 proceeded in low yields of 27% and 5%, respectively 
(Scheme 1.12C).  There are several drawbacks to this procedure such as the use of harsh 
conditions for Azm removal, the use of only hydrogenolytically-labile protecting groups on 
the other amino acid side chains and the synthesis of Fmoc-protected, Azm-protected 
tyrosine required a tedious multi-step synthesis and proceeded with somewhat low overall 
yield (Scheme 1.12A).  
 
 
Scheme 1.12.  Synthesis of residues 5-12 of PSGL-1 using the Azm-protecting group. 
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1.3.3  The sTyr building block strategy for the synthesis of sulfated peptides. 
This strategy involves the incorporation of Nα-protected sulfotyrosine into the 
growing peptide chain. In principle, this procedure is more straightforward than global 
sulfation since it allows the chemoselective control of the sulfation sites and minimizes the 
deleterious effects of sulfating agents on other residues.  However, the major obstacle th the 
application of this procedure is the intrinsic acid lability of the sulfate group. Although small 
sulfated peptides have been synthesized applying solution phase peptide synthesis utilizing 
Z-Tyr(SO3Ba1/2)OBa1/292 or Boc-Tyr(SO3Ba1/2)OBa1/293, these methods are not applicable to 
larger or more complex peptides.  Concerning the SPPS of large complex peptides, the use of 
the Boc/Bn method is highly troublesome because the repeated acid treatments employed 
during peptide chain growth as well as the highly acidic conditions employed for the final 
cleavage lead to extensive sulfate hydrolysis. On the other hand, Fmoc-solid phase peptide 
synthesis is the most feasible technique because the basic conditions used to remove the 
Fmoc group are compatible with sulfotyrosine and the only step to be considered is the final 
treatment with TFA in order to deprotect all of the side chain protecting groups and cleave 
the peptide from the resin.  
Kitagawa et al. used FmocTyr(SO3Na)OH as a building block for Fmoc-SPPS to 
construct a number of challenging sulfated peptides.90 Before performing their syntheses they 
conducted a kinetic study on the hydrolysis of the sulfate group in FmocTyr(SO3Na)OH in 
TFA.  They found that the formation and dissociation of the zwitterion (Scheme 1.3) is 
favored under acidic conditions and in nonpolar solvents.  On the other hand, polar solvents 
such as TFA or TFE and salt bridging or ion pairing moieties with cationic functional groups 
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stabilize the zwitterionic intermediate.  These effects are not translated to the transition state 
of the rate-determining desulfation step and so desulfation proceeds slower.  Importantly, 
they also found that the rate of hydrolysis of the sulfate group was greatly suppressed at 
lower temperature and, at 0 oC, the rate of hydrolysis of tert-butyl protecting group of serine 
and pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) protecting group of arginine occurs 
faster than the hydrolysis of the sulfoester.  Therefore, TFA at 0 oC was selected to be the 
best conditions for the cleavage and protection of sulfated peptides. However, another 
problem that needed to be considered was the choice of the scavenger for the 
deprotection/cleavage cocktail.  In a previous study, the same research group found that 
sulfur-containing scavengers such as ethanedithiol (EDT), thioanisole, or dimethylsulfide 
(DMS) were very detrimental to the sulfate group whereas other weaker scavengers such as 
water, m-cresol or 2-methylindole were much less harmful.94 In this context, the use of 90-
95% aqueous TFA at 0 oC was considered to be best for peptide cleavage from the resin and 
side chain deprotection.  It has to be noted that the water concentration should be kept 
between 5-10% otherwise the rates of cleavage and deprotection are drastically affected.  The 
general approach developed by Kitagawa using FmocTyr(SO3Na)OH and other Fmoc-
protected amino acids, employing the highly acid labile chlorotrityl resin and using 10% aq. 
TFA at 0 oC to remove the side chain protecting groups and to cleave the peptide from the 
support is shown in Scheme 1.13.90 Using this approach Kitagawa and his coworkers were 
able to achieve the Fmoc-based SPPS of several challenging peptides (1.40-1.46) derived 




Scheme 1.13.  Kitagawa’s approach to sTyr peptide synthesis.90 
 
 
Figure 1.12.  Peptides prepared by Kitagawa using the sTyr building block strategy. 
 
The sTyr building block strategy developed by Kitagawa is currently the most widely 
used approach for sTyr peptide synthesis.  It provides purer products with higher overall 
yields as compared to the global sulfation approach.  The side reactions created by the action 
of the sulfating agents on the fully assembled peptide are avoided.  However, this approach 
has its own drawbacks.  The presence of the sTyr residue in this ionized state can render the 
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coupling of subsequent amino acids is difficult due to aggregation or poor swelling of the 
resin and so extended coupling times are sometimes required especially when more than one 
sTyr residue is present.91 The use of aq. TFA can result in insufficient cleavage of the peptide 
from the resin and incomplete side-chain deprotection.  On top of that, even under the 
optimized conditions, 10-15% desulfation usually occurs depending on the nature of the 
synthesized peptide.90 Thus, deprotection conditions need to be optimized for every sulfated 
peptide. 
1.3.4 Enzymatic synthesis of sulfated peptides 
As mentioned in previously, sulfated peptides are synthesized in vivo by the action of 
TPST-1 and TPST-2.7 These two isozymes are obtained by heterologous over-expression in 
eukaryotic cell lines and purified by affinity methods.  Recently, TPST preparations were 
used by Seibert et al. to sulfate a 38 residue peptide corresponding to N-terminus of CXCR-
4.95  These studies were performed to determine the order of sulfation of CXCR-4 by these 
enzymes. In addition to TPSTs, arylsulfate sulfotransferase (ASST), which is a bacterial 
sulfotransferase obtained from Eubacterium A-44, has also been used to sulfate certain 
peptides in vitro.  ASST uses p-nitrophenylsulfate as a cheap sulfate donor instead of 
expensive PAPS. However, the main obstacle toward the widespread application of ASST is 
that it does not respond to tyrosine residues adjacent to acidic residues, a property which puts 
most sulfated peptides out of its spectrum.7 Although the use of enzymes for the synthesis of 




1.4  Objective 
It is clear from the above discussion that no effective and general approach has been 
developed for the synthesis of sTyr peptides.  The objective of the majority of the work 
presented in this thesis is to develop a general and effective method for preparing sTyr-









Solid-Phase Synthesis of Sulfotyrosine Peptides using a Sulfate Protecting 
Group Strategy 
2.1  Introduction 
It is clear from our discussion in chapter one on the synthesis of sTyr peptides that no 
general and effective approach has been developed for the synthesis of this class of peptides.  
Nevertheless, we envisioned a tactic that would eliminate all the aforementioned problems 
associated with the synthesis of sTyr peptides.  This tactic relies on using conventional 
Fmoc-SPPS to incorporate the sTyr residue(s) at the beginning of the synthesis as a protected 
sulfodiester(s).  After elongation of the peptide chain the peptide would be cleaved from the 
support and all other side chain protecting groups removed under the usual acidic conditions.  
The final step would involve removing the sulfate protecting group (Scheme 2.1).  The 
success of this approach depends upon choosing a protecting group for the sulfate moiety that 
is able to withstand the peptide synthesis and cleavage conditions (stable to both acid and 







































deprotect all side chains except
sTyr and cleave from support
remove sTyr PG
 
Scheme 2.1.  Our proposed strategy for the synthesis of sTyr bearing peptides. 
There are very few protecting groups for sulfate esters.  Sulfates protected with 
groups such as methyl, ethyl, benzyl or t-butyl cannot be used since they are too labile to 
bases such as piperidine.  The phenyl group has been used by Perlin and Penney to protect 
the sulfate group in sulfated carbohydrates.96  However this group would clearly be 
inappropriate to protect the sulfate group in sTyr.  Proud et al. introduced the 2,2,2-
trifluoroethyl group (TFE) group as a protecting group for the sulfate group in sulfated 
carbohydrates.97 However, its introduction required the use of trifluorodiazoethane, an 
unstable and dangerous reagent that is difficult to prepare, and we were concerned that 
sulfate esters protected with this group would be unstable to basic conditions encountered in 
peptide synthesis such as 20% piperidine in DMF. 
In 2004, the Taylor group introduced the 2,2,2-trichloroethyl (TCE) group as the first 
truly practical protecting group for sulfate esters.98  TCE-protected sulfate esters (of type 2.3) 
are prepared by subjecting phenol derivatives (of type 2.2) to chlorosulfuric acid TCE ester 
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(Cl3CCH2OSO2Cl, 2.1) in presence of a base.  Deprotection is achieved under mild reducing 
condition utilizing catalytic Pd/C or Zn powder and excess ammonium formate to yield the 
desired aryl sulfates (of type 2.4) in a high yields (Scheme 2.2).  The presence of ammonium 
formate was found to be crucial in this step since it not only acted as a source of hydrogen 
but it also buffered the solution preventing it from becoming acidic (if just H2 is used as the 
hydrogen source, the solution becomes acidic resulting in desulfation).  This methodology 
was used to prepare estrone sulfate derivatives 2.5 and 2.6 which could not be obtained by 

























X = H, F, 4-NO2, 4-CF3, 2,6-diF, 4-OCH3, 2-CH3, 4-I, 4-Cl, 4-CH3CO
2.4
2.5 = CF2H
2.6 =  CFH2
(2.1)
 
Scheme 2.2.  General scheme for using the TCE protecting group in the synthesis of aryl 
sulfates. 
 
The Taylor group has also used the TCE group to protect the sulfate group in sulfated 
carbohydrates.  However, reagent 2.1 was not very successful in introducing TCE sulfates 
into carbohydrates as illustrated for carbohydrate 2.7 in Scheme 2.3.  These results prompted 
our group to design and prepare a unique sulfating agent, compound 2.10, called a sulfuryl 
imidazolium salt (SIS) (Scheme 2.3).99  Using this reagent carbohydrate 2.7 and many others 








































Scheme 2.3.  SIS 2.10 as a sulfating agent in the preparation of TCE-protected carbohydrate 
sulfates. 
 
 Yong Liu, a former graduate student in the Taylor group, carried out some 
preliminary studies on the stability of TCE-protected aryl sulfates.  He found that they are 
remarkably stable to acids such as TFA, TFA containing 5% of 30% HBr/AcOH, 30% 
HBr/AcOH, and 4 M HCl in dioxane over a period of 24 h at room temperature (rt).  They 
are also stable to weak organic bases such as 10% Et3N in CH2Cl2, 20% N-ethylmorpholine 
in CH2Cl2 for at least 24 h, 2 equiv of aqueous LiOH in THF at 0 °C for 30 min, and 
NaBH4/MeOH.  However, they are not stable to an excess of the organic bases that are 
commonly used to remove the Fmoc group during Fmoc SPPS such as 20% piperidine in 
DMF, 50% morpholine in DMF or excess DBU in DMF.98  Thus, it appeared that no current 
sulfate protecting group was suitable for Fmoc SPPS. 
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2.2  Objectives 
 The objective of the work presented in this chapter is to develop a sulfate protecting 
group that has properties compatible with Fmoc SPPS and to use this protecting group to 




2.3  Results and Discussion 
 We reasoned that the design of a new sulfate protecting group that is compatible with 
Fmoc SPPS would be more readily achieved if we knew more about how such esters react 
with bases such as piperidine.  We focussed our initial studies on TCE-protected sulfate 
esters since a detailed investigation into how TCE sulfate esters react with bases such as 
piperidine had not been performed. 
2.3.1  Stability of TCE aryl sulfates to piperidine 
 Stability studies in 20% piperidine in DMF were performed using compound 2.11 as 
a model ester (Scheme 2.4).  Initially, we assumed that the TCE-protected sulfate esters 
would react with piperidine by one of two different pathways.  The piperidine would attack 
the sulfur atom resulting in loss of phenol (2.12) (the better leaving group based on pKa’s) 
(pathway I, Scheme 2.4).  Alternatively, the nucleophile could attack the methylene carbon 
of the TCE group resulting in loss of the TCE group and the formation of phenyl sulfate 
(2.13).  However, 1H-NMR studies of compound 2.11 in 20% piperidine/DMF-d7 revealed 
that relatively rapid elimination of HCl occurs first to give the dichlorovinyl (DCV) ester 2.14 
(Scheme 2.5). The piperidinium hydrochloride formed in the reaction immediately 
precipitated out of solution and was isolated by filtration and identified by 1H NMR. 
Compound 2.14 then underwent a slower reaction resulting in the formation of various 
















































Scheme 2.5.  Decomposition of ester 2.11 in piperidine/DMF 
 
 Although the TCE group was clearly unstable to the usual bases that are used in Fmoc 
SPPS, it was reasoned that if a base could be found that would not attack the sulfur atom of a 
dichlorovinyl (DCV)-protected sulfate ester yet be capable of rapid Fmoc removal then the 
DCV group should be employable as a sulfate protecting group during the SPPS of sTyr 
peptides.  It was reasoned further that such a base would have to be more sterically 
encumbered than piperidine yet have a basicity that was similar to piperidine.  With a more 
sterically hindered base the elimination of HCl from the TCE group would probably proceed 
at a rate similar to piperidine since the steric requirement for elimination reactions involving 
proton removal tend to be rather small while the second step of the reaction, attack on sulfur, 
would proceed more slowly compared to piperidine since the steric requirement for 
substitution reactions in general tend to be fairly large.  Recently, Hachmann and Lebl 
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reported that Fmoc deprotection of Fmoc-Ile attached to chlorotrityl resin using readily 
available 2-methylpiperidine (2-MP) occurred with a half-life that was only 1.5 times greater 
than that of piperidine.101  This lead to efforts to determine if DCV-protected sulfate esters 
are stable to 2-MP. 
2.3.2  Stability studies on dichlorovinyl ester 2.14 
In 20% 2-MP/DMF-d7, compound 2.11 still underwent elimination to give DCV-
protected compound 2.14 (accompanied by the precipitation of the hydrochloride salt of 2-
MP) as determined by 1H-NMR.  However, we were pleased to find that no further 
decomposition of 2.14 occurred even after several days at rt.  We were even able to isolate 
compound 2.14 from the reaction mixture and unequivocally identify it by NMR and mass 
spectrometry.  We subjected the isolated 2.14 to 20% 2-MP/DMF-d7, and, as expected, it 
exhibited little or no decomposition even after 5 days at rt.  In 20% piperidine/DMF-d7 it 
began to show significant decomposition after about 4 h. 
With compound 2.14 in hand we were also able to evaluate its stability in acid.  We 
were pleased to find that compound 2.14 was stable to 98%TFA/2% triisopropylsilane (TIPS 
or TIS) for 6 h, conditions that have been used to remove peptides from resins and to 
deprotect the side chains in Fmoc-based SPPS.  
2.3.3  Removal of the DCV group. 
If the DCV group is to be used for SPPS, it was necessary to find a very mild method 
for its removal.  We examined the reducing conditions that we developed to remove the TCE 
group; however these were not very effective (Table 2.1, entries 1 and 2).  Using palladium 
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black instead of Pd/C we were able to effect some loss of the DCV group but the reaction 
was slow (entry 3).  However, we found that using a combination of H2 and ammonium 
formate as the hydrogen sources the DCV group could be removed in good yield using either 
Pd/C or Pd0 (entries 4 and 5). 
















% Yield 2.13 






starting material 6/6, 24 h then 6/6, 24 h Zn/HCO2NH4a 1 
starting material 10/6, 24 h then 10/6, 24 h 10 % Pd/C/HCO2NH4 2 
Incomplete reaction 5/6, 24 h then 20/6, 24 h Pd0/ and 10 % Pd/C/ 
HCO2NH4 
3 
82%  20/6, 24 h Pd0/HCO2NH4 , H2    (1 
atm) 
4 
85%  30/6, 24 h  10 % Pd/C /HCO2NH4, 
H2 (1 atm) 
5 
 
2.3.4  2-MP as a base for Fmoc SPPS 
Although the DCV group looked promising, it appeared that it would only be possible 
to use the DCV group to protect the sulfate group of sTyr during SPPS if 2-MP could be used 
in place of piperidine during SPPS.  To determine if this was the case we compared 2-MP to 
piperidine in SPPS by preparing a simple model hexapeptide DADEYLNH2 (2.16) using 
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both bases.  Hexapeptide 2.16 corresponds to a sequence within the epidermal growth factor 
receptor.  It was chosen as a model peptide since we expected that sulfation of the tyrosine 
residue would yield a peptide that would be a good inhibitor of protein tyrosine phosphatase 
1B (PTP1B).102  PTP1B is involved in the down regulation of insulin signaling and inhibitors 
of PTP1B are being examined as drugs for treating type II diabetes.  The synthesis was 
conducted manually using Rink amide resin (this resin provides the final peptide product 
with a carboxamide terminus) and employing 4 equiv HBTU/HOBT as coupling agents in 
presence of diisopropylethylamine (DIPEA) and 1.5 h coupling times.  After the coupling of 
each Fmoc amino acid the peptide was subjected to 3 x 10 min of 20% 2-MP/DMF as 
opposed to the standard 2 x 10 minutes protocol when piperidine is used.  The completed 
peptides were cleaved from the resin using 98% TFA/2% TIPS then precipitated in ether.  
The HPLC chromatogram of the two crude peptides (Figures 2.1 A and B) consisted of 
mainly a large single peak which corresponded to the desired product (confirmed by ESMS). 
However, in case of using 2-MP the crude appeared to be cleaner (Figures 2.1 A vs B), 















Figure 2.1.  Analytical HPLC chromatograms of the DADEYLNH2 peptide (2.16) obtained 




2.3.5  Synthesis of DCV esters of aryl sulfates 
The next step was to devise a method for introducing the DCV sulfate ester group 
into an appropriately protected tyrosine derivative.  We envisioned that the best way to 
prepare DCV sulfates was to design a new SIS capable of introducing the sulfate group in its 
DCV-protected state.  The general approach is outlined in Scheme 2.6.  TCEOSO2Cl (2.1) 
would be reacted with 2-methylimidazole (2-MI) in the presence of Et3N to give compound 
2.17.  2.17 would be reacted in situ with an additional base to effect elimination of HCl and 
give the corresponding DCV sulfurylimidazole (2.18).  Treatment of 2.18 with methyl triflate 
or trimethyloxonium tetrafluoroborate should give the desired DCV sulfuryl imidazolium salt 
(DCV-SIS).  Reaction of the DCV-SIS with an Nα-, Cα-protected tyrosine derivative would 








































Scheme 2.6.  Proposed scheme for the preparation of DCV-protected sTyr. 
 
Compound 2.17 was prepared by reacting 2.1 with one equiv 2-MI and 2 equiv Et3N 
in CH2Cl2, a procedure adapted from an unpublished procedure developed by Ahmed Desoky 
in the Taylor group. After 5 hours of stirring at room temperature, 20 equivalents of 
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piperidine were added (almost the same number of equiv used in the initial stability studies 
discussed above) and the reaction was allowed to stir overnight. After an aqueous work up 
using 0.1 N HCl and purification 2.18 was obtained but in poor yield (Table 2.2, entry 1).  
Attempts to increase the yield by increasing the number of equivalents of piperidine or 
running the reaction at higher temperature resulted in an increase in yield but the yields were 
still moderate (entries 2 and 3).  It was suspected that the low yields may have been due to 
the aqueous workup.  Thus the solvent was changed to THF which resulted in the rapid 
precipitation of the piperidinium hydrochloride which could be removed by filtration.  The 
filtrate was concentrated in vacuo and the residue applied to a silica gel column.  However, 
again the yield was moderate (entry 4).  Decreasing the equivalents of piperidine and 
increasing the reaction time or changing the base to DIPEA or morpholine still resulted in 
low yields (entries 5-10).   Fortunately, an appreciable increase in the yield was obtained 
using the stronger base DBU (entries 11-13).  Finally, it was possible to obtain 2.18 in an 
88% yield by increasing the number of equivalents of 2-MI to 3.6 and using 1.5 equivalents 
of DBU as the only base (besides 2-MI) and performing an aqueous. workup using phosphate 






















1 1 2 Piperidine (20) CH2Cl2, rt, O/N, aq.work up 20 
2 1 2 Piperidine (25) CH2Cl2, rt, O/N, aq. work up 43 
3 1 2 Piperidine (20) CH2Cl2, reflux, 5 h, aq. work up 50 
4 1 2 Piperidine (20) THF, rt, O/N, no work up 55 
5 1 2 Piperidine (15) THF, rt, O/N, no work up 40 
6 1 2 Piperidine (15) THF, rt, 48 h , no work up 47 
7 1 2 Piperidine, (10) THF, rt, 4 days, no work up 46 
8 1 2 Piperidine (5) THF, rt, 4 days , no work up 48 
9 1 2 Morpholine (20) THF, rt, 7 days, no work up 20 
10 1 2 DIPEA (5) THF, rt, 7 days, no work up 10 
11 1 2 DBU (1) THF, rt, O/N, no work up 60 
12 1 2 DBU (2.5) THF, rt, O/N, aq. work up 69 
13 1 0 DBU (2) THF, rt, O/N, no work up 60 
14 3.6 0 DBU (1.5) THF, rt, 3 h, aq. work up 88 
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Attention was then turned to the formation of the SIS.  SISs are too unstable to be 
chromatographed.  Thus it was necessary to develop conditions that would result in the 
precipitation of the SIS in pure form.  The reaction of 2.18 with methyl triflate (2.19) in 
different solvents gave a semisolid composed of a mixture of starting materials and product 
(2.21) and it was not possible to isolate 2.21 in pure form by precipitation (Table 2.3, entries 
1-3).  However, upon changing to trimethyloxonium tetrafluoroborate (2.20) it was possible 
to obtain the tetrafluoroborate salt 2.22 in 83% yield (entry 4).  This was achieved by 
performing the reaction in CH2Cl2 for 5 h and then removing the solvent by rotary 
evaporation.  Trituration of the 2.22 using hot THF followed by filtration gave pure 2.22.  
Attempts to increase the yield even more by changing the solvent failed to give better results; 
indeed it appears that DCM is the optimum solvent for this reaction.  Finally, it was possible 
to obtain SIS 2.22 in 95% yield by letting the reaction proceed for 16 h followed by the 










Table 2.3.  Synthesis of sulfating agent 2.22. 
 
aND = Not determined. Mixture of starting material and product as semisolids. 
 Reagent 2.22 was tested as a sulfating reagent by reacting it (3.0 equiv) with phenol 
in the presence 3.0 equiv of 1,2-dimethylimidazole (1,2-DMI) in methylene chloride.  This 
gave ester 2.14 in 92% yield (Scheme 2.7).  Encouraged by these results we then turned our 
attention to preparing FmocTyr(SO3DCV)OH (2.23).  To prepare 2.23, FmocTyrOtBu 
(2.24)103 was reacted with 3 equiv of 2.22 in the presence of 1,2-DMI to give DCV ester 2.25 
in 94% yield (Scheme 2.8).  After the removal of the tert-butyl group using TFA the desired 
compound 2.23 was obtained in 92% yield (an overall yield of 86%, Scheme 2.8).  
Entry Alkylating agent Solvent Reaction conditions % Yield 2.21 or 2.22 
1 2.19 Ether - 20-0 oC, rt, 5 h NDa 
2 2.19 CH2Cl2 0 oC, 5 h NDa 
3 2.19 THF 0 oC, 5 h NDa 
4 2.20 CH2Cl2 rt, 5 h 83 
5 2.20 THF rt, 5 h NDa 
6 2.20 CH3CN rt, 5 h NDa 















































Scheme 2.8.  Synthesis of DCV Fmoc-tyrosine sulfate building block 2.23 using reagent 
2.22. 
 
 Since the TCE group breaks down to give the more stable DCV group in 20% 2-
MP/DMF, we also prepared TCE-protected amino acid 2.26 (Scheme 2.9).  Thus, reaction of 
2.24 with 3.0 equiv of 2.1 in presence of 2.0 equiv Et3N and 1 equiv DMAP gave amino acid 




















3 equiv  2.1
rt, 24 h
 




2.3.6  Determination of the enantiomeric purity of 2.23 and 2.26 
The enantiopurities of 2.23 and 2.26 were determined by comparing the HPLC 
chromatograms and 1H-NMR’s of dipeptides Ac-Y(SO3DCV)-A(L)-NH2 (2.28LL) and Ac-
Y(SO3TCE)-A(L)-NH2 (2.29LL) to that of dipeptides Ac-Y(SO3DCV)-A(DL)-NH2 
(2.28LD/2.28LL) and Ac-Y(SO3TCE)-A(DL)-NH2 (2.29LD/29LL).  These dipeptides were 
prepared using the same protocol described for the preparation of hexapeptide 2.16 using 2-
MP for Fmoc removal. 
As expected, the diastereomeric dipeptide mixture Ac-Y(SO3DCV)-A(DL)-NH2 
showed two peaks in the HPLC trace and two sets of peaks in the 1H-NMR spectrum 
corresponding to peptides 2.28LD and 2.28LL (Figure 2.2 and 2.3). Peptide Ac-
Y(SO3DCV)-A(L)-NH2 showed almost one peak in the HPLC trace and one set of peaks in the 
1H-NMR spectrum corresponding to peptide 2.28LL (Figures 2.4 and 2.5).  Based on peak 















































































































































































































































































































































































Figure 2.2.  300 MHz 1H-NMR (CD3OD) spectrum of diastereomeric dipeptides Ac-













Figure 2.3.  Analytical HPLC chromatogram of diastereomeric dipeptides Ac-Y(SO3DCV)-
A(DL)-NH2 (2.28LD and 2.28 LL).   
 
2.28LD and 2.28LL 
2.28LD and 2.28LL 
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Ac-Y(SO3TCE)-A(LD)-NH2 showed two sets of peaks in the 1H-NMR corresponding 
to diastereomeric dipeptides 2.29LD and 2.29LL (Figure 2.6).  Small amounts of the 
diastereomeric dipeptides 2.28LD and 2.28LL were also evident (as indicated by two 
singlets at 7.56 and 7.58 ppm) which were formed by the action of 2-MP on the TCE 
protecting group during peptide synthesis. Ac-Y(SO3TCE)-A(DL)-NH2 showed four peaks in 
its HPLC chromatogram (Figure 2.7).  Two of these (the larger set) correspond to (2.29LD 
and 2.29LL).  The two extra smaller set of peaks correspond to 2.28LD and 2.28LL.  The 
amount of 2.28LD and 2.28LL present in the HPLC chromatogram appears to be 
considerably greater than that indicated by NMR.  For HPLC analysis, the detector was set to 
220 nm and this apparent discrepancy is due to the greater absorbance of the DCV group at 
220 nm in comparison to the TCE group.  






































































































































































































































































































Figure 2.6.  300 MHz 1H-NMR (CD3OD) spectrum of diastereomeric dipeptide Ac-
Y(SO3TCE)-A(LD)-NH2 (2.29LD and 2.29LL).  Note that a small quantity of diastereomeric 
dipeptides 2.28LD and 2.28LL (as indicated by the two singlets at 7.56 and 7.58 ppm) is also 
present which was formed during peptide synthesis.  
















Figure 2.7.  Analytical RP-HPLC chromatogram (λ = 220 nm) of diastereomeric dipeptide 
Ac-Y(SO3TCE)-A(LD)-NH2 (2.29LD and 2.29LL, tR= 38.9 and 40.4 min).  Note the presence 
of diastereomeric dipeptides 2.28LD and 2.28LL formed during peptide synthesis (tR= 34.9 
and 36.8 min).  In comparison with the 1H-NMR of this mixture (Figure 2.6) the amount of  
2.28LD and 2.28LL present appears to be considerably greater.  This is due to the greater 
absorbance of the DCV group at 220 nm in comparison to the TCE group.   
 
Peptide Ac-Y(SO3TCE)-A(L)-NH2 showed peaks in the 1H-NMR corresponding to 
peptide 2.29LL.  2.28LL was also present as indicated by the small peak at 7.56 ppm.  This 
was again due to the action of 2-MP on the TCE group (Figure 2.8).  No peaks 
corresponding to 2.29DL or 2.28DL were evident. The HPLC chromatogram showed two 
peaks, one corresponding to 2.29LL and the other corresponding to 2.28LL (Figure 2.9).  
No peaks corresponding to 2.29DL or 2.28DL were evident.  These results indicate that 




















































































































































































































































Figure 2.8.  300 MHz 1H-NMR (CD3OD) spectrum of dipeptide dipeptide Ac-Y(SO3TCE)-
A(L)-NH2 (2.29LL).  A small quantity of dipeptide 2.28LL is also present (as indicated by the 















Figure 2.9.  Analytical RP-HPLC chromatogram (λ = 220 nm) of dipeptide Ac-Y(SO3TCE)-
A(L)-NH2 (2.29LL, tR = 38.9 min).  Note the presence of dipeptide 2.28LL (tR = 34.9 min) 
that was formed during peptide synthesis.  In comparison with the NMR of this mixture 
(Figure 2.8) the amount of 2.28LL present appears to be considerably greater.  This is due to 





2.3.7  Synthesis of model sulfated compound DADEsYLNH2 (2.30)  
Both the DCV and TCE-protected amino acids 2.23 and 2.26 were examined as 
building blocks in the synthesis of a simple model monosulfated compound DADEsYLNH2 
2.30 using 2-MP for Fmoc removal.  Manual SPPS was performed on a Rink amide resin and 
using the same conditions described above for the synthesis of the DADEYLNH2 (2.16) 
peptide.  When TCE-protected building block 2.26 was used the hydrochloride salt of 2-MP, 
which was produced during each Fmoc removal, formed a precipitate although most of this 
precipitate was removed by treatment with CH2Cl2 after each Fmoc deprotection. Using 
DCV-protected amino acid 2.23, the HPLC chromatogram of the crude peptide before DCV 
removal showed mainly a single peak corresponding to DADEY(SO3DCV)LNH2 (2.31, 
Figure 2.10) as confirmed by mass spectrometry analysis.  Using TCE-protected amino acid 
2.26, the HPLC chromatogram of the crude peptide before hydrogenolysis showed mainly 
two major peaks in an apparent 1:1 ratio corresponding to DADEY(SO3DCV)LNH2 (2.31) 
and DADEY(SO3TCE)LNH2 (2.32) (Figure 2.11) as confirmed by mass spectrometric 
analysis.  No peaks corresponding to the desulfated peptide or 2-MP-sulfonamide peptide 
(from attack of 2-MP on the sulfur of the DCV-protected sulfate group) were detected in 
either case.  To remove the DCV and TCE groups, the crude cleaved peptides were subjected 
to 30 wt% of 10% Pd/C, H2 gas (balloon) and 9 equiv of ammonium formate in MeOH at rt 
for 1-3 h.  The HPLC chromatogram of the crude peptides consisted of mainly a single peak 
which corresponded to peptide 2.30 and again no peak corresponding to the desulfated 
peptide was detected as confirmed by the coinjection with its unsulfated analogue 2.16 




Figure 2.10.  Analytical HPLC chromatogram of the crude DADEY(SO3DCV)LNH2 (2.31) 
obtained using amino acid 2.23. 
 
 
Figure 2.11.  Analytical HPLC chromatogram of the crude hexapeptides 






Figure 2.12.  Analytical HPLC chromatogram of the hexapeptide DADEsYLNH2 (2.30) 
obtained using amino acid 2.23 as building block. 
 
 
Figure 2.13.  Analytical HPLC chromatogram of crude DADEsYLNH2 (2.30) (tR= 14.1 min) 
SPIKED with hexapeptide DADEYLNH2 2.16 (tR= 15.2 min).  This experiment further 




When 2.23 was used as the building block, pure peptide 2.30 was obtained in a 71% 
yield after RP-HPLC purification.  When 2.26 was used as the building block, peptide 2.30 
was obtained in about a 45% yield.  The lower yield using 2.26 was a result of our repeated 
attempts to remove a small amount of an unidentified impurity that exhibited a very similar 
retention time to 2.30 which we were unable to completely remove.  In addition to the usual 
techniques for analyzing peptides (mainly HPLC and electrospray mass spectrometry 
(ESMS)), we also found that we could readily determine if any desulfated peptide was 
present after purification by 1H-NMR.  Figures 2.14 and 2.15 shows the 1H-NMR’s of the 
aromatic regions of peptide 2.16 (DADEYLNH2) and peptide 2.30 (DADEsYLNH2) 
respectively.  It is very clear from these spectra that peptide 2.30 is not contaminated with 







































































Figure 2.15.  500 MHz 1H NMR (D2O) spectrum of the aromatic region of pure 
DADEsYLNH2 (2.30) obtained using amino acid 2.23. 
 
2.3.8  Synthesis of more complex sulfated peptides 
To demonstrate the broad applicability of our methodology we prepared more 
complex sulfated peptides which contained various numbers of sTyr residues and a wide 
range of amino acid residues.  Although both 2.23 (DCV-protected) and 2.26 (TCE-
protected) could be used to prepare sTyr peptides, 2.23 was used for all of our future studies.  
One reason is because the yield of the model hexapeptide 2.30 was greater using 2.23.  
Another reason has to do with the synthesis of multisulfated peptides:  when using 2.26, 
some of the TCE group is converted into the DCV group during peptide synthesis which 
means that the crude HPLC chromatograms of peptides bearing multiple sTyr residues 
(before TCE/DCV removal) could be very complex making it difficult to assess the quality of 
the peptide before TCE/DCV removal.   
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First, we prepared the trisulfated octapeptide, AcsYEsYLDsYDFNH2 (2.33) which 
corresponds to residues 5-12 of mature P-selectin glycoprotein ligand 1 (PGSL-1, see chapter 
1, section 1.2.1).22  This peptide has been synthesized by others in a 27% yield using a global 
sulfation strategy (see chapter 1, page 36).91  The synthesis was done using a Quartet 
automated peptide synthesizer from Protein Technologies at 25 μM scale (all subsequent 
peptides throughout this chapter were prepared using the Quartet peptide synthesizer).  In 
general, each coupling cycle started with an Fmoc removal step (3 x 10 min) followed by a 
washing step then a coupling step using HBTU/HOBt in the presence of DIPEA for 1.5 h 
except for the first amino acid which coupled as a pentafluorophenyl ester in the presence of 
HOBt (applying double coupling for 1.5 h each).  Cleavage from the resin was done using 
5% TIPS in TFA and the peptide was precipitated with t-butyl methyl ether.  The analytical 
RP-HPLC chromatogram of the DCV-protected peptide, 
AcY(SO3DCV)EY(SO3DCV)LDY(SO3DCV)DFNH2 (2.34), shows one major peak in 
addition to several minor peaks (Figure 2.16).  Pure 2.33 was obtained in a 46% yield after 
removal of the three DCV groups using 50 wt% of 10% Pd/C in presence of 21 equivalent of 





Figure 2.16.  Analytical HPLC chromatogram of the crude octapeptide 
AcY(SO3DCV)EY(SO3DCV)LDY(SO3DCV)DFNH2 (2.34, tR= 44.3 min).  Note that the 











The monosulfated octapeptide AcYEsYLDYDFNH2 (2.35) was also prepared since 
others reported difficulties in preparing this peptide using a global sulfation strategy and 
were able to obtain this peptide in only a 5% yield.91  Applying the protocol described above 
for the trisulfated analogue 2.33, the DCV-protected monosulfated octapeptide 
AcYEY(SO3DCV)LDYDFNH2 (2.36) appeared as mainly a single peak in the analytical 
HPLC chromatogram after cleavage from the support and precipitation with ether (Figure 
2.18).  After hydrogenolysis using 50 wt% of 10% Pd/C in the presence of 9 equiv of 
ammonium formate under hydrogen atmosphere, we obtained pure peptide 2.35 in a 63% 
yield and the analytical HPLC chromatogram for this peptide is shown in Figure 2.19.   This 
represents a dramatic increase in yield compared to a previous report of 5% as mentioned 
above. 
 
Figure 2.18.  Analytical HPLC chromatogram of the crude peptide 





Figure 2.19.  Analytical RP-HPLC chromatogram of pure AcYEsYLDYDFNH2 (2.35, tR= 
15.9 min). 
 
In order to demonstrate conclusively that no desulfation occurs during the synthesis 
steps we prepared the nonsulfated analogue AcYEYLDYDFNH2 (2.37).  The analytical 
HPLC chromatogram for this purified peptide is shown in Figure 2.20.  The 1H NMR’s of 
the aromatic regions of peptides 2.33, 2.35 and 2.37 are shown in Figures 2.21-2.23 
respectively.  The aromatic tyrosyl protons for the unsulfated peptide 2.37 between 6.35 ppm 
to 6.80 ppm (set # 1) while the aromatic protons for the Phe residue appear between 6.9 ppm 
to 7.1 ppm (set #2)  (Figure 2.23). Sulfation of one tyrosyl moiety (peptide 2.35) resulted in 
a downfield shift of four protons from the first to second set (Figure 2.22).  When the three 
tyrosyl moieties are sulfated (peptide 2.33) all the aromatic protons appear above 6.7 ppm 
(Figures 2.21). These NMR experiments, in conjunction with our HPLC and MS results, 



















































































































































































































Figure 2.22.  500 MHz 1H-NMR (D2O) of the aromatic region of pure AcYEsYLDYDFNH2 




























































































































Next the attention was turned to an even more challenging target, a multisulfated 
peptide derived from the N-terminal region of chemokine receptor D6 (see chapter 1, section 
section 1.2.2.2 for a discussion of D6).  Although it is known that D6 is sulfated in its N-
terminal region, it is not known which tyrosines are sulfated.59  The Sulfinator, a software 
tool that predicts tyrosine sulfation sites in protein sequences,104  predicted that tyrosine 
residues 23, 24, 25 and 27 are all potential sulfation sites and it is possible that all four are 
sulfated.  Therefore, we decided to prepare a tetrasulfated 20-mer, Ac-
DADSENSSFsY23sY24sY25DsY27LDEVAFNH2 (2.38) that corresponds to residues 14-33 in 
D6.  With its four sY residues three of which occur consecutively and with a total of 10 
acidic residues (acidic residues are known to have a destabilizing effect on sY residues in 
peptides) this peptide represents a particularly stringent test of our methodology.  
Our first trial to prepare 2.38 employing our usual coupling procedure (5 equiv of 
HBTU/HOBt, 5 equiv DIPEA and 5 equiv  amino acid for 1.5 h) and using 2-MP for Fmoc 
removal (3 x 10 min) failed to give the desired DCV-protected peptide very cleanly as the 
crude analytical HPLC chromatogram showed many peaks.  Repeating the synthesis with the 
incorporation of a capping step after each coupling cycle (treating the peptide with 
Ac2O/pyridine after each coupling cycle to acetylate any remaining free amino groups), or 
performing double couplings together with capping did not improve the synthesis 
significantly.  However, analysis of the major peaks in the HPLC trace of the latter trial 
showed the desired DCV-protected peptide 
AcDADSENSSF(DCV)Y23(DCV)Y24(DCV)Y25D(DCV)Y27LDEVAFNH2 (2.39) along with deletion 
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peptides resulting from incomplete coupling between DCV-protected residue 25 and 24 or 24 
and 23 (Figure 2.24).  
 
Figure 2.24.  Analytical HPLC chromatogram of the mixture obtained after cleavage from 
the resin from the synthesis of peptide 2.39 using HBTU/HOBt as coupling agents and 
capping using Ac2O/pyr. The peak at tR = 45.2 min corresponds to 
AcDADSENSSF(DCV)Y23(DCV)Y24(DCV)Y25D(DCV)Y27LDEVAFNH2 (2.39) which is the desired 
DCV-protected peptide.  The peak at tR = 40.6 min corresponds to the deletion peptide 
AcDADSENSSF(DCV)Y(DCV)Y25D(DCV)Y27LDEVAFNH2.  The peak at tR = 32.7 min 
corresponds to the deletion peptide AcY25D(DCV)Y27LDEVAFNH2.   
 
It was then decided that the coupling agent HCTU, which has been reported to be a 
better coupling agent than HBTU yet of almost similar price, should be used.105 After the 
application of double couplings for 45 min using HCTU/HOCt followed by capping, the 
crude HPLC chromatogram showed a major peak corresponding to our desired peptide 2.38 






Figure 2.25.  Analytical HPLC chromatogram of the mixture obtained after cleavage from 
the resin from synthesis of peptide 2.39 using HCTU/HOCt as coupling agents and capping 
using Ac2O/pyr. The peak at  tR= 44.88 min corresponds to the desired peptide 
AcDADSENSSF(DCV)Y23(DCV)Y24(DCV)Y25D(DCV)Y27LDEVAFNH2 (2.39). 
 
In order to determine if the difficulties in making this peptide arose from intrinsic 
nature of the peptide or due to the presence of the DCV groups we prepared the unsulfated 
20-mer, AcDADSENSSFY23Y24Y25DY27LDEVAFNH2 (2.40) using the HCTU protocol 
mentioned above.  After cleavage from the support, the crude HPLC trace showed many 
peaks (Figure 2.26) indicating that the difficulty of the synthesis was not probably stemming 





Figure 2.26.  Analytical HPLC chromatogram of the mixture obtained after cleavage from 
the resin during the synthesis of peptide 2.40 using the HCTU/HOCt protocol. 
 
In order to improve the synthesis of 2.38, residues 23, 24 and 25 were incorporated 
using HATU/HOAt, an even stronger coupling agent.106  This significantly improved the 
quality of the crude peptide 2.39 as indicated by analytical RP-HPLC (Figure 2.27).  The 
deprotection of sTyr residues was achieved using 50 wt% of 10% Pd/C in the presence of 30 
equiv HCOONH4 under one atm. H2 which gave the desired sulfated peptide 2.38 in a 39% 
yield after HPLC purification (Figure 2.28). 
 
Figure 2.27.  Analytical HPLC chromatogram of the mixture obtained after cleavage from 
the resin from the synthesis of peptide 2.39 using the HCTU/HOCt-HATU/HOAt protocol 





Figure 2.28.  Analytical HPLC chromatogram of pure 
AcDADSENSSFsYsYsYDsYLDEVAFNH2 (2.38). 
 
Encouraged by the above successful results on the 20-mer from D6, we also prepared 
the disulfated 22-mer Ac-TTPDsYGHsYDDKDTLDLNTPVDKNH2 (2.41) which 
corresponds to residues 7-28 of C5aR (see chapter 1, section 1.2.3 for a discussion of C5aR).  
The disulfated 22-mer contains two sTyr residues as well as a variety of basic and acidic 
amino acid residues.  The synthesis was done automatically on a Quartet peptide synthesizer 
using Rink amide resin and applying the usual Fmoc-deprotection protocol.  HCTU/HOCt in 
the presence of DIPEA was used for couplings.  After cleavage from the support, the HPLC 
trace showed one major peak corresponding to the DCV-protected peptide 
AcTTPD(DCV)YGH(DCV)YDDKDTLDLNTPVDKNH2 (2.42) as confirmed by mass 
spectrometry (Figure 2.29).   Deprotection of the DCV groups was done using 50 wt% of 
10% Pd/C in the presence of 19 equiv HCOONH4 under a hydrogen atmosphere which gave 




Figure 2.29.  Analytical HPLC chromatogram of crude 









2.3.9  An improved synthesis of amino acid 2.23. 
Before attempting to prepare any other sTyr peptides, we wished to devise a more 
economical approach to the synthesis of the key amino acid 2.23.  In SPPS, the amino acid 
building blocks are used in considerable excess and so it is important that economical 
methods are available for their preparation.  Our current approach utilizes reagent 2.22 whose 
preparation involves a three step synthesis and requires expensive trimethyloxonium 
tetrafluoroborate (2.20).  We wished to devise a method for preparing 2.23 without using 
reagent 2.22.  The key to the preparation of 2.22 in high yield was the use of DBU to effect 
elimination of HCl from 2.17 to give compound 2.18 (Scheme 2.6).   We reasoned that if we 
incorporated our TCE sulfate using Cl3CCH2OSO2Cl (2.1) into amino acid 2.43 and then 
subjected the resulting amino acid 2.44 to DBU we should be able to obtain amino acid 2.45 
(Scheme 2.10).  Removal of the Boc and tert-butyl groups using TFA followed by reaction 




























Scheme 2.10.  Potential alternative route to amino acid 2.23. 
  
Compound 2.44 was prepared using our optimized conditions (2.43/DMAP/Et3N) for 
the introduction of 2.1 into phenol derivatives98 except ether was used as solvent instead of 
THF since we anticipated that the triethylammonium hydrochloride formed in the reaction 
would precipitate out better in ether and so be easier to remove.  The reaction was allowed to 
proceed overnight (about 12 h, reaction complete as determined by TLC) and the mixture 
was filtered.  Compound 2.44 was not purified.  One equiv of DBU was added to the filtrate 
every hour until all of 2.44 was consumed as determined by TLC (this required 3 equiv of 
DBU).  The hydrochloride salt of DBU that was produced during the reaction was formed as 
thick, glue-like oil.  Nevertheless, the mixture was filtered and the filtrate was concentrated 
and the residue was purified by silica gel flash chromatography. We were pleased to find that 
this gave compound 2.45 albeit in a modest 62% yield (Table 2.4, entry 1).  We then 
attempted the synthesis using THF as solvent hoping that the hydrochloride salt of DBU 
would form a precipitate and be easier to remove by filtration.  This did indeed turn out to be 
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the case; however a slightly larger quantity of DBU (3.5 equiv) was required to consume all 
of 2.44.  We also performed an aqueous workup of the reaction using 2% aq. H3PO4 (to 
remove unreacted DBU) since Quagliato et al. have reported that the Boc group will 
withstand these mildly acidic conditions.107  This gave 2.45 in a 81% yield.  This reaction 
was repeated except 5 equiv of DBU was used to ensure complete conversion of 2.44 to 2.45.  
An aq. workup was performed after both steps of the synthesis except 0.05 M phosphate 
buffer (pH 7.2) was used instead of 2% H3PO4 to ensure no loss of the Boc or tert-butyl 
groups.  This gave 2.45 in an 88% yield.   










1.  3 equiv 2.1, 1 equiv DMAP
     2 equiv Et3N, 12 h
2.  DBU
 
Entry Solvent Work up DBU % Yield 
1 Et2O None 3 equiva 62 
2 THF 2% H3PO4 3.5 equivb 81 
3 THF Phosphate buffer, pH 7.2 5 equiv
c 88 
aAdded as one equiv every hour.  Total reaction time of step 2 was 4 
h.  bAdded as one equiv every hour with the last 0.5 equiv added after 
hour 3.  Total reaction time of step 2 was 5 h.  cAdded as one equiv 
every hour.  Total reaction time of step 2 was 6 h 
 
An attempt to simultaneously remove the tert-butyl and Boc groups by treating 2.45 
with 95% aqueous TFA for 1 hour followed by Fmoc installation using Fmoc-OSu according 
to a previously reported procedure108 resulted in a moderate yield of 2.23 (57% yield).  
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However, Nowick et al.109 and others110 reported that simultaneous removal of Boc and tert-
butyl groups can be accomplished in high yield by subjecting the amino acid to repetitive 
treatments with neat TFA.  Thus, 2.45 was subjected to neat TFA for 2 h and then all of the 
TFA was removed by high vacuum rotary evaporation.  This was repeated and then a third 
treatment was performed overnight.  The TFA was removed again and the residue was 
triturated with CHCl3 to give a white solid which upon treatment with FmocOSu gave 2.23 in 
a 85% yield (overall yield of 75%) (Scheme 2.11) 
 
 
Scheme 2.11.  Synthesis of 2.23 from 2.45.   
The enantiopurity of 2.23 synthesized from 2.45 was determined via the synthesis of 
dipeptides peptides Ac-Y(SO3DCV)-A(L)-NH2 (2.28LL) and Ac-Y(SO3DCV)-A(DL)-NH2 
(2.28LD/2.28LL) followed by analysis by HPLC and 1H-NMR as previously described in 
section 2.3.6.  The HPLC chromatograms of these peptides are shown in Figures 2.31 and 
2.32 and the 1H-NMR spectra are shown in Figures 2.33 and 2.34.  Comparing the 1H-NMR 
spectra of 2.28LL (Figure 2.34) to that of the 2.28LD/2.28LL mixture (Figure 2.33) it 
appears that none of the undesired diastereomeric peptide (the DL isomer) is present in 
Figure 2.34 which suggests that 2.33 was prepared in very high ee.  On the other hand, the 
HPLC chromatogram of 2.28LL (Figure 2.32) exhibits a large peak corresponding to the 
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desired LL dipeptide (at tR = 29.2 min) and a very small peak (at tR = 30.6 min) which, from 
the HPLC chromatogram of the 2.28LD/2.28LL mixture (Figure 2.31), appears to be the 
undesired DL dipeptide.  Nevertheless, integration of these peaks indicates that 2.23 was still 
obtain in very good ee (> 98 %).   
 
Figure 2.31.  Analytical HPLC chromatogram of diastereomeric dipeptides Ac-Y(SO3DCV)-
A(DL)-NH2 (2.28LD and 2.28LL).  Amino acid 2.23, prepared using the route outlined in 
Scheme 2.10, was used to prepare this mixture.   
 
Figure 2.32.  Analytical HPLC chromatogram of dipeptide Ac-Y(SO3DCV)-A(L)-NH2 
(2.28LL).  Amino acid 2.23, prepared using the route outlined in Scheme 2.10, was used to 




Figure 2.33.  1H NMR (CD3OD) spectrum of diastereomeric dipeptides Ac-Y(SO3DCV)-
A(DL)-NH2 (2.28LD and 2.28LL).  Amino acid 2.23, obtained using the route outlined in 
Scheme 2.10, was used to prepare this mixture.   
 
Figure 2.34.  1H NMR spectrum (CD3OD) of dipeptide Ac-Y(SO3DCV)-A(DL)-NH2 
(2.28LL).  Amino acid 2.23, obtained using the route outlined in Scheme 2.10, was used to 
prepare this peptide.   
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2.3.10  Exploring alternative methods for DCV removal. 
One of the concerns of our approach to sTyr peptides was that our sulfate 
deprotection conditions (hydrogenolysis) would result in partial reduction of the indole ring 
in tryptophan residues to give 2,3-dihydrotryptophan or even octahydrotryptophan. This 
phenomenon has been reported by several groups upon subjecting Trp-bearing peptides or 
Trp derivatives to H2-Pd/C111, formic acid-Pd/C,112, 113 formic acid/Pd black,114 or ammonium 
formate/Pd(OAc)2.113  Therefore we embarked on a study to find methods other than to Pd/C-
ammonium formate-H2 for removing the DCV group using 2.14 as a model substrate. 
We initially examined conditions that have been used to remove trichloroethyl-based 
protecting groups.  Zinc/triethylamine115 or zinc/triethylamine in the presence of 
acetylacetone,116 which have been used to remove the 2,2,2-trichloroethoxycarbonyl (Troc) 
group from amines and TCE moieties from TCE-protected phosphates, failed to effect 
deprotection (Table 2.5, entries 1 and 2).  Zn(Cu)/DMF117 (entry 3) successfully removed the 
DCV. However, the reaction turned deep brown upon completion with the formation of a 
heavy precipitate which we anticipated would be problematic when applied to peptides.  
Tributylphospine has been used remove the 1,1-dimethyl-2,2,2-trichloroethyl group from 
protected phosphates.118 However, this was not successful with the DCV group.  Ogilvie et 
al. utilized tetra-n-butylammonium fluoride (TBAF) to remove the TCE and phenyl groups 
from protected phosphates and they suggested that reactions via the attack of fluoride ion on 
the phosphorus atom displacing the alcohols.119  However, TBAF in presence of 
triethylamine or TBAF in presence of a nucleophilic catalyst and in less polar solvents failed 
to result in loss of the DCV group (entries 5-7).  Replacing TBAF with tetra-n-
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butylammonium iodide (TBAI), a stronger nucleophile, did not result in deprotection (entries 
8, 9).  Self-catalyzed transesterification with 2-dimethylaminoethanol at room temperature 
was adopted by Barton et al. to cleave a protected peptide linked to Merrifield resin linked 
via an ester bond.120  The resulting ester with 2-dimethylaminoethanol was easily hydrolyzed 
using aqueous sodium carbonate or simply aqueous DMF.  We thought that this procedure 
might also be effective to remove the DCV group from 2.14.  Unfortunately, 2-
dimethylaminoethanol in DMF alone or in the presence of DBU failed to give any reaction 


















Table 2.5.  Attempts to deprotect DCV using 2.14 as model compound 
 
Entry Reaction Conditions Outcome 
1 
20 equiv Zn, 6 equiv Et
3
N, MeOH, rt for 
24 h  
No reaction  
2 
20 equiv Zn, 6 equiv Et
3
N, 10 equiv  
acetyl-acetone,MeOH, rt for 24 h  
No reaction  
3 
20 equiv Zn-Cu couple, 19 equiv Et
3
N, 
10 equiv acetyl-acetone/DMF, rt for 24 h 





P, 2 equiv Et
3
N, DMF, 
rt for 24 h 
No reaction  
5 1 equiv TBAF, 2 equiv Et3N, dioxane: H2O 5:1, rt for 24 h 
No reaction 
6 1 equiv TBAF, 1 equiv DMAP,  DMF, rt for 24 h No reaction 
7 1 equiv TBAF, 1 equiv DMAP, NMP, rt for 24 h No reaction 
8 5 equiv TBAI, DMF: H2O 1:1, rt for 24 h No reaction 
9 5 equiv TBAI, 1 equiv DMAP, NMP:H2O 1:1, rt for 24 h 
No reaction 
10 10 equiv (CH3)2NCH2CH2OH, DMF, rt for 24 h No reaction 


























Scheme 2.12.  Mechanism of degradation of Dichlorvos 
Dichlorvos or 2,2-dichlorovinyl dimethyl phosphate (2.46, DDVP) is an 
organophosphorus compound widely used as a fumigant in public health, to control 
household pests and for protecting stored product from insects.121   DDVP contains a DCV 
group bonded to phosphorus and interestingly a number of studies showing that this bond is 
very labile bond and DDVP is hydrolyzed at neutral pH through the attack of water at the 
phosphorus atom and the dichlorovinylate acts as leaving group (Scheme 2.12).121-123   The 
rate of hydrolysis increases with increasing pH.124-126 These results encouraged us to examine 
whether we could remove the DCV group from peptide 2.31 by hydrolysis.  Surprisingly, no 
appreciable deprotection occurred in phosphate buffer at pH 5.5, 7.0 and 9.0 at 40 0C for 24 h 
(Table 2.6, entries 1-3).  Changing the buffer to ammonium acetate (pH 7.0) together with an 
increase in the concentration did not cause any hydrolysis (entry 4).  No loss of the DCV 
group in peptide 2.31 occurred even when it was exposed to 4 equiv NaOH in dioxane-water 





Table 2.6.  Attempts to remove the DCV from peptide DADEY(SO3DCV)LNH2 (2.31) by 
hydrolysis. 
 
Entry Reaction Conditions Outcome 
1 0.1 M Phosphate buffer, pH= 5.5, 10 mL for 10 mg 2.31 at 40 oC for 24 h No reaction 
2 0.1 M Phosphate buffer, pH= 7.0, 10 mL for 10 mg 2.31 at 40 oC for 24 h No reaction 
3 0.1 M Phosphate buffer, pH= 9.0, 10 mL for 10 mg 2.31 at 40 oC for 24 h No reaction 
4 1 M CH3COONH4, pH= 7.0, 10 mL for 10 mg 2.31 at 40 oC for 24 h No reaction 
5 4 equiv NaOH in H2O:dioxane 1:4 (0.1M NaOH) at 40 oC for 24 h, 10 mg 2.31 No reaction 
6 4 equiv NaOH in H2O:dioxane 4:1 (0.1 N NaOH) at 40 oC for 24 h, 10 mg 2.31 No reaction 
 
 After performing these studies we became aware of a paper by Medzihradszky-
Schweiger who reported that hydrogenolysis of carbobenzyloxy (CBz) protecting groups in 
Trp-bearing peptides using H2 and 10% Pd/C (MeOH as solvent) did not result in the 
reduction of the indole ring when the hydrogenolysis was performed in the presence of bases 
such as Et3N.127  This prompted us to examine whether the DCV group could be removed 
under basic hydrogenolysis conditions.  Peptide 2.31 was suspended in water and 2 drops of 
concentrated ammonium hydroxide or 5 equiv of triethylamine (1 equiv per acidic group in 
the peptide plus one extra equiv) was added which resulted in solublization of the peptide.  
Hydrogenolysis of the mixture using H2 (balloon pressure) as hydrogen source cleanly gave 
the desired peptide 2.30 in essentially quantitative yields (Table 2.7, entries 1 and 2) as 
indicated by HPLC. Pd(OH)2 worked as well as Pd/C as catalyst (entry 3).   
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Table 2.7.  Removal of the DCV from peptide DADEY(SO3DCV)LNH2 (2.31) by 
hydrogenolysis in the presence of base. 
 
Entry Reaction Conditions % Yield 2.30a 
1 30 wt% of 10 % Pd/C, H2, H2O, 2 drops of ammonium hydroxide, rt, O/N 99 
2 30 wt % of 10 % Pd/C, H2,5 equiv Et3N, H2O, rt , O/N 
99 
3 50 wt % of Pd(OH)2, H2, 5 equiv Et3N, H2O, rt , O/N 
99 
aCrude yield based on HPLC monitoring of the reaction. 
 To confirm that no hydrogenation of the indole ring in Trp would occur when 
subjected to our basic hydrogenolysis conditions, we prepared dipeptide Ac-Trp-Ala-NH2 
(2.47) and subjected it to 50 wt % of Pd(OH)2, H2 (balloon pressure), 2 equiv Et3N in H2O at 
rt for 16 h.   Figure 2.35 and 2.36 show the 1H-NMR spectrum of peptide 2.47 before and 
after the reduction, respectively. No reduction of the indole ring has occurred confirming the 




Figure 2.35.  1H-NMR (CD3OD) spectrum of peptide 2.47. 
 
Figure 2.36.  1H-NMR (CD3OD) spectrum of peptide 2.47 after being subjected to 50 wt% 
of Pd(OH)2, H2, 2 equiv Et3N for 16 h. 


















































































































































































2.3.11  Exploring the stability of the DCV group to cleavage cocktails containing sulfur-
based scavengers. 
 There were two other potential problems with our approach to sTyr peptides.  Both 
involved peptides bearing sulfur-containing amino acids.  It is well-known that sulfur-
containing compounds can poison Pd catalysts rendering them ineffective.  So we were 
initially concerned that we would not be able to use our methodology for peptides bearing 
methionine or cysteine.  However, Medzihradszky-Schweiger reported that hydrogenolysis 
of carbobenzyloxy (CBz) protecting groups in sulfur-containing peptides using H2 and 10% 
Pd/C (MeOH as solvent) proceeds readily when done in the presence of bases such as Et3N.  
So after confirming that we could remove the DCV group under these conditions (discussed 
above) this was no longer a concern to us.127  The other potential problem concerned the 
oxidation of Met residues when cleaving Met-bearing peptides from the polymer support.  
With Met-bearing peptides it is usually crucial that the cleavage cocktails contain sulfur-
based reagents such as ethanedithiol (EDT) or thioanisole as these help suppress oxidation of 
the side chain of Met.  Even for peptides that do not contain Met it is common to add these 
reagents to the cleavage cocktails since they trap the highly reactive carbocations (i.e. tert-
butyl cations from tert-butyl protecting groups) produced during the cleavage process.  
Sulfur containing scavengers like EDT and thioanisole are among the most powerful and 
common scavengers.  So far we have been adding triisopropylsilane (TIPS) to the cleavage 
cocktail to scavenge the cations. However, for Met-containing peptides EDT or thioanisole 
will also have to be present.  As mentioned in Chapter 1 (section 1.3.3) the use of EDT or 
thioanisole is prohibited when unprotected tyrosine sulfate(s) is used to construct sTyr 
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peptides since an unprotected sulfate group is unstable to such reagents.94  However, we did 
not know if the DCV group would be stable to cleavage cocktails containing EDT or 
thioanisole.  To determine this, peptide 2.31 was subjected to variety of commonly used 
cleavage cocktails that contain EDT or thioanisole (Table 2.8) for 2 h and then examined by 
HPLC.  No peptide resulting from loss of the DCV group was detected indicating that the 
DCV group is stable to these cleavage cocktails.   








2.3.12  Synthesis of CXCR61-20 
Although the studies outlined in sections 2.3.10 and 2.3.11 suggested that we could 
use our methodology for the synthesis of sTyr peptides that also have Trp as well as residues 
with sulfur-containing side chains we decided to confirm this by constructing some 
challenging sTyr peptides bearing these residues.  First, we turned our attention to the 
synthesis of a peptide that corresponds to residues 1-20 of the N-terminal region of CXCR6:  
AcMAEHDsY6HEDsY10GFSSFNDSSQNH2 (2.48) (see chapter 1, section 1.2.2.3 for a 
discussion of CXCR6).   This peptide bears a methionine residue at position 1.  As mentioned 
in Chapter 1, the N-terminal region of CXCR6 contains two sTyr residues at positions 6 and 
 
 94 
10.  The significance of the presence of tyrosine sulfates in CXCR6 is not well understood.  
To our knowledge, no sulfated peptides corresponding to any part of the N-terminal region of 
CXCR6 have been synthesized.  This turned out to be an extremely challenging peptide to 
prepare.   
Our first attempt to synthesize CXCR6 employed our usual conditions discussed 
earlier using Rink amide resin (0.71 mmol/g), 2-MP for Fmoc removal, HBTU/HOBt as 
coupling reagents (one time for 1.5 h) followed by a capping step.  After the assembly of the 
peptide chain the peptide cleavage from the resin was achieved using TFA:TIPS:H2O:EDT 
(92.5:2.5:2.5:2.5).  However, the HPLC chromatogram of the material obtained after 
cleavage showed many peaks (Figure 2.37).  The mass spectrum of the mixture did indeed 
show that the desired peptide, AcMAEHD(DCV)YHED(DCV)YGFSSFNDSSQNH2 (2.49), was 
present along with many other peptides.  
 
Figure 2.37. HPLC chromatogram of the material obtained after cleavage from the support 
from our first attempt to prepare peptide 2.49. HBTU/HOBt used as coupling reagents (one 
time for 1.5 h) followed by a capping step. 
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We then attempted to prepare 2.49 using HCTU/HOCt as coupling agents and 
performing double couplings (2 x 45 min) followed by a capping step.  Unfortunately, this 
did not improve the synthesis as indicated from the HPLC trace of the mixture after cleavage 
from the support (Figure 2.38).  The mass spectrum of the mixture showed that our desired 
peptide, 2.49, was again present.  Two other significant peaks in the mass spectrum were 
identified as having resulted from two truncated peptides corresponding to the residues 9-20 
and 10-20. 
 
Figure 2.38. HPLC chromatogram of the material obtained after cleavage from the support 
from our second attempt to prepare peptide 2.49. HCTU/HOCt as coupling agents and 
performing double couplings (2 x 45 min) followed by a capping step. 
 
Since two truncated peptides corresponding to the residues 9-20 and 10-20 were 
obtained in our previous attempt, for our third attempt we incorporated Glu8 and Asp9 using 
HATU/HOAt as coupling agents while the reminder of the amino acids where incorporated 
using HCTU/HOCt, double coupling followed by capping. The crude HPLC trace showed 
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some improvement in that the largest major peak (tR = 30.73 min) corresponded to peptide 
2.49 (Figure 2.39).  However, many other peptides were present indicating that incorporation 
of other amino acids besides residues 8 and 9 were challenging.  
  
Figure 2.39.  HPLC chromatogram of the material obtained after cleavage from the support 
from our third attempt to prepare peptide 2.49. Glu8 and Asp9 were incorporated using using 
HATU/HOAt as coupling agents while the reminder of the amino acids where incorporated 
using HCTU/HOCt.  
 
 One of the major problems involved in SPPS is poor solvation of the growing peptide 
chain which stems from aggregation of hydrophobic residues or protecting groups and/or the 
formation of secondary structures such as β-sheet formation. Such aggregation leaves a 
limited number of free amino groups available for coupling resulting in poor coupling yields.  
Over the years a number of techniques have been developed to overcome the problem of 
aggregation such as the use of mixed solvent systems for resin swelling and coupling,128-131 
running the reactions at elevated temperature,132 adding chaotropic salts to the solvent,133-136 
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and replacing the hydrogen of some of the amide moieties with a dimethoxybenzyl group. 137, 
138 More recently, a unique approach involving tethering an amido group of the amide 
backbone with the side chain hydroxyl group of a serine or threonine residue via an aldehyde 
or ketone to form oxazolidines has been developed.139-141 The formed oxazolidines have 
structural features analogous to proline and are thus called “pseudoproline”.  When 
pseudoproline is incorporated into a peptide chain it induces a kink in the peptide backbone 
which disrupts the intermolecular or intramolecular aggregations commonly experienced 
during peptide synthesis and this can result in an improvement in the yield of the peptide 
(Figure 2.40).  The pseudoprolines are converted back to serine or threonine during the acid 
conditions used for cleaving the peptide from the support and removing side chain protecting 









Figure 2.40.  Incorporating pseudoproline (ΨMe,MePro shown) into a peptide induces a kink 
in the peptide backbone.  R1 = H (if derived from serine) or R1 = CH3 (if derived from 
threonine). 
 
Consequently we decided to incorporate one of these pseudoproline residues during 
the synthesis of the 2.49. There are four possible sites within 2.49 where pseudoproline can 
be incorporated:  Ser13, Ser14, Ser18, and Ser19.  Because the latter two are near the C-
terminus it would be of minor beneficial effect to replace either of them with pseudoproline.  
So we decided to incorporate the pseudoproline at residues 13 or 14.  Pseudoprolines are 
 
 98 
incorporated into peptides as dipeptides: Fmoc-AA-ΨPro-OH.   FmocSer(tBu)ΨMe,MeProOH 
(2.50, Scheme 2.13) is a known compound and is even commercially available.  Therefore 
we elected to replace Ser14 with ΨMe,MePro.  Although 2.50 is commercially available it is 
very expensive so we decided to synthesize it according to Scheme 2.13.139-141  The 
succinimide ester of FmocSer(OtBu)OH (2.52) was prepared through the reaction of the 
amino acid 2.51 with N-hydroxysuccinimide in the presence of diisopropylcarbodiimide 
(DIPCDI).  Compound 2.52 coupled smoothly with unprotected serine to form dipeptide 
FmocSer(OtBu)SerOH (2.53) in a good yield. Reaction of 2.53 with 2,2-dimethoxypropane 



























































Our fourth attempt to synthesize 2.49 employed conditions that were the same as our 
third attempt except dipeptide 2.50 was used.  Interestingly, the use of pseudoproline 2.50 
resulted in a truly dramatic improvement in the quality of crude 2.49 as indicated by the 
HPLC trace of the crude product which showed a single major peak corresponding to our 
target compound (Figure 2.41) as well as a few other minor peaks. We also repeated the 
synthesis using HATU/HOAt to incorporate pseudoproline 2.50 (2 x 20 min) while the rest 
of the amino acids were incorporated using HCTU/HOCt (2 x 20 min) and the results were 
almost identical to those shown in Figure 2.41. 
  
Figure 2.41.  Analytical HPLC chromatogram of the material obtained after cleavage from 
the support from our fourth attempt to prepare peptide 2.49.  Dipeptide 2.50 was used.  
Double couplings (2 x 45 min) were performed and HATU/HOAT was used to incorporate 
Glu8, Asp9  and dipeptide 2.50 and HCTU/HOCt for the incorporation of all other residues.  





The removal of the DCV groups in 2.49 was achieved using 50% w/w Pd(OH)2 under 
H2 atmosphere (balloon pressure) in water/methanol (1:1) containing 11 equivalents of Et3N 
and stirring for 24 h.  The reaction mixture was centrifuged and the crude peptide was 
collected through decantation of the supernatant. The HPLC trace of the crude peptide 
composed of mainly of one major peak corresponding to our wanted compound and there is 
no sign of desulfation, attack of the 2-MP at sulfur atom of sulfate and/or oxidation of 
methionine. After HPLC purification (Figure 2.42), peptide 2.48 was obtained in a very 
respectable 41 % overall yield (> 97 % purity).  
 
 
Figure 2.42.  Analytical HPLC chromatogram of pure 
AcMAEHDsYHEDsYGFSSFNDSSQNH2 (2.48).  
 
2.3.13  Synthesis of DARC8-42 
 For the synthesis of a Trp-containing peptide we decided to construct a peptide 
corresponding to residues 8-42 of the N-terminus region of the chemokine receptor DARC 
(see Chapter 1, section 1.2.2.2 for a discussion on DARC):  
AcAELSPSTENS17S18QLDFEDVW26NS28S29sY30GVNDSFPDGDsY41DNH2 (2.54).  
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Peptide 2.54 is 35-residue peptide containing sTyr residues at positions 30 and 41 as well as 
Trp at position 26.  To our knowledge, no sulfated peptides corresponding to any part of the 
N-terminal region of DARC have been synthesized.  If successful, we believe that this would 
be the largest multisulfated peptide ever made.  
 Our strategy for synthesis of DCV-protected precursor to peptide 2.54, peptide 
AcAELSPSTENS17S18QLDFEDVWNS28S29(DCV)YGVNDSFPDGD(DCV)YD-NH2  (2.55), 
was to use HATU/HOAt to incorporate pseudoproline dipeptide 2.50 at positions 17 and 18 
(Ser17-Ser18) and 28 and 29 (Ser28-Ser29) while incorporating all other amino acids using 
HCTU/HOCt.  Double coupling (2 x 20 min) and capping after each coupling would also be 
employed.  Again, Fmoc deprotection and cleavage from the support were done using our 
usual protocols (using 2-MP for Fmoc removal (3 x 10 min) and using TFA:TIPS:H2O:EDT 
(92.5:2.5:2.5:2.5) for 2 h for cleavage from the support).  Employing this strategy and after 
the cleavage from the support, the crude mixture exhibited two major peaks at tR= 23.7 and 
26.3 min along with a variety of minor peaks in the HPLC chromatogram (Figure 2.43).  
Interestingly, the ratio between the two peaks and appearance of new peaks occurred upon 
incubation of the peptide mixture in ammonium acetate buffer at pH = 9 for several hours.  
Upon HPLC separation and MS analysis of these two peaks we found that the peak at tR= 
23.7 min corresponded to peptide 2.55 while the peak at tR= 26.3 differed from 2.55 by just 




Figure 2.43.  Analytical HPLC chromatogram of the material obtained after cleavage from 
the support from our first attempt to prepare peptide 2.55.  HATU/HOAt was used to 
incorporate pseudoproline dipeptide 2.50 at positions 17 and 18 (Ser17-Ser18) and 28 and 29 
(Ser28-Ser29).  For all other amino acids HCTU/HOCt was used as coupling agent.  Double 
coupling (2 x 20 min) and capping after each coupling were also employed.   
 
 Upon close inspection of the target sequence we noticed that Asp38 was on the N-
terminus side of Gly39 (Asp38-Gly39).  Asp-Gly sequences within peptides are known to be 
very susceptible to aspartimide formation as outlined in Scheme 2.14.142  The reaction 
involves attack of the nitrogen of the amide backbone on the carbonyl of the Asp residue and 
formation of the aspartimide (2.58 in Scheme 2.14).  This reaction occurs most readily 
during peptide synthesis when the Asp residue is protected (as illustrated in Scheme 2.14).  
The presence of a tert-butyl protecting group (as opposed to a benzyl ester protecting group) 
on the Asp side chain is known to help suppress but not completely prevent this reaction.143  
The reaction is base-catalyzed and so this can be a major problem during Fmoc-based SPPS.  
However, this reaction is also known to take place even when the Asp side chain is 
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unprotected such as during peptide cleavage from the support and it has even been reported 
that this can even occur during storage in a buffered solution.142  The rate of the reaction 
depends very much on what amino acid is C-terminal to the Asp residue but occurs most 
readily if that amino acid is glycine.142 When this reaction does occur during Fmoc-based 
SPPS peptide synthesis the resulting aspartimide can react with piperidine (if piperidine is 
used for Fmoc removal) to give tertiary amides (2.59 and 2.60 in Scheme 2.14).  Depending 
on what cleavage cocktail is used (and exposure time), the resulting tertiary amide can be 
hydrolyzed to the desired α-Asp-containing peptide and to the undesired β-Asp peptide (2.61 
and 2.62 in Scheme 2.14) but this does not occur very readily.  The aspartimide can also be 
hydrolyzed to the α-Asp and β-Asp peptides.  The aspartimide residue is also quite 
susceptible to epimerization.143   Because peaks at tR= 23.7 and 26.3 min (Figure 2.43) 
correspond to that of peptide 2.55 and 2.55 minus water (or something with a MW = 18), this 
suggests that imide formation occurred during treatment with the cleavage cocktail or 2-MP 
is simply too sterically hindered to attack the imide and the imide survived the peptide 
synthesis.  We should also point out that Asn residues can also undergo succinimide 
formation in the presence of acid and this is also sequence dependent and occurs most readily 
with Asn-Gly sequences.  However, if this occurred in our peptide then we would have seen 






























































R = H (piperidine)
















Scheme 2.14.  Mechanism of aspartimide formation using an Asp-Gly peptide an example. 
  
Although there is more than one way to avoid aspartimide formation including adding 
HOBt and dinitrophenol (DNP) to the piperidine/DMF solution and/or protecting the β-
carboxy side chain with very bulky groups such as the 1-adamantyl (1-Ada) or 3-methylpent-
3-yl (OMpe) groups, apparently the most effective way is N-backbone protection with the 2-
hydroxy-4-methoxybenzyl (Hmb) group or, preferably, the 2,4-dimethoxybenzyl (Dmb) 
group.142, 143  Consequently, we decided to attempt to overcome the proposed aspartimide 
formation problem by incorporating residues Asp38 and Gly39 as the protected dipeptide 












Figure 2.44.  Structure of FmocAsp(OtBu)Gly(DMB)OH (2.63). 
 
Dipeptide 2.63 is commercially available from Novabiochem.  However, it is very 
expensive so we decided to prepare it ourselves.  Surprisingly, there is only one report 
showing the synthesis of dipeptide 2.63 without much detail about the synthesis and 
characterization of the intermediates and final product.144 The synthesis of 2.63 involved 
forming known amine 2.66 by a reductive amination reaction between glycine (2.64) and 



































Compound 2.66 has been prepared by Sasaki et al. in a 38% yield by reacting glycine 
(2.64) with aldehyde 2.65 in 50% aqueous methanol in the presence of Pd/C and H2.145 We 
were able to repeat this reaction obtaining 2.66 in an identical yield.  Several attempts to 
improve the yield using NaBH4 as reductant (used in the preparation of the Hmb analogue of 
2.66146) or using ethyl or benzyl glycine esters as substrates and using NaCNBH3 or 
NaBH(OAc)3 as reductants147, 148 either failed or gave the amine products in low yields. 
Coupling of 2.66 with pentafluorophenyl (Pfp) ester 2.67 in the presence of 
bis(trimethylsilyl)acetamide (BSA) (to introduce the trimethylsilyl group as a temporary 
carboxyl protecting group144) went smoothly to give the desired dipeptide 2.63 in a good yield 
(71%).  
Our second attempt to prepare 2.55 was performed under the same conditions as our 
first attempt except dipeptide FmocAsp(OtBu)Gly(Dmb)OH (2.63) was substituted for 
Asp38 and Gly39. The HPLC trace of the crude product after cleavage from the resin 
indicated little or no aspartimide formation had occurred as indicated by the absence of a 
significant peak at tR= 23.7 min (Figure 2.45). Removal of the DCV groups was achieved by 
subjecting crude 2.55 to 50% w/w of Pd(OH)2 in the presence of Et3N (17 equiv), and H2 
(balloon pressure) in water:methanol (1:1) for 24 h.  After workup, the HPLC trace of the 
crude peptide showed mainly one major peak corresponding to our wanted compound and 
there was no sign of desulfation, attack of the 2-MP at the sulfur atom of the sulfate and/or 
tryptophan destruction (Figure 2.46).  After HPLC purification, we obtained peptide 2.54 in 




Figure 2.45.  HPLC chromatogram of the material obtained after cleavage from the support 
from our second attempt to prepare peptide 2.55.  Conditions were identical to those used 
during our first attempt except FmocAsp(OtBu)Gly(Dmb)OH (2.63) was substituted for 









Figure 2.47.  Analytical HPLC chromatogram of purified peptide 2.54.  
 
2.3.14  Shorter Fmoc deprotection times with 2-MP and using piperidine instead of 2-
MP. 
So far we have been removing the Fmoc group by subjecting the peptide to 3 x 10 
min of 20% 2-MP in DMF, the total reaction time being 30 minutes.  This reaction time was 
chosen because Hachmann and Lebl reported that Fmoc deprotection of FmocIle attached to 
chlorotrityl resin using 2-MP occurred with a half-life that was 1.5 times greater than that of 
piperidine.101  When using piperidine to remove the Fmoc group a 2 x 10 minute (total time 
20 min) treatment is standard.  Hence we do a 30 minute treatment using 2-MP.  However, 
we never examined whether a shorter reaction time would suffice.  Some researchers use 
reaction times shorter than 20 minutes, such as in two steps of 3 min and 11 min each, to 
remove Fmoc groups during SPPS using piperidine.108  To determine if shorter reaction times 
could be employed using 2-MP we prepared the 12-residue crude peptide 
AcISDRD(DCV)YMGWMDF-NH2 (2.56) which (when the DCV group is removed) 
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corresponds to residues 1-12 in CCK-12. Cholecystokinin (CCK), originally isolated from 
porcine intestine as a 33-residue peptide, has been shown to display various biological effects 
including stimulation of both pancreatic exocrine secretion and gallbladder contraction.  We 
set up two parallel experiments. In both we used 2-MP for Fmoc removal except in one we 
used our standard 3 x 10 min deprotection time and the other we used a 3 min + 11 min 
deprotection time.  After cleavage from the resin, the crude peptides were examined by 
analytical HPLC (Figures 2.48 A and B).  The chromatograms are identical indicating that 













Figure 2.48.  Analytical HPLC chromatogram of crude peptide 2.56.  A: Removing the 
Fmoc groups using 2-MP and a 3 x 10 min protocol.  B:  Removing the Fmoc groups using 
2-MP and a 3 min + 11 min protocol.   
 
Since piperidine reacts with DCV-protected sulfates by attack on the sulfur atom and 
displacement of the DCV group, we had assumed that piperidine could not be used with our 
protocol for preparing sTyr peptides (see section 2.3.2).  However, Hari and Miller have 
shown that resin-supported (Wang) sulfonates exhibit superior stability to organic bases 
compared to their solution counterparts.149  This report prompted us to examine whether 





sTyr peptide synthesis.  Thus, the CCK-12 peptide (2.56) was prepared using the same 
protocol as described above except piperidine was used for Fmoc removal using a 3 min + 11 
min protocol. The HPLC trace of the crude peptide (Figure 2.49) is identical to those 
obtained using 2-MP (Figures 2.48 A and B).  The mass spectrum of the crude peptide 
indicated that no product was formed resulting from attack of piperidine at sulfur.  Although 
these results suggest that the resin-supported DCV sulfates are not as sensitive toward 
piperidine as we initially thought, it is important to point out that this study was done on only 
a 12-mer peptide and the DCV-protected sTyr residue was not incorporated until the seventh 
residue.  Thus the DCV group was only exposed to a total of 84 min to piperidine.  It is 
possible that during the synthesis of larger sTyr peptides where the DCV-protected tyrosine 
residue is incorporated at an early stage in the synthesis, some loss of the DCV group will 
occur.  During our stability studies on DCV ester 2.14 (section 2.3.2) in 20% 
piperidine/DMF-d7 we noted that 2.14 did not begin to exhibit significant decomposition 
until the 4 h mark.  So if we use the shorter deprotection times (3 min + 11 min) as discussed 
above, it should be possible to use piperidine for Fmoc removal and incorporate 17 residues 
after the incorporation of the first DCV-protected sTyr residue before significant problems 
appear. If the resin is indeed capable of protecting the DCV esters to some extent then it may 
be possible to incorporate even more than 17 residues before significant decomposition of the 
DCV group appears.  Further studies will be required to ascertain if this is indeed the case.  
In any case, as discussed in section 2.3.16 (see below), there is really no advantage to using 




Figure 2.49.  Analytical HPLC chromatogram of crude peptide 2.56.  The Fmoc groups were 
removed using piperidine (3 min + 11 min protocol).   
 
2.3.15  Recent work by other groups on the synthesis of sTyr peptides. 
 While our work was in progress, two other groups reported new approaches to the 
Fmoc-based SPPS of sTyr peptides.  One was reported by the Liskamp group at the 
University of Utrecht in the Netherlands.150  Their approach is outlined in Scheme 2.16.  In 
this approach the tyrosine residues that are to eventually be sulfated are introduced with their 
phenolic hydroxyl groups protected with the highly acid labile 2-chlorotrityl (2-Cl-Trt) 
group.  After the peptide is constructed the 2-Cl-Trt group is selectively removed using 1 % 
TFA, 5% TIS in DCM which leaves all other side chain protecting groups intact and the 
peptide bound to the resin.  The resulting peptide is then sulfated using our sulfating agent 
2.1.  The peptide is then cleaved from the resin and the protecting group on the side chains of 
the other amino acids are removed using 95% TFA, 2.5% TIPS, 2.5% H2O.  The resulting 
peptide is purified by HPLC.  The TCE group is then removed using Zn/ammonium formate 
and the final peptide purified by HPLC.  Using this procedure they synthesized mono and 
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disulfated peptides corresponding to residues 7-28 in C5aR (peptide 2.41).  No yield was 
reported and no HPLC traces were given of the crude peptides after cleavage from the 
support.  Although this procedure appears to work well in that the desired peptides were 
obtained in good purity, it requires two extra manipulations of the peptide (removal of the 2-
Cl-Trt group, sulfation of the tyrosine residues) compared to our procedure.  Moreover, the 
peptides had to be purified by HPLC twice: after introduction of the TCE-protected suflate 
























































1. 1 % TFA, 5 % TIS, DCM
2. 5% TEA, DCM
TCEOSO3Cl (2.1)
1. 95% TFA, 2.5 % TIS
2.5 % H2O
1. Zn, ammonium formate
MeOH-H2O
2. Purify by HPLC
2. Purify by HPLC
 
Scheme 2.16.  Liskamp’s approach to the synthesis of sTyr peptides. 
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 The second recently reported approach, developed by Simpson and Widlanski at 
Indiana University in the USA, is very similar to our approach in that the sulfate group is 
introduced at the beginning of the synthesis as a protected sulfodiester.108  The neopentyl 
(nPt) group is used to protect the sulfate moiety.  FmocTyr(OSO3nPt)OH, which is used to 
introduce the protected sTyr residue, is prepared by subjecting BocTyrOtBu (2.43) to one 
equiv NaHMDS at -78 oC followed by the addition of (CH3)3CCH2OSO2Cl then allowing the 
mixture to warm to rt followed by purification by flash chromatography.  The resulting fully 
protected material, BocTyr(OSO3nPt)OtBu, is then subjected to aq. TFA and then Fmoc-OSu 
to give FmocTyr(OSO3nPt)OH in an overall yield of 66% (compared to 75% yield we 
obtained for our key building block (2.23) using the procedures outlined in Scheme 2.10.).  
Fmoc-based SPPS is used to incorporate the protected sTyr residue and piperidine is used for 
Fmoc removal (two treatments of 3 min + 11 min) (Scheme 2.17).  After cleavage from the 
support, the nPt group is removed by dissolving the crude peptide in 0.5-3.0 mL of DMSO 
and then adding 50 mL of 1-2 M ammonium acetate (pH 7.0) and heating for 6-12 h at 37 oC.  
This results in loss of the nPt group by an assisted SN1 reaction with methyl participation and 
rearrangement.  The peptide is purified by loading the entire mixture (> 50 mL) directly into 
an HPLC equipped with a 2.0 cm x 25 cm reversed-phase column.  Using this procedure and 
mainly manual SPPS they prepared mono and disulfated peptides corresponding to residues 
8-23 of chemokine receptor CCR3, the CCK-12 sulfated peptide and peptide 2.35 in a very 
good yields and purity.  For these syntheses, the highly acid labile 2-chlorotrityl resin (2-Cl-
Trt, which gives carboxyl C-termini) or the Sieber amide resin (which gives carboxamide C-
termini) were used and the peptides were removed from the support by treating the resin-
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bound peptide 8 times with 1-2% TFA in DCM (filtered after each treatment).  After the final 
filtration the combined filtrates were concentrated and the side chain protecting groups were 
removed by treating the peptides with 90% TFA, 5% MeOH. 5% TIPS (or 88% TFA, 4% 
MeOH. 54% TIPS, 4% thioanisole for Met-containing peptides).  The approach was not 
tested using less acid labile resins such as the more commonly used (and cheaper) Rink 
amide resin that we used.  The main advantages of this approach over ours are the very mild 
conditions that are used to remove the nPt group and, after removing the nPt group, being 
able to load the mixture directly into an HPLC for purification.   
 
 
Scheme 2.17.  Simpson and Widlanski’s procedure for preparing sTyr peptides. 
 
2.3.16 More about 2-MP versus piperidine for Fmoc removal 
 Both Liskamp’s and Widlanski’s procedures allow for the use of piperidine to remove 
the Fmoc group.  Although this may appear to be an advantage over our approach, which 
requires the use of 2-MP for Fmoc removal (at least we suspect so for the synthesis of large 
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sTyr peptides), we do not think that this is an advantage.  First of all, we have already shown 
that Fmoc deprotection times using 2-MP can be reduced from 30 minutes (3 x 10 min) to 14 
minutes (3 min + 11 min).  Moreover, as pointed out by Hachmann and Lebl101 piperidine is 
a controlled substance.  According to United States Code, Title 21, Chapter 13, Subchapter I, 
Part C-Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances, 
the distribution of piperidine is carefully monitored.  As pointed out by Hachmann and Lebl, 
piperidine is supposed to be stored in a locked cabinet with restricted access, its use has to be 
reported and, therefore (as Hachmann and Lebl pointed out), the use of piperidine can be a 
nuisance especially for peptide synthesis companies that deal with large quantities of 
piperidine.  None of these restrictions or regulations apply to 2-MP.  It is these restrictions 
that prompted Hachmann and Lebl to examine other bases such as 2-MP for Fmoc removal. 
2-MP is about 25% cheaper than piperidine.   For example, from Aldrich Chemical Co., 1.18 
L (1 kg) of 2-MP (cat. # W424401, 98%, highest purity available from Aldrich) is $113.50 
CDN ($ 96.00/L) while 1 L of piperidine (cat. # 104094, 99%, lowest purity and cheapest 
available from Aldrich) is $129.50 CDN. We obtained 2.96 L (3 kg) of 2-MP (98% pure) 
from Waterstone Technologies in the USA for $180.00 USD ($60.81/L) three years ago and 
we are still using this same batch (no further purification of it was required).    
2.4  Summary, Conclusions and Future Studies 
 Several novel and important results were obtained from our studies.  First of all, we 
developed a new protecting group for sulfates, namely, the dichlorovinyl (DCV) group.  This 
was accomplished by conducting a careful analysis of the reaction of a TCE-protected sulfate 
ester with piperidine and 2-MP.  By constructing a unique sulfuryl imidazolium reagent, 
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2.22, we were able to incorporate DCV-protected sulfate esters into compounds such as 2.25 
to give DCV sulfate esters such as sTyr derivative 2.23.  We should point out that reagent 
2.22 should allow us to incorporate DCV-protected sulfate esters into other biomolecules 
such as carbohydrates and steroids.  Sulfated carbohydrates and steroids are important 
biomolecules involved in a variety of crucial biochemical processes.  We also developed a 
more economical synthesis of amino acid 2.23 that did not require reagent 2.22.  We 
developed a new and general approach to Fmoc-based SPPS of sTyr peptides using amino 
acid 2.23 and 2-MP for Fmoc removal.  We expect that with our approach, as well as with 
other approaches that were recently developed,  sTyr peptides will now be readily accessible 
and their synthesis will no longer be the challenge that it has been for the last approximately 
50 years.  We are pleased to point out that Dr. Peter White, manager of product development 
at Novabiochem, the world’s leading manufacturer and supplier of amino acids and peptide 
synthesis reagents, has contacted us and expressed a desire to commercialize amino acid 
2.23.  We have also shown that 2-MP is an economical and practical replacement for 
piperidine during SPPS.  
 Future studies will examine whether the sTyr peptide synthesis strategy can be 
applied to the synthesis of peptide glycans.  For example, PSGL-1 is actually a glycoprotein.  
Part of the N-terminal structure of PSGL-1 (2.57) is shown in Figure 2.50.  Several groups 
have been tackling its synthesis. The most notable work in this area has been done by Chi-
Huey Wong’s group at Scripps West.  Because of its complexity, the Wong group has 
focused on using enzymes for introducing the carbohydrate residues in the latter part of their 
syntheses.  For example, during an attempted synthesis of glycopeptides 2.62 and 2.63 (a 
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partial synthesis of 2.57) they were attempting to convert compounds 2.58 and 2.59 to 
compounds 2.60 and 2.61 using bovine β-1,4-galactosyltransferase (β-1,4-GalT) and then 
convert these compounds to 2.62 and 2.63 using rat α2,3-sialyltransferase (α-2,3SiaT) and 
CMP-NeuAc (Scheme 2.18).151, 152 The β1,4-GalT reaction proceeded readily with 
nonsulfated substrate 2.58 but very sluggishly with sulfated substrate 2.59.  The α-2,3SiaT 
reaction also proceeded readily with nonsulfated substrate 2.60 but not at all with sulfated 
substrate 2.61.  A structural study indicated that there are no significant structural differences 
between substrates 2.58 and 2.59 and 2.60 and 2.61.  It was hypothesized that the difference 
in reactivity between the nonsulfated and sulfated substrates was caused by unfavorable 
electrostatic interactions of the anionic sulfate group on the peptide portion with the 
enzymes.  We anticipate that such unfavorable interactions will be eliminated if the sulfate 
group is protected.  Consequently, the Taylor group will be embarking on the synthesis of the 
DCV-protected analog of 2.58 and examine its ability to act as a substrate for β-1,4-GalT and 
α-2,3SiaT.  Should these studies be successful, then removal of the DCV group would give 
the desired compound 2.63.  Successful results here would provide us with the impetus to 



















Figure 2.50.  The N-terminal structure of PSGL-1. (abbreviations:  Fuc stands for fucose, 

































































2.58, R = H
2.59, R = SO3-
β-1,4-GalT
2.60, R = H
2.61, R = SO3-
α-2,3-SiaT
CMP-NeuAc
2.62, R = H
2.63, R = SO3-  
 




Figure 2.51.  Structure of compound 2.64. 
 
2.5  Experimental 
2.5.1  General Information: 
All starting materials and reagents unless otherwise noted were obtained from Aldrich 
Chemical Company (Oakville, ON, Canada).  Rink amide resin, amino acids and coupling 
reagents used for peptide synthesis were purchased from Novabiochem Corp. (San Diego, 
CA, USA) and/or Advanced Chem Tech, Inc (Louisville, KY, USA). Amino acids were used 
for all peptide syntheses unless stated otherwise.  All automated SPPS was performed using 
the Rink amide resin and were performed on a Quartet peptide synthesizer from Protein 
Technologies (USA) on a 25 μM scale.  All reactions were carried out under argon with 
freshly distilled solvents. Tetrahydrofuran (THF) and Et2O were distilled from sodium metal 
in the presence of benzophenone under argon. CH2Cl2 was distilled from calcium hydride 
under nitrogen. DMF was dried and distilled over calcium hydride under vacuum and stored 
over 4 angstrom sieves under argon.  Flash chromatography was performed using silica gel 
60Å (234-400 mesh) obtained from Silicycle (Laval, Quebec, Canada). Chemical shifts (δ) 
for 1H NMR spectra run in CDCl3 are reported in ppm relative to the internal standard 
 
 121 
tetramethylsilane (TMS). Chemical shifts (δ) for 1H NMR spectra run in DMSO-d6 are 
reported in ppm relative to residual solvent protons (δ 2.49). Chemical shifts (δ) for 1H NMR 
spectra run in CD3OD are reported in ppm relative to residual solvent protons (δ 3.30). 1H 
NMR spectra for hexa and octapeptides were run on a Brüker Avance 500 MHz instrument 
using D2O as solvent and utilizing gradient water suppression method.153  For 13C NMR 
spectra run in CDCl3 chemical shifts are reported in ppm relative to the CDCl3 (δ 77.0 for 
central peak). 13C NMR spectra run in DMSO-d6, chemical shifts are reported in ppm relative 
to DMSO-d6 (δ 39.5). 13C NMR spectra run in CD3OD, chemical shifts are reported in ppm 
relative to CD3OD (δ 49.5). For the 19F NMR spectra chemicals shifts are reported relative to 
an external fluoroform standard. Analytical and semipreparative RP-HPLC was achieved 
using Waters 600 controller equipped with a Waters 2487 detector.  Analytical HPLC was 
performed with a Vydac 218TP54 C18 column (5 μm, 4.6 mm x 250 mm) and/or Higgins 
PROTO 200 C18 column (5 μm, 4.6 mm x 250 mm) using a 1.0 mL/min flow rate. Semi-
preparative HPLC was conducted on Vydac 218TP1022 C18 column (10 μm, 22 mm x 250 
mm) using an 8.0 mL/min flow rate.  Electron impact (EI) mass spectra were acquired with a 
JEOL HX110 double focusing mass spectrometer. Positive and negative ion electrospray 
(ESI) experiments were performed with a Waters/Micromass QTOF Ultima Global mass 
spectrometer. 1:1 CH3CN/H2O + 0.2% formic acid is used as a solvent for +ve ion work or 





2.5.2  Synthesis of non-peptidyl compounds and dipeptides 
2,2,2-Trichloroethyl phenyl sulfate (2.11).98   
 
To a solution of phenol (2.12) (0.50 g, 5.31 mmol, 1 equiv), Et3N (0.88 mL, 6.37 
mmol, 1.2 equiv) and DMAP (0.60 g, 5.31 mmol, 1.00 equiv) in dry THF (20 mL) was added 
drop by drop over a period of 15 minutes a solution of 2,2,2-trichloroethoxy sulfurylchloride 
(2.1)100 (1.50 g, 6.37 mmol, 1.20 equiv) in dry THF (10 mL).  The solution was stirred for 10 
h. EtOAc was added (100 mL) and the solution washed with H2O (40 mL), 0.5 N HCl (2 x 40 
mL), H2O (40 mL) and sat. brine (40 mL). The organic layer was dried (MgSO4), 
concentrated in vacuo, and the residue was subjected to flash chromatography (ethyl 
acetate:hexane 10:90) to yield pure compound 2.1 (1.4 g, 86%). NMR spectra were identical 
to that reported.98  1H NMR (300 MHz, CDCl3): δ 7.50-7.45 (m, 2H, HAr), 7.40-7.37 (m, 3H, 









2,2-Dichlorovinyl phenyl sulfate (2.14).   
 
To a solution of phenol (2.12) (0.50 g, 5.31 mmol, 1.00 equiv) in CH2Cl2 (20 mL) at 
0 oC was added 1,2-DMI (1.50 g, 15.9 mmol, 3.00 equiv) followed by compound 2.22 (5.70 
g, 15.9 mmol, 3.00 equiv).  The reaction was allowed to come to room temperature and 
stirred for 5 h.  The reaction was then diluted with 20 mL of CH2Cl2, washed with sat. 
NaHCO3 (2 x 10 mL), brine (2 x 10 mL) followed by H2O (2 x 10 mL). The organic layer 
was dried (MgSO4), concentrated and the residue subjected to flash chromatography (ethyl 
acetate:hexane, 1:9) which gave compound 2.14 as a colorless oil (1.32 g, 92% yield).  1H 
NMR (300 MHz, CDCl3): δ 7.46-7.41 (m, 2H, HAr), 7.38-7.35 (m, 1H, HAr), 7.33-7.29 (m, 
2H, HAr), 7.15 (s, 1H, HDCV); 13C NMR (75 MHz, CDCl3): δ 150.0, 133.6, 130.2, 128.2, 
121.1, 117.3; HRMS (EI+): calculated for C8H6Cl2O4S (M)+ 267.9364, found 267.9373. 








2.  DBU (1.5  equiv),
    THF, 3 hr
1.  2-MI (3.6 equiv), 





To a solution of 2-MI (4.00 g, 49.4 mmol, 3.60 equiv) in dry THF (28 mL) at 0 oC 
was added dropwise a solution of compound 2.1 (3.40 g, 13.7 mmol, 1.00 equiv) in dry THF 
(36 mL). The reaction mixture was allowed to stir for 1 h at 0 oC followed by 1 h at room 
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temperature. The reaction mixture was then filtered and the filtrate was cooled (ice bath). 
DBU (3.10 mL, 20.6 mmol, 1.50 equiv) was added dropwise and reaction mixture was 
allowed to stir for another 1 h at 0 oC followed by 2 h at room temperature.  The reaction 
mixture was filtered after the addition of ether (130 mL) and the filtrate was washed with 
phosphate buffer (pH = 7.2 x 30 mL), brine (2 x 30 mL), dried (MgSO4) and concentrated in 
vauco.  Flash chromatography of the residue (ethyl acetate:hexane, 2:3) furnished compound 
2.18 as a yellow oil (3.1 g, 88%). 1H NMR (300 MHz, CDCl3): δ 7.21 (d, J = 1.2 Hz, 1H, 
Himi), 6.92 (s, 1H, HDCV), 6.90 (d, J = 1.2 Hz, 1H, Himi), 2.59 (s, 3H, CH3imi); 13C NMR (75 
MHz, CDCl3): δ 145.8, 131.8, 127.8, 120.3, 119.5, 14.2; HRMS (EI+): calculated for 
C6H6Cl2N2O3S (M)+ 255.9476, found 255.9476. 



















A solution of compound 2.18 (3.00 g, 11.7 mmol, 1.00 equiv) in CH2Cl2 (33 mL) was 
added dropwise to a suspension of trimethyloxonium tetrafluoroborate (2.20) (1.70 g, 11.7 
mmol, 1.00 equiv) in CH2Cl2 (16 mL) at 0 oC.  The reaction mixture is allowed to come 
slowly to room temperature and then stirred overnight. The solvent was evaporated in vacuo 
and the residue was triturated with hot THF (5 mL).  The mixture was filtered and the filter 
cake was dried to give pure 2.22 (4.00 g, 95%).  MP= 123-127 oC (decomp.). 1H NMR (300 
MHz, DMSO-d6): δ 8.27 (d, J = 2.4, 1H, Himi), 7.98 (s, 2H, Himi & HDCV), 3.87 (s, 3H, CH3-
imi), 2.84 (s, 3H, CH3-imi); 13C NMR (75 MHz, DMSO-d6): δ 149.6, 134.5, 124.5, 122.2, 
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121.4, 36.5, 12.2; 19F NMR (282 MHz, DMSO-d6): δ -148.04; HRMS (ESI+): calculated for 
C7H9Cl2N2O3S (M-BF4)+ 270.9701, found 270.9711. 
Nα-[(Fluoren-9-yl)methoxylcarbonyl]-L-tyrosine dichlorovinyl sulfate (2.23).   
 Method A: From 2.25 
 
Compound 2.25 (1.30 g, 2.04 mmol, 1.00 equiv) was dissolved in trifluoroacetic acid 
(TFA) (5.7 mL) and the resulting solution was stirred at room temperature for 16 h. The TFA 
was removed under reduced pressure and the residue was subjected to flash chromatography 
(CH2Cl2:MeOH, 95:5) which gave 2.23 as a white foam (1.09 g, 92% yield).  1H NMR (300 
MHz, DMSO-d6): δ 12.90 (br-s, 1H, COOHTyr), 8.07 (s, 1H, HDCV), 7.88 (d, J = 7.5 Hz, 2H, 
HFmoc), 7.76  (d, J = 8.4 Hz, 1H, NHTyr), 7.66-7.63 (m, 2H, HFmoc), 7.45-7.27 (m, 8H, HFmoc, 
and HTyr), 4.23-4.17  (m, 4H, CH2-Fmoc, CHFmoc and CHTyr), 3.17-2.88 (m, 2H, CH2-Tyr); 13C 
NMR (75 MHz, CDCl3): δ 173.5, 156.4, 148.63, 144.2, 141.2, 139.1, 135.4, 131.6, 128.1, 
127.5, 125.7, 125.6, 121.4, 120.5, 118.2, 66.1, 55.6, 47.1, 36.1; HRMS (ESI+): calculated for 

































2.45 2.23  
Compound 2.45 (6.00 g, 11.7 mmol, 1.00 equiv) was dissolved in TFA (23 mL) and 
the mixture was stirred at room temperature for 2 h then concentrated by rotary evaporation.  
This process was repeated using the same quantity of TFA.  After rotary evaporation a third 
portion of TFA (23 mL) was added and the mixture was stirred overnight. The mixture was 
concentrated by rotary evaporation and the residue was suspended in CHCl3 (50 mL) and 
concentrated by rotary evaporation and this process was repeated several times until a white 
solid formed which was dried under high vacuum.  The residue was dissolved in an aq. 
solution of sodium carbonate (42.0 mL, 3.72 g, 35.1 mmol, 3.0 equiv) and the mixture was 
cooled using an ice bath.  A solution of Fmoc-OSu (5.92 g, 17.6 mmol, 1.50 equiv) in 
dioxane (42 mL) was added and the reaction was allowed to warm to rt then stirred 
overnight. The reaction mixture was acidified using 1 M HCl (to pH = 2), extracted with 
EtOAc (3 x 100 mL), dried (MgSO4), filtered and concentrated by rotary evaporation.  The 
residue was subjected to flash chromatography (100% CH2Cl2 to 5% MeOH in CH2Cl2) 
which gave pure 2.23 as off-white foam 5.75 g (85%). 1H NMR and 13C NMR data were 




Nα-[(Fluoren-9-yl)methoxylcarbonyl]-L-tyrosine tert-butyl ester (FmocTyrOtBu, 










This was prepared according to the procedure of Wang et al.103  Fmoc-OSu  (1.56 g, 
4.63 mmol, 1.10 equiv) was added to a solution of L-tyrosine tert-butyl ester (1.00 g, 4.21 
mmol, 1.00 equiv) in 14 mL of dioxane and 12 mL of 10% Na2CO3 at 0 oC (ice bath).  The 
mixture was stirred for 4 h at 0 oC then 12 h at room temperature. The mixture was extracted 
with ethyl acetate (2 x 50 mL), and the combinded organics were washed with brine (2 x 20 
mL) and H2O (2 x 20 mL).  The organic layer was dried (Na2SO4), concentrated, and the 
residue purified by flash chromatography (ether: hexane, 1:1) to give pure compound 
FmocTyrOtBu (2.24) (1.74 g, 90% yield).  NMR spectra were identical to that reported.103  1H 
NMR (300 MHz, CDCl3): δ 7.78 (d, J = 7.2 Hz, 2H, HFmoc), 7.59 (d, J = 7.2 Hz, 2H, HFmoc), 
7.42  (dd,  J =  7.5 and 7.2 Hz,  2H, HFmoc), 7.32 (dd,  J =  7.2 and  7.5 Hz,  2H, HFmoc), 7.02 
(d, J = 8.1 Hz, 2H, HTyr), 6.75 (d, J = 8.1 Hz, 2H, HTyr), 5.40 (s, 1H, OHTyr), 5.33 (d, J = 8.1 
Hz, 1H, NHTyr), 4.54-4.36 (m, 3H, CH2-Fmoc,and CHTyr), 4.22 (dd, J1 =J2 = 6.9 Hz, 1H, 
CHFmoc), 3.04 (m, 2H, CH2-Tyr), 1.45 (s, 9H, Htert-but); 13C NMR (75 MHz, CDCl3): δ 171.0, 
155.9, 155.1, 143.7, 141.3, 130.6, 127.7, 127.6, 127.1, 125.1, 120.0, 115.4, 82.6, 67.1, 55.4, 























CH2Cl2, rt, 3 hr
2.22 2.252.24  
To a solution of FmocTyrOtBu (2.24) (1.00 g, 2.17 mmol, 1.00 equiv) in CH2Cl2 (8.7 
mL) at 0 oC was added 1,2-DMI (0.62 g, 6.52 mmol, 3.00 equiv) followed by portionwise 
addition of compound 2.22 (2.33 g, 6.52 mmol, 3.00 equiv).  The reaction mixture was 
allowed to come to room temperature and then allowed to stir for 3 h. The reaction mixture 
was diluted with another 8 mL of CH2Cl2, washed with brine (3 x 5 mL) and H2O (3 x 5 mL) 
then dried (Na2SO4) and concentrated.  The residue was purified using flash chromatography 
(ethyl acetate:hexane, 20:80) to give pure 2.25 (1.29 g, 94% yield).  1H NMR (300 MHz, 
CDCl3): δ 7.80 (d, J = 7.5 Hz, 2H, HFmoc), 7.61 (d, J = 7.2 Hz, 2H, HFmoc), 7.44 (dd,  J1 =  J2 
= 7.2 Hz,  2H, HFmoc), 7.35 (dd,  J =  7.2 and 7.5 Hz,  2H, HFmoc), 7.28-7.25 (m, 4H, HTyr), 
7.18 (s, 1H, HDCV), 5.39 (d, J = 7.8 Hz, 1H, NHTyr), 4.58-4.37 (m, 3H, CH2-Fmoc,and CHTyr), 
4.24 (dd, J1 =  J2 = 6.6 Hz, 1H, CHFmoc), 3.14-4.13 (m, 2H, CH2-Tyr), 1.44 (s, 9H, Htert-but); 13C 
NMR (75 MHz, CDCl3): δ 170.1, 155.4, 148.9, 143.8, 143.6, 141.3, 136.6, 133.5, 131.2, 
127.7, 127.0, 125.0, 124.9, 120.9, 112.0, 119.9, 117.4, 82.7, 66.8, 54.9, 47.1, 37.8, 27.9; 





















2.27 2.26  
  Compound 2.27 (0.50 g, 0.74 mmol, 1.0 equiv) was dissolved in TFA (3.3 mL) and 
the resulting solution was stirred at room temperature for 16 h.  The TFA was removed under 
reduced pressure and the residue was subjected to flash chromatography (CH2Cl2: MeOH, 
95:5) which gave pure compound 2.26 (0.41 g, 89% yield).  1H NMR (300 MHz, DMSO-d6): 
δ 12.77 (br-s, 1H, COOHTyr), 7.84 (d, J = 7.2 Hz, 2H, HFmoc), 7.72  (d, J = 8.1 Hz, 1H, 
NHTyr), 7.63-7.59 (m, 2H, HFmoc), 7.38-7.23 (m, 8H, HFmoc, and HTyr), 5.30 (s, 2H, HTCE), 
4.18-4.12  (m, 4H, CH2-Fmoc, CHFmoc and CHTyr),  3.13-2.84 (m, 2H, CH2-Tyr); 13C NMR (75 
MHz, CDCl3): δ 173.5, 156.4, 148.6, 144.2, 144.21, 141.17, 138.7, 131.4, 128.1, 127.5, 
125.7, 125.6, 121.6, 120.5, 93.4, 80.5, 66.1, 55.7, 47.0, 36.2; HRMS (ESI+): calculated for 
C26H23Cl3NO8S (M+H)+ 614.0210, found 614.0217. 
















THF, 0 oC-rt, 3 hr
2.272.24  
To a solution of FmocTyrOtBu (2.24) (0.50 g, 1.08 mmol, 1.00 equiv) and 2,2,2-
trichloroethoxy sulfurylchloride 2.1 (0.80 g, 3.26 mmol, 3.00 equiv) in dry THF (2 mL) at 0 
oC (ice bath) was added dropwise a solution of DMAP (0.13 g, 1.08 mmol, 1.00 equiv) and 
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Et3N (0.30 mL, 2.17 mmol, 2.00 equiv) in dry THF (2.3 mL). The ice bath was removed and 
the reaction was stirred for 3 h. The mixture was filtered and the filtrate was concentrated in 
vacuo.  Flash chromatography of the residue (ethyl acetate:hexane, 1:3) gave pure 2.27 (0.72 
g, 98% yield).  1H NMR (300 MHz, CDCl3): δ 7.80 (d, J = 7.2 Hz, 2H, HFmoc), 7.61 (d, J = 
7.5 Hz, 2H, HFmoc), 7.43 (dd, J  = 7.2 and 7.5 Hz, 2H, HFmoc), 7.37-7.22 (m, 6H, HFmoc, HTyr), 
5.38 (d, J = 7.5 Hz, 1H, NHTyr), 4.83 (s, 2H, HTCE), 4.57-4.39 (m, 3H, CH2-Fmoc,and CHTyr), 
4.23 (dd, J1 = 6.6 & J2 = 6.9 Hz, 1H, CHFmoc), 3.13-3.12 (m, 2H, CH2-Tyr), 1.43 (s, 9H, Htert-
but); 13C NMR (75 MHz, CDCl3): δ 170.3, 155.6, 149.1, 143.9, 143.8, 141.37, 141.35, 136.5, 
131.2, 127.8, 127.1, 125.15, 125.07, 121.0, 120.09, 120.06, 92.5, 82.7, 80.4, 66.9, 55.2, 47.2, 
37.8, 28.0; HRMS (ESI+): calculated for C30H31Cl3NO8S (M+H)+ 670.0836, found 670.0822. 















This was prepared according to the procedure of Stefan.154  A solution of sodium 
bicarbonate (1.70 g, 20.2 mmol, 1.10 equiv) in water (49 mL) was added to a suspension of 
L-tyrosine tert-butyl ester (4.35 g, 18.3 mmol, 1.00 equiv) in acetone (39 mL).  A solution of 
di-tert-butyldicarbonate (4.40 g, 20.2 mmol, 1.10 equiv) in acetone (10 mL) was added 
dropwise and the resulting solution was stirred at rt overnight. The acetone was removed by 
rotary evaporation and the residue was dissolved in ethyl acetate (100 mL).  This solution 
was washed with 0.1 N HCl (25 mL) then dried (Na2SO4), filtered and concentrated by rotary 
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evaporation to yield 6.10 g (99% yield) of 2.43 as a yellowish-white solid, MP =114-115 oC 
(reported MP = 115.8-116.7 oC).  1H NMR (300 MHz, CDCl3): δ 7.10 (d, J = 8.3 Hz, 2H, 
HTyr), 6.71 (d, J = 8.4 Hz, 2H, HTyr), 4.95 (d, J = 6.9 Hz, 1H, NHTyr), 4.77 (s, 1H, OH), 4.38-
4.36 (m, 1H, CHTyr), 2.96-2.94 (m, 2H, CH2-Tyr), 1.40 (s, 9H, Htert-but), 1.39 (s, 9H, Htert-but). 
13C NMR (75 MHz, CDCl3): δ 171.4, 155.5, 155.4, 130.5, 127.4, 115.4, 82.3, 80.1, 55.1, 
37.6, 28.3, 27.9. 




















1. 2.1, DMAP, Et3N, THF
2.43
2.45  
To a solution of 2.43 (6.00 g, 17.7 mmol, 1.00 equiv) in dry THF (24 mL) at 0 oC was 
added reagent 2.1 (15.7 g, 53.3 mmol, 3.00 equiv) followed by a solution of DMAP (2.17 g, 
17.7 mmol, 1.00 equiv) and Et3N (4.9 mL, 35.5 mmol, 2.00 equiv) in dry THF (48 mL). The 
reaction was allowed to warm to room temperature then stirred overnight and filtered.  The 
filtrate was diluted with EtOAc (200 mL) and the resulting solution was washed with 
phosphate buffer (pH = 7.2, 2 x 100 mL) and brine (2 x 100 mL) then dried (MgSO4), filtered 
concentrated by rotary evaporation.  The residue was dissolved in THF (72 mL) and 1 equiv 
of DBU (2.5 mL, 17 mmol) was added at 1 hour intervals over 4 h for a total of 5 equiv 
DBU.  After 6 h the reaction mixture was filtered and the filtrate was diluted with EtOAc (2 
x 100 mL).  This solution was washed with phosphate buffer (pH = 7.2, 2 x 100 mL), and 
brine (2 x 100 mL) then dried (MgSO4), filtered and concentrated by rotary evaporation.  The 
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residue was purified by flash chromatography using ethyl acetate:n-hexane (15:85) to yield 
8.01 g of 2.45 as pale yellow glassy semisolid (yield 88%). 1H NMR (300 MHz, CDCl3): δ 
7.25-7.18 (m, 4H, HTyr), 7.12 (s, 1H, HDCV), 5.02 (d, J = 7.3 Hz, 1H, NHTyr), 4.43-4.40 (m, 
1H, CHTyr), 3.06-3.04 (m, 2H, CH2-Tyr), 1.39 (s, 9H, Htert-but), 1.36 (s, 9H, Htert-but); 13C NMR 
(75 MHz, CDCl3): δ 170.5, 154.9, 148.8, 137.1, 133.6, 131.2, 120.8, 117.2, 82.2, 79.7, 54.7, 





























To a solution of dipeptide 2.53 (4.00 g, 8.50 mmol, 1.00 equiv) in THF (170 mL) was 
added pyridinium p-toluenesulfonate (0.43 g, 1.70 mmol, 0.20 equiv) followed by 2,2-
dimethoxypropane (5.2 mL, 42.5 mmol, 5.00 equiv).  The resulting solution was refluxed 
under Ar overnight during which the condensate was passed over 4 Å molecular sieves 
before returning to the reaction vessel.  After cooling, triethylamine (0.36 mL, 2.6 mmol, 
0.31 equiv) was added and the solution was stirred for 5 min afterward the solution was 
concentrated to dryness by rotary evaporation.  The residue was taken up in ethyl acetate 
(250 mL), washed with water (3 x 120 mL), dried (MgSO4), filtered and concentrated to 
dryness by rotary evaporation.  Flash chromatography of the residue (1% MeOH/CH2Cl2 to 
10% methanol/CH2Cl2) gave a crude foamy product which was dissolved in ether (5.5 mL) 
and isopropanol (2.7 mL).  Pentane (27 mL) was added and the mixture stirred for 15 min.   
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More pentane (24 mL) was added over 1 h and resulting mixture was allowed to stir at room 
temperature for overnight. After an additional 2 h of stirring at 0 oC, the resulting solid was 
filtered and dried which gave 3.21 g of 2.50 as an off-white solid (74% yield). MP = 156-158 
oC.  1H NMR (300 MHz, CD3OD): δ 7.76 (d, J = 7.4 Hz, 2H, HFmoc), 7.63-7.59 (m, 2H, 
HFmoc), 7.35 (dd, J 1=J 2  7.3 Hz, 2H, HFmoc), 7.28 (dd, J =  7.2 and 7.1 Hz, 2H, HFmoc), 4.99 
(s, 1H, NH), 4.44-4.18 (m, 6H, CH2-Fmoc, CHFmoc, CH2-Asp and CHPeptide), 3.50-3.40 (m, 2H, 
CH2-Asp), 1.63 (s, 3H, CH3), 1.51 (s, 3H, CH3), 1.15 (s, 9H, Htert-but); 13C NMR (75 MHz, 
DMSO-d6): δ 168.2, 155.6, 144.3, 144.1, 141.1, 128.1, 127.5, 126.0, 125.9, 120.5, 95.8, 73.4, 
67.0, 66.4, 63.7, 53.3, 47.0, 27.4, 25.7, 23.1. HRMS (ESI+): calculated for C28H35N2O7 
(M+H)+ 511.2444, found 511.2432. The analytical HPLC chromatogram (linear gradient of 
30:70 CH3CN: (0.1%TFA) water to 80:20 CH3CN: (0.1%TFA) water over 30 min showed a 
single peak at tR= 27.5 min. 
N-α-Fmoc-O-tert-butyl-L-serine N-hydroxysuccinimide ester (2.52)155 
 
To a solution of FmocSer(OtBu)OH (2.51, 2.87 g, 7.50 mmol, 1.00 equiv) in dioxane 
(20 mL) was added a solution of N-hydroxysuccinimide (1.58 g, 13.6 mmol, 1.82 equiv) in 
dioxane:water (5.5 mL, 9:1) followed by DIPCDI (1.5 mL, 9.75 mmol, 1.3 equiv). The 
reaction mixture was stirred overnight at rt then concentrated by rotary evaporation.  The 
residue was then dissolved in ethyl acetate and washed with 0.001 M HCl (3 x 25 mL, pH = 
3), dried (MgSO4), filtered and concentrated in vacuo leaving an off-white solid.  The residue 
 
 134 
was recrystallized using ethanol/n-hexane to give 3.31 g of pure 2.52 as a white solid (92% 
yield). MP = 81-83 oC.  1H NMR (300 MHz, CD3OD): δ 7.79 (d, J = 7.4 Hz, 2H, HFmoc), 
7.66-7.65 (m, 2H, HFmoc), 7.38 (dd,  J1 =  J2 = 7.4 Hz,  2H, HFmoc), 7.30 (dd,  J =  7.4 and 7.3 
Hz,  2H, HFmoc),  7.79-7.76 (m, 1H, HAsp), 4.39-4.22 (m, 3H, CH2-Fmoc,and CHFmoc), 3.88-3.72 
(m, 2H, CH2-Asp), 2.82 (s, 4H, HSucc), 1.21 (s, 9H, Htert-but); 13C NMR (75 MHz, CD3OD): δ 
167.7, 166.7, 156.8, 143.8, 143.7, 141.1, 127.4, 126.8, 124.8, 119.5, 73.6, 66.9, 61.3, 53.5, 
































L-Serine (1.86 g, 17.7 mmol, 2.00 equiv) was dissolved in aq. sodium carbonate (65 
mL, 3.76 g, 35.5 mmol, 4.00 equiv) and added dropwise to a solution of 2.52 (4.27 g, 8.88 
mmol, 1.00 equiv) in acetone (50 mL). After stirring overnight at rt the reaction mixture was 
acidified to pH = 2-3 using conc. HCl, extracted with ethyl acetate (3 x 100 mL) and the 
combined organics were dried (MgSO4), filtered and concentrated by RV.  The residue was 
subjected to FC (1% CH3OH in CH2Cl2 to 10% CH3OH in CH2Cl2) which gave 3.52 g of 
pure 2.53 (85% yield). MP = 88-91 oC. 1H NMR (300 MHz, CD3OD): δ 7.77 (d, J = 7.4 Hz, 
2H, HFmoc), 7.63-7.59 (m, 2H, HFmoc), 7.36 (dd, J =  7.2 and 7.4 Hz, 2H, HFmoc), 7.28 (dd, J =  
7.3 and 7.4 Hz, 2H, HFmoc), 4.45-4.19 (m, 5H, CH2-Fmoc, CHFmoc and 2 CHPeptide), 3.93-3.78 
(m, 2H, CH2-Asp), 3.62-3.59 (m, 2H, CH2-Asp), 1.18 (s, 9H, Htert-but); 13C NMR (75 MHz, 
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CD3OD): δ 171.2, 157.0, 143.9, 143.7, 141.1, 127.4, 126.8, 124.8, 119.5, 73.5, 66.7, 61.7, 
61.6, 55.1, 54.7, 46.9, 26.2. The analytical HPLC chromatogram (linear gradient of 30:70 
CH3CN: (0.1%TFA) water to 80:20 CH3CN: (0.1%TFA) water  over 30 min) showed a 
































To a suspension of 2.66 (0.26 g, 1.04 mmol, 1.20 equiv) in CH2Cl2 (2 mL) was added 
bis(trimethylsilyl)acetamide (BSA) (0.64 mL, 2.6 mmol, 3.0 equiv) and the mixture was 
stirred for 20 min until the suspension became a clear solution. Compound 2.67 (0.50 g, 0.87 
mmol, 1.0 equiv) was added and the mixture stirred overnight at rt.  The mixture was diluted 
with DCM (2 mL) and a 10% of citric acid solution (1.6 mL) was added and the mixture 
stirred for 5 min.  The layers were separated and the organic layer was dried (MgSO4), 
filtered and concentrated by RV.  The residue was subjected to FC (1% MeOH:CHCl3 to 4% 
MeOH:CHCl3) which gave a crude foamy product.  This material was the dissolved in ether 
(4 mL) and precipitated using pentane which gave pure 0.38 g 2.63 as a white solid (71% 
yield). MP = 87-90 oC. 1H NMR (300 MHz, CD3OD): δ 7.76 (d, J = 7.3 Hz, 2H, HFmoc), 7.62 
(d, J = 7.3 Hz, 2H, HFmoc), 7.35-7.26 (m, 4H, HFmoc), 7.09 (dd, J  = 8.4 and 8.3 Hz, 1H, H2,4-
dimethoxybenzyl), 6.49-6.35 (m, 2H, H2,4-dimethoxybenzyl), 5.29-5.24 (m, 1H, Hoxaz), 4.67-4.50 (m, 
2H, CHpeptide), 4.38-3.97 (m, 5H, CHpeptide), 3.76 (d, J = 11 Hz, 3H, OCH3), 3.70 (d, J = 8 Hz, 
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3H, OCH3), 2.46-2.75 (m, 2H, CH2-Asp), 1.39 (d, J = 7.5 Hz, 9H, Htert-butyl); 13C NMR (75 
MHz, CDCl3): δ 171.9, 171.8, 171.1, 170.8, 170.0, 169.9, 161.1, 160.8, 158.8, 158.7, 156.5, 
156.3, 143.8, 143.7, 141.97, 141.97, 141.94, 130.6, 129.9, 127.3, 126.7, 124.9, 124.8, 119.5, 
116.2, 115.6, 104.2, 104.0, 98.6, 97.7, 80.8. 54.43. 54.30, 48.13, 47.00, 44.54, 38.05, 37.75, 
26.84. HRMS (ESI+): calculated for C34H38N2O9Na (M+Na)+ 641.2465, found 641.2475. The 
analytical HPLC chromatogram (linear gradient of 40:60 CH3CN: (0.1%TFA) water to 80:20 















A 50% aq. methanol solution (~ 200 mL) was added to gylcine (2.64, 1.50 g, 20 
mmol, 1.0 equiv) and 2,4-dimethoxybenzaldehyde (2.65, 3.35 g, 20 mmol, 1.0 equiv) until all 
of the solid material dissolved.  Acetic acid (1 mL) was added and the mixture was subjected 
to hydrogenation using 10% Pd/C (350 mg) and hydrogen gas (balloon pressure) for 6 h.  
The catalyst was removed by filtration and the solution concentrated by RV.  The residue 
was dissolved in n-butanol and washed with water.  The organic phase was concentrated and 
the residue was triturated with ether to give 1.71 g of 2.66 as a white solid (38% yield). MP= 
188-191 oC.1H NMR (300 MHz, CD3OD): δ 7.24 (d, J = 8.4 Hz, 1H, HAr), 6.60 (d, J = 2.1 
Hz, 1H, HAr), 6.53 (dd, J =  8.4 and 2.1 Hz, 1H, HAr), 4.13 (s, 2H, CH2), 3.88 (s, 3H, OCH3), 
3.79 (s, 3H, OCH3), 3.39 (s, 2H, CH2) ; 13C NMR (75 MHz, CD3OD): 169.5, 162.6, 159.2, 
132.3, 111.3, 104.7, 98.0, 54.7, 54.5, 47.9, 46.1. 
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 To an ice-cooled solution of FmocAsp(OtBu)OH (1.00 g, 2.43 mmol, 1.00 equiv) and 
pentafluorophenol (0.45 g, 2.43 mmol, 1.00 equiv) in ethyl acetate was added DIPCDI (0.30, 
2.43 mmol, 1.00 equiv) and the mixture was stirred at 0 oC for 1 h and followed by an 
additional 1 h at rt.  The mixture was filtered and the solvent was removed by RV leaving a 
solid residue.  Recrystallization of the residue using n-hexane gave 1.26 g of pure 2.67 (90% 
yield). MP = 95-96 oC (reported MP= 97-100 oC).  1H NMR (300 MHz, CDCl3): δ 7.74 (d, J 
= 7.4 Hz, 2H, HFmoc), 7.58 (d, J = 6.93 Hz, 2H, HFmoc), 7.38 (dd, J  = 7.2 and 7.4 Hz, 2H, 
HFmoc), 7.29 (dd, J  = 7.3 and 7.4 Hz, 2H, HFmoc), 5.96 (d, J = 8.9 Hz, 1H, NH), 4.99-4.96 (m, 
1H, HAsp), 4.50-4.21 (m, 3H, CH2-Fmoc,and CHFmoc), 3.17-2.85 (m, 2H, CH2-Asp), 1.47 (s, 9H, 
Htert-but); 13C NMR (75 MHz, CDCl3): δ 169.7, 167.4, 155.8, 143.7, 143.5, 141.3, 127.7, 
127.1, 125.1, 120.0, 82.7, 67.5, 50.2, 47.0, 37.6, 28.0. 19F NMR (282 MHz, DMSO-d6): δ -
152, -157, -162.  
2.5.3    Determination of the enantiopurity of compounds 2.23 and 2.26.   
 The enantiopurity of compounds 2.23 and 2.26 was determined by constructing the 
following dipeptides and analyzing them by HPLC and 1H-NMR: AcY(SO3DCV)A(DL)NH2 
(2.28LD/2.28LL), AcY(SO3DCV)A(L)NH2 (2.28LL), AcY(SO3TCE)A(DL)NH2 
(2.29DL/2.29LL) and AcY(SO3TCE)A(L)NH2 (2.29LL).  Manual Fmoc-SPPS was 
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performed using a plastic syringe equipped with a porous filter and the Rink amide resin (50 
mg, loading of 0.71 mmol/g, preswollen in DMF for 1 h before use).  Fmoc-(L)-Ala was used 
for the synthesis of 2.28LL and 2.29LL and racemic Fmoc-(D,L)-Ala was used for the 
synthesis of the diastereomeric mixtures 2.28LD/2.28LL and 2.29LD/2.2LL.  Amino acids 
were coupled using the following reagents, molar equivalents and reaction times: Fmoc-AA-
OH (4.0 equiv), HBTU (4.0 equiv), HOBt (4.0 equiv) and DIPEA (4.0 equiv) in less than 1 
ml of DMF (stirred 10 min at room temperature before being added to the resin) and then 
shaken with resin (2 x 90 min for first amino acids and 1 x 90 min for second amino acids).  
Fmoc removal was achieved using 20% 2-MP/DMF (1-2 mL, 3 x 10 min).  After the removal 
of the terminal Fmoc group the resin was washed with DMF (3 mL, 5 x 3 min) and then 
treated with 2 mL of 2:1 pyridine: acetic anhydride solution for 3 h then washed with DMF 
(3 mL, 5 x 3 min), methanol (3 mL, 5 x 3 min) and CH2Cl2 (3 mL, 5 x 3 min) then dried.  
The dipeptides were cleaved from the resin by shaking with a cleavage cocktail consisting of 
TFA:triisopropylsilane (TIPS) (98:2, 2 mL) for 2.5 h after which the mixture was filtered.  
The resin was treated with another 2 mL of the cocktail for 30 min, filtered, and then the 
resin was washed with successive portions of the cleavage cocktail (3 x 0.5 mL).  The 
combined filtrates were concentrated under reduced pressure and the residue subjected to 
flash chromatography (CH2Cl2:MeOH, 9:1) which gave the desired dipeptides.  The resulting 
dipeptides were analyzed using analytical C-18 RP-HPLC eluting with CH3CN/H2O (0.1% 




AcY(SO3DCV)A(DL)NH2 (2.28LD/2.28LL). 1H NMR (300 MHz, CD3OD): δ 7.58 (s, 1H, 
HDCV), 7.56 (s, 1H, HDCV), 7.36-7.25 (m, 8H, HTyr), 4.61 (dd, J 1 = 5.4 and J 2 = 9.0 Hz, 1H, 
CHpeptide), 4.41 (dd, J 1 = 7.5 and J 2 = 7.8 Hz, 1H, CHpeptide), 4.30 (dd, J  = 6.9 and 14.1 Hz, 
1H, CHpeptide), 4.17 (dd, J  = 7.2 and 14.4 Hz, 1H, CHpeptide), 3.18 (dd, J  = 5.4 and 14.1 Hz, 
1H, CH2-Tyr), 3.08-2.87 (m, 3H, CH2-Tyr), 1.91 (s, 3H, HAc), 1.88 (s, 3H, HAc), 1.32 (d, J  = 7.2 
Hz, 3H, HAla), 1.13 (d, J  = 7.5 Hz, 3H, HAla). HRMS (ESI+): calculated for C16H20Cl2N3O7S 
(M+H)+ 468.0399, found 468.0409.  Analytical HPLC showed two peaks with tR= 33.2, 35.0 
min.  See Figures 2.2 and 2.3 for the 1H-NMR spectrum and HPLC chromatogram. 
AcY(SO3DCV)A(L)NH2 (2.28LL).  1H NMR (300 MHz, CD3OD): δ 7.56 (s, 1H, HDCV), 7.38 
(d, J = 8.7 Hz, 2H, HTyr), 7.26 (d, J = 8.7 Hz, 2H, HTyr), 4.60 (dd, J  = 5.4 and 9.0 Hz, 1H, 
CHpeptide), 4.30 (dd, J  = 7.2 and 14.4 Hz, 1H, CHpeptide), 3.18 (dd, J  = 5.4 and 13.8 Hz, 1H, 
CH2-Tyr), 2.90 (dd, J  = 9.0 and 13.8 Hz, 1H, CH2-Tyr), 1.88 (s, 3H, HAc), 1.32 (d, J  = 7.2 Hz, 
3H, HAla); HRMS (ESI+): calculated for C16H20Cl2N3O7S (M+H)+ 468.0399, found 468.0409.  
Analytical HPLC showed one peak tR= 33.6 min.  See Figures 2.4 and 2.5 for the 1H-NMR 
spectrum and HPLC chromatogram. 
AcY(SO3TCE)A(DL)NH2 (2.29DL/2.29LL).  1H NMR (300 MHz, CD3OD): δ 7.38-7.28 
(m, 8H, HTyr), 5.06 (s, 2H, HTCE), 5.04 (s, 2H, HTCE), 4.59 (dd, J  = 5.4 and 7.7 Hz, 1H, 
CHpeptide), 4.40 (dd, J 1 = J 2 = 7.8 Hz, 1H, CHpeptide), 4.30 (dd, J  = 7.2 and 14.4 Hz, 1H, 
CHpeptide), 4.17 (dd, J  = 7.2 and 14.4 Hz, 1H, CHpeptide), 3.17 (dd, J  = 5.7 and 14.1 Hz, 1H, 
CH2-Tyr), 3.03-2.87 (m, 3H, CH2-Tyr), 1.91 (s, 3H, HAc), 1.88 (s, 3H, HAc), 1.32 (d, J  = 7.2 Hz, 
3H, HAla), 1.13 (d, J  = 7.5 Hz, 3H, HAla); HRMS (ESI+): calculated for C16H20Cl2N3O7S 
(M+H)+ 468.0399, found 468.0409 and C16H21Cl3N3O7S (M+H)+ 504.0166, found 504.0172.  
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Analytical HPLC showed four peaks tR= 34.9, 36.8, 38.9, 40.4 min. See Figures 2.6 and 2.7 
for the 1H-NMR spectrum and HPLC chromatogram. 
AcY(SO3TCE)A(L)NH2 (2.29LL).  1H NMR (300 MHz, CD3OD): δ  7.36 (d, J = 8.7 Hz, 2H, 
HTyr), 7.31 (d, J = 8.7 Hz, 2H, HTyr), 5.04 (s, 2H, HTCE), 4.60 (dd, J  = 5.7 and 9.0 Hz, 1H, 
CHpeptide), 4.32-4.26 (m, 1H, CHpeptide), 3.17 (dd, J  = 5.7 and 14.1 Hz, 1H, CH2-Tyr), 2.97-2.83 
(m, 1H, CH2-Tyr), 1.88 (s, 3H, HAc), 1.32 (d, J  = 7.2 Hz, 3H, HAla), HRMS (ESI+): calculated 
for C16H20Cl2N3O7S (M+H)+ 468.0399, found 468.0409 and C16H21Cl3N3O7S (M+H)+ 
504.0166, found 504.0172. Analytical HPLC showed four peaks tR= 34.9, 38.8 min. See 
Figures 2.8 and 2.9 for the 1H-NMR spectrum and HPLC chromatogram. 
2.5.4   Synthesis of crude hexapeptides 2.16, 2.31 and 2.32.  
Manual SPPS was performed using the same resin and procedures described for the 
synthesis of dipeptides 2.28 and 2.29.  Coupling of the first amino acid was carried out with 
the pentafluorophenyl ester of FmocLeu (4.0 equiv), HOBt (4.0 equiv) and DIPEA (4.0 
equiv) in DMF (stirred 10 min at room temperature before being added to the resin) and then 
shaken with resin (2 x 90 min).  All subsequent couplings were performed using HBTU (4.0 
equiv), HOBt (4.0 equiv), DIPEA (4.0 equiv) and Fmoc-AA-OH (4.0 equiv). tert-Butyl 
protection was used for the side chains of Asp, Glu and Tyr. After the final Fmoc 
deprotection the resin was washed with DMF (3 mL, 5 x 3 min), methanol (3 mL, 5 x 3 min), 
ethanol (3 mL, 5 x 3 min) and diethyl ether (3 mL, 5 x 3 min) then left exposed to air to dry.   
Cleavage of the peptides from the resin was achieved by shaking with a cleavage 
cocktail consisting of TFA:TIPS (98:2, 2 mL) for 2.5 h after which the mixture was filtered.  
The resin was treated with another 2 mL of the cocktail for 30 min, filtered, and then the 
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resin was washed with successive portions of the cleavage cocktail (3 x 0.5 mL).  The 
combined filtrates were concentrated to half volume under reduced pressure.  The material 
was transferred to a 50 mL centrifuge tube and t-butyl methyl ether was added which resulted 
in the precipitation of the peptides.  The mixture was cooled in a dry ice-acetone bath for 30 
min then centrifuged (5000 rpm, -4 oC).  The supernatant was decanted and acetonitrile was 
added to the resulting pellet until the pellet dissolved.  The solution was transferred to a 
round bottom flask and concentrated to dryness.  The residue was dissolved or suspended in 
water and lyophilized.   
The resulting crude peptides were analyzed by analytical RP-HPLC (linear gradient 
of 5:95 CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 60 min). The 
analytical HPLC of crude DADEY(SO3DCV)LNH2 (2.31) obtained using amino acid 2.23 
showed mainly a single peak at tR= 26.0 min (see Figure 2.10).  This was used without 
further purification for the synthesis of peptide 2.30.  The analytical HPLC of the mixture of 
crude DADEY(SO3DCV)LNH2 (2.31) and DADEY(SO3TCE)LNH2 (2.32) obtained using 
amino acid 2.26 showed mainly two major peaks at tR= 27.9 and 28.7 min in an apparent 1:1 
ratio (see Figure 2.11).  This was used without further purification for the synthesis of 
peptide 2.30. 
DADEYLNH2 (2.16). 
Lyophilization after the post cleavage manipulation afforded almost pure peptide in a 98% 
yield.  1H NMR of the aromatic region (500 MHz, D2O): δ 6.80 (d, J = 8.5 Hz, 2H, HTyr), 
6.48 (d, J = 8.5 Hz, 2H, HTyr) (see Figure 2.14); HRMS (ESI-): calculated for 
C31H44Cl2N7O13 (M-H)- 722.2997, found 722.2993. Analytical HPLC showed a single peak 
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at tR= 14.5 min (linear gradient of 5 to 95 CH3CN:H2O (0.1% TFA) over 60 min) (see Figure 
2.1, B). 
2.5.5   General procedure for the removal of the DCV- or TCE-protecting groups in 
peptides 2.31, 2.32, 2.34, 2.36, 2.39 and 2.42. 
Ammonium formate (9 equiv for peptides 2.31, 2.32 and 2.36, 21 equiv for peptide 
2.34) was added to a solution of peptide in HPLC grade methanol (approximately 1 mL per 
10 mg peptide) followed by 30 wt% of 10% Pd/C.  The reaction was fitted with a balloon 
filled with H2, stirred at rt and the reaction was monitored by HPLC for the disappearance of 
starting material (CH3CN/H2O (0.1% TFA) as eluent, linear gradient from 5 to 95 CH3CN in 
60 min).  For peptide 2.31 (when amino acid 2.23 was used) the reaction was complete after 
1 h.  For the mixture of peptides 2.31 and 2.32 (when amino acid 2.26 was used) the reaction 
was complete after 3 h.  For peptides 2.34 and 2.36, after 2 h another 20 wt% of 10% Pd/C 
was added.  For peptide 2.34 the reaction was complete after an additional 3 h while for 
peptide 2.36 it was complete after an additional 1 h.  For peptides 2.39 and 2.42 ammonium 
formate (30 equiv and 19 equiv respectively) was added to a solution of the peptide in 
methanol (approximately 2 mL per 10 mg peptide) followed by 50 wt% of 10% Pd/C and the 
reaction was allowed to stir under H2 atmosphere for 15 h at room temperature.  
After the reactions were complete, the mixture was transferred to an Eppendorf tube 
and centrifuged in a microcentrifuge to pellet the Pd/C.  The supernatant was removed and 




2.5.6    Synthesis of DADEsYLNH2 (2.30).   
Deprotection of the DCV group from peptide 2.31 (when amino acid 2.23 was used) 
or the DCV/TCE from 2.31/2.32 mixture (when amino acid 2.26 was used) was performed 
using the general procedure described in section 2.5.5.  The analytical HPLC chromatogram 
of crude deprotected peptide 2.30 exhibited essentially a single major peak (tR= 14.14 min; 
linear gradient from 5% to 95% CH3CN in H2O (0.1% TFA) over 60 min, λ = 220 nm) (see 
Figure 2.12).  To further confirm that no desulfation occurred during DCV deprotection a 
sample of the crude peptide 2.30 was spiked with peptide 2.16 (DADEYLNH2) and then 
analyzed by analytical HPLC.  The chromatogram exhibited two peaks corresponding to 
peptides 2.16 and 2.30 at tR= 15.2 min and 14.1 min respectively (linear gradient from 5% to 
95% CH3CN in H2O (0.1% TFA) over 60 min, λ = 220 nm) (see Figure 2.13).  Purification 
of peptide 2.30 by semi-preparative RP-HPLC (CH3CN/20 mM ammonium acetate, pH = 
6.8, linear gradient from 5% to 20% CH3CN over 40 min, tR= 13.5 min, λ = 220 nm) 
afforded peptide 2.30 as a flocculent white powder.  When using amino acid 2.23 the yield 
was 71%.  Analytical HPLC of this material using a linear gradient of 1:99 CH3CN:20 mM 
ammonium acetate to 80:20 CH3CN:20 mM ammonium acetate over 40 min showed single 
peak at tR = 11.0 min.  1H NMR of the aromatic region (see Figure 2.15) (500 MHz, D2O): δ 
6.95 (d, J = 8.5 Hz, 2H, Hs-Tyr), 6.89 (d, J = 8.0 Hz, 2H, Hs-Tyr); HRMS (ESI-): calculated for 
C31H44N7O16S (M-+NH4)- 802.2565, found 802.2561.  When using amino acid 2.26 the yield 
was 45%.  However the analytical HPLC chromatogram indicated that this material was 
contaminated with a small amount of impurity which could not be removed.  The 1H NMR of 
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the aromatic region and HRMS of this material were identical to that of peptide 2.30 that was 
obtained using amino acid 2.23.  
2.5.7    Synthesis of AcsYEsYLDsYDFNH2 (2.33, PSGL-15-12, trisulfated), 
AcYEsYLDYDFNH2 (2.35, PSGL-15-12, monosulfated at Tyr7) and AcYEYLDYDFNH2 
(2.37, PSGL-15-12, nonsulfated).   
Automated SPPS was used. For the first amino acid the following protocol was used: 
Step Operation Volume (mL) Duration (min) Reps 
1 DMF wash 1 10 3 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 90 1 
5 Couplinga 1 90 1 
6 DMF wash 1 0.5 3 
aA solution of Fmoc-AA-OPfp (4 equiv), HOBt (4 equiv) and DIPEA 
(4 equiv) in DMF (stirred 10 min at room temperature) was added 
manually to the resin. 
 
For subsequent amino acids the following protocol was used: 
Step Operation Volume (mL) Duration (min) Reps 
1 DMF wash 1 0.5 6 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Coupling a 1 90 1 
5 DMF wash 1 0.5 3 
aAddition of Fmoc-AA-OH (5 equiv) in DMF followed by addition of 




For the last amino acid the following protocol was used: 
Step Operation Volume (mL) Duration (min)  Reps 
1 DMF wash 1 0.5 6 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 90 1 
5 DMF wash  1 0.5 6 
6 20% 2-MP/DMF 1 10 3 
7 DMF 1 0.5 6 
8 Acetylationb 1 180 1 
9 DMF wash 1 10 3 
10 MeOH wash 1 10 3 
11 DCM wash 1 10 3 
12 Dry 1 60 1 
aAddition of Fmoc-AA-OH (5 equiv) in DMF followed by addition of 
HOBt (5 equiv)/HBTU (5 equiv)/DIPEA (5 equiv) in DMF. bA 1 mL 2:1 
mixture of pyridine:acetic anhydride was added manually to the resin.  
 
Peptides were cleaved form the support using the procedure outlined in section 2.5.4.  
This gave crude peptides AcY(SO3DCV)EY(SO3DCV)LDY(SO3DCV)DFNH2 (2.34), and 
AcYEY(SO3DCV)LDYDFNH2 (2.36) and AcYEYLDYDFNH2 (2.37).  Peptides 2.34 and 
2.36 were analyzed by analytical RP-HPLC eluting with a linear gradient of 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 60 min (λ = 220 nm).  The 
analytical HPLC chromatogram of crude 2.34 showed mainly one major peak in the HPLC 
chromatogram (tR= 44.3 min) (see Figure 2.16).  This was used without further purification 
for the synthesis of peptide 2.33.  The analytical HPLC chromatogram of crude 2.36 showed 
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mainly one major peak in the HPLC chromatogram, (tR= 31.6 min) (see Figure 2.18).  This 
was used without further purification for the synthesis of peptide 2.35.  
Peptide 2.33 was prepared from peptide 2.34 using the general deprotection 
procedure described in section 2.5.5.  Preparative HPLC purification (CH3CN/ 20 mM 
ammonium acetate as eluent, linear gradient from 1% to 30% CH3CN over 30 min, tR= 21.4 
min, λ = 220 nm) afforded pure 2.33 as a flocculent white powder (16.9 mg, 46%).  The 
analytical HPLC chromatogram (linear gradient of 1:99, CH3CN:20 mM ammonium acetate 
to 80:20 CH3CN:20 mM ammonium acetate over 40 min) showed a single peak at tR= 13.7 
min (see Figure 2.17).  1H NMR of the aromatic region (see Figure 2.21) (500 MHz, D2O): 
δ 7.03-6.89 (m, 9H, 4Hs-Tyr and 5HPh), 6.85-6.79 (m, 6H, 4Hs-Tyr), 6.72 (d, J = 8.0 Hz, 2H, Hs-
Tyr); HRMS (ESI-): calculated for C57H66N9O27S3 (M-3+NH4)3- 468.1076, found 468.1070. 
Peptide 2.35 was prepared from peptide 2.36 using the general deprotection 
procedure described in section 2.5.5.  Preparative HPLC purification of the crude peptide 
(CH3CN/20 mM ammonium acetate as eluent, linear gradient from 1% to 50% CH3CN over 
30 min, tR= 19.5 min, λ = 220 nm) afforded pure 2.35 as a flocculent white powder (19.9 mg, 
63%).  The analytical HPLC chromatogram (linear gradient of 1:99 CH3CN:20 mM 
ammonium acetate to 80:20 CH3CN:20 mM ammonium acetate over 40 min) showed a 
single peak at tR= 15.9 min (see Figure 2.19). 1H NMR of the aromatic region (see Figure 
2.22) (500 MHz, D2O): δ 7.00-6.87 (m, 9H, 4Hs-Tyr and 5HPh), 6.68 (d, J = 8.0 Hz, 2H, HTyr), 
6.56 (d, J = 7.5 Hz, 2H, HTyr), 6.41 (dd, J = 8.0 and 9 Hz, 4H, HTyr); HRMS (ESI-): 
calculated for C57H67N9O21S (M-H-+NH4)2-  622.7086, found 622.7083. 
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Preparative HPLC purification of crude 2.37 (CH3CN/20 mM ammonium acetate as 
eluent, linear gradient from 1 % to 50 % CH3CN over 30 min, tR= 21.3 min, λ = 220 nm) 
afforded 2.37 as a flocculent white powder (20.0 mg, 68%). The analytical HPLC 
chromatogram (linear gradient of 1:99 CH3CN:20 mM ammonium acetate to 80:20 
CH3CN:20 mM ammonium acetate over 40 min) showed a single peak at tR= 16.5 min (see 
Figure 2.20).  1H NMR of the aromatic region (see Figure 2.23) (500 MHz, D2O): δ 7.01-
6.90 (m, 5H, HPh), 6.75 (d, J = 8.0 Hz, 2H, HTyr), 6.70 (d, J = 8.0 Hz, 2H, HTyr), 6.52 (d, J = 
8.0 Hz, 2H, HTyr), 6.44 (dd, J1 = J2 = 8.0 Hz, 4H, HTyr), 6.39 (d, J = 8.0 Hz, 2H, HTyr); HRMS 
(ESI-): calculated for C57H68N6O18 (M-H)-  1166.4682, found 1166.4684.  
2.5.8    Synthesis of Ac-DADSENSSFsY23sY24sY25DsY27LDEVAFNH2 (2.38, D614-33, 
tetrasulfated) and Ac-TTPDsYGHsYDDKDTLDLNTPVDKNH2 (2.41, C5aR7-28).   
           Automated SPPS was used.  For the first amino acid the following protocol was used: 
Step Operation Volume (mL) Duration (min) Reps 
1 DMF wash 1 10 3 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 90 1 
5 Couplinga 1 90 1 
6 DMF wash 1 0.5 6 
7 Cappingb 2 10 1 
8 DMF wash 1 0.5 6 
aA solution of FmocPheOPfp for 2.38 or FmocLys(Boc)OPfp for 2.41 (4.0 
equiv), HOCt (4.0 equiv) and DIPEA (4.0 equiv) in DMF (stirred 1-2 min at 





For subsequent amino acids the following protocol was employed: 
Step Operation Volume (mL) Duration (min) Reps 
1 DMF wash 1 0.5 3 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 45 2 
5 Couplinga 1 45 2 
6 DMF wash 1 0.5 6 
7 Cappingb 2 10 1 
8 DMF wash 1 0.5 6 
aFor peptide 2.38 and 2.41:  Addition of Fmoc-AA-OH (5.0 equiv) in 
DMF followed by addition of HOCt (5 equiv)/HCTU (5 equiv)/DIPEA (5 
equiv) in DMF b2:1:3 solution of pyridine:acetic anhydride :DMF 
 
For peptide 2.38, residues 23-25 were incorporated using the following protocol: 
Step Operation Volume (mL) Duration (min) Reps 
1 DMF wash 1 0.5 3 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 45 1 
5 Couplinga 1 45 1 
6 DMF wash 1 0.5 6 
7 Cappingb 2 10 1 
8 DMF wash 1 0.5 6 
aA solution of Fmoc-AA-OH (5.0 equiv), HATU (5.0 equiv) and DIPEA 
(5.0 equiv), in 1 mL of DMF (stirred 1-2 min at room temperature) was 







For the last amino acid the following protocol was used:  
Step Operation Volume (mL) Duration (Min)  Reps 
1 DMF wash 1 0.5 6 
2 20% 2-MP/DMF 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 45 2 
5 Couplinga 1 45 2 
6 DMF wash 1 0.5 6 
7 20% 2-MP/DMF 1 10 3 
8 DMF wash 1 0.5 6 
9 Capping 2 60 1 
10 DMF wash 1 10 3 
11 DCM wash 1 10 3 
12 Dry 1 60 1 
aFor peptide 2.38 and 2.41:  Addition of Fmoc-AA-OH (5.0 equiv) in 
DMF followed by addition of HOCt (5 equiv)/HCTU (5 equiv)/DIPEA (5 
equiv) in DMF b2:1:3 solution of pyridine:acetic anhydride :DMF 
 
The peptides were cleaved from the resin using the procedure described in section 
2.5.4.  The resulting crude peptides  
AcDADSENSSF(DCV)Y23(DCV)Y24(DCV)Y25D(DCV)Y27LDEVAFNH2 (2.39), and 
AcTTPD(DCV)YGH(DCV)YDDKDTLDLNTPVDKNH2 (2.42), were analyzed by analytical 
HPLC (eluting with a linear gradient of 5:95 CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O 
(0.1% TFA) over 60 min, λ = 220 nm).  The analytical HPLC chromatogram of crude 2.39 
showed mainly one major peak in the HPLC chromatogram (tR = 44.9 min) (see Figure 
2.27).  This was used without further purification for the synthesis of peptide 2.38.  The 
analytical HPLC chromatogram of crude 2.42 showed mainly one major peak in the HPLC 
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chromatogram, (tR = 28.9 min) (see Figure 2.29).  This was used without further purification 
for the synthesis of peptide 2.41. 
Peptide 2.38 was prepared from peptide 2.39 (20 mg) using the general deprotection 
procedure described in section 2.5.5.  Preparative HPLC purification (CH3CN/ 100 mM 
ammonium acetate (pH = 9) as eluent, linear gradient from 10% to 30% CH3CN over 60 min, 
tR= 23.0 min, λ = 220 nm) afforded pure 2.38 as a flocculent white powder after 
lyophilization (9.7 mg, 39% from resin loading). The analytical HPLC chromatogram (linear 
gradient of 10:90 CH3CN:100 mM ammonium acetate to 40:60 CH3CN:100 mM ammonium 
acetate over 40 min) showed a single peak at tR= 14.2 min (see Figure 2.28).  LRMS (ESI-): 
calculated for C112H143N22O53S4 (M-H)-1 2771.8059, found 2771.7405. 
Peptide 2.41 was prepared from peptide 2.42 (20 mg) using the general deprotection 
procedure described in section 2.5.5.  Preparative RP-HPLC purification (CH3CN/ 100 mM 
ammonium acetate (pH = 9) as eluent, linear gradient from 5% to 20% CH3CN over 40 min, 
tR= 27.0 min, λ = 220 nm) afforded pure 2.41 as a flocculent white powder after 
lyophilization (14.0 mg, 58% from resin loading). The analytical HPLC chromatogram 
(linear gradient of 5:95 CH3CN:100 mM ammonium acetate to 30:70 CH3CN:100 mM 
ammonium acetate over 40 min) showed a single peak at tR= 18.8 min (see Figure 2.30). 





2.5.9    Synthesis of AcMAEHDsY6HEDsY10GFSSFNDSSQNH2 (2.48, CXCR61-20) 
Automated SPPS was used.  The following general protocol was used for all amino 
acid unless mentioned otherwise. 
Step Operation Volume (mL) Duration (Min) Reps 
1 DMFa 1 0.5 3 
2 20% 2-MP 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplingb 1 20 1 
5 Couplingb 1 20 1 
6 DMF wash 1 0.5 6 
7 Cappingc 2 10 1 
8 DMF wash 1 0.5 6 
a For the first AA duration is extended 10 minX 3 times. bFmoc-AA-OH (5 
equiv) in DMF followed by addition of a solution of HOCt (5 equiv), HCTU (5 
equiv), DIPEA (5 equiv) in DMF.  c2:1:3 solution of pyridine:acetic anhydride 
:DMF 
 Residues Glu8, Asp9 and pseudoproline 2.50 (position 13-14) were incorporated into the 
growing peptide chain using the following protocol: 
Step Operation Volume (mL) Duration (Min) Rep 
1 DMF wash 1 0.5 3 
2 20% 2-MP 1 10 3 
3 DMF wash 1 0.5 6 
4 Couplinga 1 45 2 
4 Couplinga 1 45  2 
6 DMF wash 1 0.5 6 
7 Cappingb 2 10 1 
9 DMF wash 1 0.5 6 
aA solution of Fmoc-AA-OH (4 equiv) or pseudoproline dipeptide 2.50 HATU 
(4 equiv) and DIPEA (4 equiv) in DMF was added manually to the resin.  
b2:1:3 solution of pyridine:acetic anhydride :DMF 
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The last amino acid was attached to the growing peptide and acetylated using the 
same procedure described for insertion of the last amino acid in 2.39 (section 2.5.8).  
Cleavage of the peptide from the resin was achieved by mixing the resin for 2.5 h with the 
cleavage cocktail (TFA:TIS:H2O:EDT 92.5:2.5:2.5:2.5), followed by 5 min washing time 
with the same cocktail.  After cleavage from the support the crude peptide, 
AcMAEHD(DCV)YHED(DCV)YGFSSFNDSSQNH2 (2.49), was isolated using the same 
procedure as that described in section 2.5.4.  Crude peptide, 2.49, was analyzed by analytical 
HPLC eluting with a linear gradient of 5:95 CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O 
(0.1% TFA) over 60 min, λ = 220 nm. The analytical HPLC chromatogram of crude 2.49 
showed mainly one major peak in the HPLC chromatogram (tR = 30.5 min) (see Figure 
2.41).  Peptide 2.49 was used without further purification for the synthesis of peptide 2.48.  
Peptide 2.48 was prepared from peptide 2.49 by dissolving 2.49 (10 mg) in H2O (1 mL) 
containing of Et3N (5.56 μL, 11 equiv) and the resulting solution was diluted with HPLC 
grade methanol (1 mL).  Pd(OH)2  (20% w/w, 5 mg) was added and the mixture was stirred at 
rt under hydrogen gas (balloon pressure) for 24 h. The mixture was transferred to a 
microcentrifuge tube and centrifuged.  The solution was decanted and the residue 
resuspended in 0.5 mL of methanol and centrifuged and decanted again. The combined 
supernatants were purified using preparative HPLC (CH3CN/20 mM ammonium acetate as 
eluent, linear gradient of 10 to 15 % CH3CN over 30 min) which gave 3.8 mg of pure 2.48 as 
a flocculent white powder after lyophilization (41% yield). The analytical HPLC 
chromatogram (linear gradient of 10:90 CH3CN:20 mM ammonium acetate to 15:85 
CH3CN:20 mM ammonium acetate over 30 min) showed a single peak at tR= 25.9 min (see 
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Figure 2.42). LRMS (ESI-): calculated for C103H134N27O45S3 (M-H)-1 2564.8195, found 
2564.5745.  
2.5.10  Synthesis of AcAELSPSTENSSQLDFEDVWNSSsY30GVNDSFPDGDsY41DNH2 
(2.54, DARC8-42).    
Automated SPPS was used.  The general protocol used for peptide 2.48 (section 
2.5.9) was used for peptide 2.54 except for the last amino acid and residues Asp38, Glu39, 
Ser17, Ser18, Ser28 and Ser29.  The last amino acid was attached to the growing peptide and 
acetylated using the same procedure described for the insertion of the last amino acid in 2.38 
and 2.41 (section 2.5.8.).  Asp38 and Glu39 were incorporated as dipeptide 2.63 and residues 
Ser28 and Ser29 and Ser17-and Ser18 were incorporated as pseudoproline dipeptide 2.50 
using the same protocol described in section 2.5.9 for the incorporation of 2.50 in peptide 
2.48.  The peptide was cleaved from the support using the same procedure described for 
peptide 2.48 (section 2.5.9).  The resulting crude peptide  
AcAELSPSTENSSQLDFEDVWNS28S29(DCV)YGVNDSFPDGD(DCV)YD-NH2  (2.55), was 
analyzed by analytical RP-HPLC eluting with a linear gradient of 5:95 CH3CN:H2O (0.1% 
TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 60 min, λ = 220 nm. The analytical HPLC 
chromatogram of crude 2.49 showed mainly one major peak in the HPLC chromatogram (tR 
= 24.05 min) (see Figure 2.45). 
Peptide 2.54 was prepared from peptide 2.55 using the same procedure described for 
peptide 2.49 (section 2.5.9) except 17 equiv of triethylamine was used.  Peptide 2.54 was 
purified using preparative HPLC (CH3CN/20 mm ammonium acetate as eluent, linear 
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gradient from 15%  to 20% CH3CN over 60 min, tR= 15.8 min) which gave  2.9 mg of pure 
2.54 (32% yield). The analytical HPLC chromatogram (linear gradient of 15:85 CH3CN:20 
mM ammonium acetate to 25:75 CH3CN:20 mM ammonium acetate over 30 min) showed a 
single peak at tR= 14.26 min (see Figure 2.47). LRMS (ESI-): calculated for 
C169H234N41O74S2 (M-H)-1 4085.5255, found 4085.2175.  
2.5.11  Crude AcISDRD(DCV)YMGWMDFNH2 (2.56) 
 Automated SPPS was used employing the general protocol described above for 
peptide 2.48 (section 2.5.9) but using Fmoc deprotection times of either 3 x 10 min or 3 min 
+ 11 min and using either 2-MP or piperidine.  Peptide cleavage and post cleavage 
manipulations were performed as described for peptide 2.48 (section 2.5.9).   The crude 
peptides (2.56) were analyzed by analytical HPLC using a linear gradient of 5:95 
CH3CN:H2O (0.1% TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 60 min, λ = 220 nm. (see 





Synthesis of a Peptide Corresponding to PSGL-143-50 Containing the Non-
Hydrolyzable Sulfotyrosine Mimic 4-(Sulfonomethyl)phenylalanine using a 
Sulfonate protecting Group Strategy 
3.1  Introduction  
The development of a facile method for the synthesis of sTyr-containing peptides is 
important since these peptides can be used for determining the requirement for sTyr residues 
within sTyr-bearing proteins.  However, such peptides have limitations as far as drug 
development is concerned due to the hydrolytic lability of the sulfate group.  For drug 
development, a stable substitute for the sulfate group is preferred.  One of the most widely 
used non-hydrolyzable sTyr mimics is 4-(sulfonomethyl)phenylalanine (3.2, Smp).  It retains 
almost the same dimensions and charge as sTyr but it is much more stable than sTyr.  
 
Figure 3.1.  Sulfotyrosine (sTyr) and 4-(sulfonomethyl)phenylalanine (Smp). 
 Marseigne and Roques, 1988, were the first to propose Smp as a stable replacement 
for sTyr.156  They developed a racemic synthesis of AcSmp (3.8 in Scheme 3.1) and using 
Boc solution phase peptide synthesis constructed Ac(D,L)Smp-Nle-Gly-Trp-Nle-Asp-Phe-
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NH2 a heptapeptide that corresponds to residues 27-33 in CCK.  In this peptide, sTyr27 in 
CCK has been replaced with a Smp group and the Met residues at positions 28 and 31 have 
been replaced with Norleucine (Nle).   The D,L mixture of peptide isomers were separated by 
chromatography.  The L-isomer displayed an affinity for pancreatic binding sites (Ki = 1.7 
nM) almost equal to that of its sTyr analog.157  Moreover, it was a full agonist in the 
stimulation of pancreatic amylase secretion as well as in the induction of guinea pig ileum 
contractions (EC50 = 3.2 nM).157  In 1991, Roques and coworkers reported a synthesis of 
Smp in which racemic precursor 3.9 (Scheme 3.1) was subjected to a kinetic resolution using 
hog kidney acylase (Scheme 3.1) to give 3.10 predominantly as the L-isomer. Compound 
3.10 was then converted into L-BocSmp (3.12, 80% ee).  This amino acid was then 
incorporated into Ac-Asp-Smp-Nle-Gly-Trp-Nle-Asp-Phe-NH2 an octapeptide that 
corresponds to residues 26-33 in CCK using SPPS and Boc chemistry.158  This compound 
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Scheme 3.2.  Synthesis of building block 3.19 according to Rivier and coworkers’  
procedure.159 
 
 In 1993, Rivier and coworkers reported an enantioselective synthesis of L-FmocSmp 
(3.16) (Scheme 3.2).  This synthesis appears to be very straightforward starting from readily 
available Ac-L-PheOEt (3.13) though the yield of the last two steps was low (9% yield of 
pure product obtained over these two steps).  These workers then used 3.16 as a building 
block to incorporate Smp into a variety of CCK analogs using SPPS.  For example they 
prepared a peptide corresponding to residues 1-33 in CCK.  In this peptide Tyr27 was 
replaced with Smp, Met residues 7, 28 and 31 were replaced with Nle and Trp30 was 
replaced with 2-naphthylalanine (Nal).  The crude peptide preparation was extremely 
complex.  Nevertheless, they were able to obtain pure peptide after multiple HPLC 
columns.159  This peptide was 30 times less potent than CCK-8 in the stimulation of 
pancreatic amylase secretion.159  They suggested that this reduction in activity compared to 
CCK-8 was due to the large number of unnatural amino acids present in their modified 
peptide. 
 In 2007, Herzner and Kunz wished to construct a peptide corresponding to part of the 
N-terminus of PSGL-1 (see chapter 1, section 1.2.1 for a discussion of PSGL-1) except that 
they wished to replace the sTyr residues with Smp.160  They reported that they were unable to 
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repeat Rivier and coworkers’ synthesis of amino acid 3.16.  So they embarked on a study to 
develop a more reliable synthesis of this key building block.  Their first trial started with 
hydroxymethyl derivative 3.9 which was prepared following Marseigne and Roques 
chemistry in five steps starting from p-methyl-benzonitrile (Scheme 3.1).156  Resolution of 
the D,L-mixture was done using an acylase enzyme followed by carboxyl protection and 
Fmoc installation. Reaction of hydroxymethyl derivative 3.25 with N-bromosuccinimide and 
triphenylphosphine provided the corresponding alkylbromide 3.26 in a good yield.  
Installation of the sulfonate group followed by enzymatic hydrolysis of the ester afforded the 
desired building block (Scheme 3.3).  Because this route involves many steps and the low 


















6 d, 37 oC, MeOH, SOCl2
40 h, rt,
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H2O, dioxane, 20 h, rt
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3.20, 83%3.21, 100%3.16, 76%  
Scheme 3.3.  Synthesis of building block 3.16 according to Herzner and Kunz (route 1). 
 
Their next route started with the synthesis of the triflate derivative 3.23 which in turn 
was reacted with potassium cyanide in a nickel-catalyzed reaction to give the corresponding 
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cyano derivative 3.24 in a 58% yield (Scheme 3.4).  Reduction of the cyano group using 
Raney-Nickel followed by diazotization and hydrolysis gave the corresponding 
hydroxymethyl derivative 3.25 in low yield.  The rest of manipulations were done in analogy 
to Scheme 3.3 expect that there are extra two steps involving Boc removal and Fmoc 
installation. Again the synthesis is relatively long and proceeds in low overall yield.  
 
 
Scheme 3.4.  Synthesis of building block 3.19 according to Herzner and Kunz (route 2). 
 
In attempt to improve the yield of compound 3.19 (in Scheme 3.3) Herzner and Kunz 
performed a palladium-catalyzed reductive carbonylation of Fmoc-protected tyrosine 
derivative 3.29 to give formyl derivative 3.30 (Scheme 3.5).  Unfortunately, the reaction 
proceeded in low yield. The reduction of the formyl group using sodium borohydride 
occurred smoothly to furnish the hydroxymethyl derivative 3.19 which was subsequently 
























Scheme 3.5.  Synthesis of building block 3.19 according to Herzner and Kunz (route 3). 
 
Having the building block 3.16 in hand, they decided to explore the utility of it in the 
SPPS of a protected octapeptide corresponding to residues 43-50 in PSGL-1 (3.31, Figure 
3.2). The coupling of the first four amino acids proceeded smoothly.  However, coupling of 
the fifth amino acid (the second Smp) turned out to be difficult and even after performing 
double couplings for 16 h the yield did not exceed 50%.  Furthermore, the coupling of the 
seventh amino acid was difficult and the yield did not exceed 34% even after double 
couplings for 16 h.  The researchers did not comment if the difficulty in the synthesis was 
due to the use of 3.16 or if it was due to the peptide sequence itself.  The overall yield was 




Figure 3.2.   Partially protected peptide corresponding to residues Ala43-Asp50 of PSGL-1 
(3.31). 
 
Very recently (2008), Bewley et al. examined Smp as a replacement for the sTyr 
residues in CCR5. It has been shown that the HIV-1 co-receptor, CCR5, has two sTyr 
residues at positions 10 and 14, whose presence is required for binding HIV-1 gp-120 and 
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mediating viral entry.161  It has been suggested that peptides or other compounds that can 
interact with these sTyr residues may be used as anti-HIV drugs since they might be able to 
compete with HIV-1 for binding to CCR5.  When they tried to develop an assay to screen for 
sTyr-based inhibitors of CCR5 Nt-gp120 interactions they found that the sTyr residues 
lacked sufficient chemical stability which made their assay results questionable (they also 
mentioned that the large scale synthesis of sTyr peptides in the quantities and quality 
required for their assays was difficult using the methods that had been published at that time).  
In order to find an alternative substitute for the sulfate groups, they prepared a number of 
peptides (Figure 3.3) where the sTyr residues in peptide 3.32 were replaced with 
phosphotyrosine (pTyr) at one of the two positions (3.33 and 3.34, Figure 3.3) or both of 
them (3.35), or the two sulfate groups were replaced with Smp (3.36) (no mention was made 
as to how the Smp-bearing peptide was constructed) and tested them for their ability to bind 
to the CD4-gp120 complex using saturation transfer difference NMR and surface plasmon 
resonance.162  The phosphate groups generally diminished the binding affinity as illustrated 
by the complete loss of binding affinity of 3.35.  Based on the results of the binding affinities 
of 3.33 and 3.34 it was concluded that position 10 is more accommodating to the phosphate 
than position 14.  Such an observation can be reasoned by the fact that the binding pocket for 
sTyr14 contains only one positive charge and hence cannot accommodate the double charged 
phosphate group very well. Most importantly, they found that sulfonate analogue 3.36 had 
only a slightly diminished affinity compared to 3.32.  The slight reduction of the binding 
occurs because a hydrogen bond that is formed between the ester oxygen (S-O-C oxygen) in 
the sTyr residue and one of the residues in binding site is completely lost in the sulfonate 
 
 163 
analogue. On the top of that, there is a steric clash between the methylene hydrogens of the 
sulfonate residue and the active site. Overall, the authors decided that Smp is the best 




























































3.32  R1= OH, R2=R3=OSO3
- 
3.33  R1= OH, R2=OSO3
-,R3=OPO3
2- 
3.34  R1= OH, R2=OPO3
2-,R3=OSO3
-
3.35  R1= OH, R2=R3=OPO3
2-
3.36  R1= OH, R2=R3=CH2SO3
-  
Figure 3.3.  CCR5 Nt peptide and analogue 
 
It is clear for the above discussion that Smp is a useful non-hydrolyzable sTyr mimic.  
However, it is also clear from the above discussion that there are issues concerning its 
synthesis and its incorporation into peptides.  Several years ago, our group reported the 
enantioselective synthesis of compounds 3.46 and 3.47 using the approach outlined in 
Scheme 3.6.163 These building blocks were used to incorporate L-
[sulfono(difluoromethyl)]phenylalanine (F2Smp) into peptides.163 The syntheses were done 
manually using HATU/HOAt as coupling agent and 20% piperidine in DMF for Fmoc 
deprotection. The HPLC traces of the crude TCE-protected peptides of type 3.49 exhibited 
numerous peaks compared to the relatively clean neopentyl protected peptide (3.48).  The 
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removal of the neopentyl group was achieved using 1:1 CH3CN:0.1% TFA (H2O) for 4-5 

































3.37 3.38, 93% 3.39, 89% 3.40, R = nPt, 93%
3.41, R = TCE, 92%
3.42, R = nPt, 90%
3.43, R = TCE, 71%
3.44, R = nPt, 45%
3.45, R = TCE, 44%
3.46, R = nPt, 91%
3.47, R = TCE, 89%
SPPS
FmocHN COOHpeptideCOHN CONH-peptidepeptideCOHN CONH-peptide









3.48, R = nPt
3.49, R = TCE3.50
 
Scheme 3.6.  Synthesis of sulfotyrosine mimics 3.51 and 3.52. 
 
 The ease with which F2Smp was incorporated into peptides has prompted us to 
examine whether a similar approach, where the sulfonate moiety is incorporated as a 
protected ester, could be used for the synthesis of peptides bearing Smp.  We wished to 
construct FmocSmp with the sulfonate group protected and then use this as a building block 
to prepare Smp-bearing peptides.  Dr. Bryan Hill, a post-doc in the Taylor lab attempted to 
prepare FmocSmp derivatives with the sulfonate moiety protected with either a neopentyl or 
a TCE group (Scheme 3.7).  The TCE group has never been examined as a protecting group 
for sulfonate esters; however, as discussed in chapter 2, this moiety is an effective protecting 
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group for sulfate esters and is removed under very mild reducing conditions.  It was 
anticipated that it might be suitable as a protecting group for the sulfonate group in Smp 
during SPPS if we used 2-methylpiperidine (2-MP) for Fmoc removal as we did for the 
synthesis of sTyr peptides (see Chapter 2).  The key step in Dr. Hill’s approach to these 
compounds was the selective deprotection of the carboxylic acid and amino functionalities in 
3.53 and 3.54 without loss of the sulfonate protecting group (Scheme 3.7).  We were pleased 
to find that this could be achieved with the TCE-protected compound 3.53 by refluxing 3.53 
in 6 N HCl for 12 h which gave amino acid 3.55 in a 91% yield.  This reaction demonstrates 
the remarkable stability of TCE-protected sulfonates to acid.  However, subjecting the 
neopentyl ester 3.54 to the same conditions resulted in hydrolysis of the neopentyl ester to 
give Smp in 68% yield.  He was unable to find conditions that would allow us to selectively 
remove the ethyl and acetyl groups without removing the neopentyl group.  TCE-protected 
FmocSmp (3.56) was obtained in an 85% yield from 3.55 by reacting 3.55 with Fmoc-Cl 
under standard Schotten-Baumann conditions. 
3.2 Objectives 
 The objective of the work carried out in this chapter is to determine if Smp-bearing 






































3.53, R = OTCE, 70%










THF, 0 oC to rt
O/N
3.55, R = OTCE, 91%






Scheme 3.7.  Synthesis of amino acid derivative 3.56. 
3.3   Result and Discussion  
3.3.1  Stability of TCE-protected phenylsulfonates 
Before attempting to prepare peptides using compound 3.56 we determined 
conditions for removing the TCE group and we examined the stability of TCE sulfonate 
esters by subjecting model sulfonate 3.57 (Scheme 3.8) to a variety of conditions.  The TCE 
group in 3.57 was readily removed using mild reducing conditions such as Zn/ammonium 
formate in MeOH, Zn in HOAc and hydrogenolysis (H2 or ammonium formate with 10% 
Pd/C).  Not surprisingly, compound 3.57 is stable to 100% TFA with no detectable reaction 
occurring even after several days and to TFA containing scavenging reagents such as 
triisopropylsilane (TIPS), anisole and thioanisole.  It is also stable to mild reducing agents 
such as NaBH4.  It is stable to sterically hindered organic bases such as triethylamine but 
slowly decomposes in the presence of an excess of stronger or less sterically hindered 
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organic bases.  For example, 1H NMR studies in 20% piperidine/DMF-d7 revealed that ester 
3.57 undergoes nucleophilic attack by piperidine on the sulfur atom to give compound 3.58 
(Scheme 3.8) which was isolated and also characterized by mass spectrometry and 1H NMR.  
Compound 3.57 was completely consumed within 24 hours. This is in contrast to the 
previously mentioned aryl sulfate 2.11 which undergoes a relatively rapid elimination of HCl 
to give dichlorovinyl (DCV) ester 2.14 followed by a slower substitution reaction to give 
2.15 and other decomposition products.  
 
 
Scheme 3.8.  Decompostion of sulfate 2.11 and sulfonate 3.57 in presence of 20%piperidine. 
 
We have also shown (see chapter 2) that although 20% 2-methylpiperidine (2-MP) in 
DMF also converts sulfate ester 2.11 into DCV sulfate ester 2.14, no further reaction between 
2-MP and ester 2.14 occurs even after several days.  Furthermore, 2-MP was used in the 
preparation of number of difficult peptides and worked as well as piperidine during SPPS 
(see chapter 2).  This encouraged us to examine the stability of compound 3.57 in the 
presence of 20% 2-MP.  1H NMR studies of ester 3.57 in 20% 2-MP/DMF-d7 revealed that 
although attack of 2-MP on the sulfur atom still occurs, the reaction is considerably slower 
compared to when piperidine is used and even after 8 hours only 8% of 3.57 had reacted.  
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These results together with fact that sulfonates exhibit superior on-resin stability compared to 
in solution as illustrated by Hari and Miller149 suggested to us that amino acid 3.56 could be 
used in SPPS if 2-MP was used as the base for Fmoc removal.   
3.3.2  Determination of the enantiopurity of compounds 3.56 
Although Dr. Bryan Hill had prepared amino acid derivative 3.56 he had not 
determined its enantiopurity.  The enantiopurity of 3.56 were determined by constructing 
dipeptides Ac-Phe(p-CH2SO3TCE)-A(L)-NH2 (3.59LL) and Ac-Phe(p-CH2SO3TCE)-A(DL)-
NH2 (3.59LL/3.59DL) and comparing their HPLC chromatograms and 1H-NMR spectra. 
These dipeptides were prepared using the same protocol described for the preparation of 
hexapeptide 2.16.   
As expected, the diastereomeric dipeptide mixture Ac-Phe(p-SO3TCE)-A(DL)-NH2 
showed two peaks in the HPLC trace and two sets of peaks in the 1H-NMR spectrum 
corresponding to peptides 3.59LL and 3.59LD (Figure 3.4 and 3.5).  Peptide Ac-Phe(p-
SO3TCE)-A(L)-NH2 on the other hand showed only one peak in the HPLC trace and one set of 
peaks in the 1H-NMR spectrum corresponding to peptide 3.59LL (Figures 3.6 and 3.7) 












































































































































































































































































































































































Figure 3.6.  Analytical HPLC chromatogram of dipeptide 3.59LL.  
 




























































































































































































































Figure 3.7.  300 MHz 1H NMR (CD3OD) spectrum of dipeptide 3.59LL. 
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3.3.3  Synthesis of a model sulfonated peptide corresponds to residues 43-50 of PSGL-1 
(3.60) 
In order to demonstrate the utility of our TCE-protected FmocSmp in peptide 
synthesis we prepared an octapeptide, Ac-Ala-Thr-Glu-Phe(p-CH2SO3-)-Glu-Phe(p-CH2SO3-
)-Leu-Asp-NH2 (3.60), which corresponds to residues 43-50 of P-selectin glycoprotein 
ligand-1 (PSGL-1) in which the sTyr residues at positions 46 and 48 are replaced with Smp.  
This was chosen as a model peptide since Herzner and Kunz (see section 3.1.1) reported 
difficulties in preparing benzyl-protected version of 3.60 (3.31 in Figure 3.2) using 
sulfonate-unprotected amino acid 3.16.160  Automated SPPS was performed using the Rink 
amide resin and HBTU/HOBt as coupling reagents.  The removal of the Fmoc group was 
removed using 3 x 10 min of 20% 2-MP/DMF. After the completion of the peptide chain, the 
completed peptide was cleaved from the resin using 98% TFA/2% TIPS then precipitated in 
ether.  The analytical HPLC chromatogram of the crude peptide consisted of one major peak 
plus a few minor peaks (Figure 3.8).  Furthermore, the –ESI mass spectrum of the crude 
peptide indicated that the major product in the crude mixture was desired TCE-protected 
peptide Ac-Ala-Thr-Glu-Phe(p-CH2SO3TCE)-Glu-Phe(p-CH2SO3TCE)-Leu-Asp-NH2 (3.61) 
and no peaks corresponding to peptides that had undergone substitution of the TCE group 
with 2-MP were detected.  After subjecting crude peptide 3.61 to H2 (balloon), 30 wt. % of 
10% Pd/C, and 15 equiv. ammonium formate for 6 h, HPLC analysis of the crude reaction 
mixture revealed one major peak plus a variety of minor peaks  (Figure 3.9).  Purification by 





Figure 3.8.  Analytical HPLC chromatogram of the crude peptide Ac-Ala-Thr-Glu-Phe(p-
CH2SO3TCE)-Glu-Phe(p-CH2SO3TCE)-Leu-Asp-NH2  (3.61, tR= 34.0 min). 
   
Figure 3.9.  Analytical HPLC chromatogram of the crude peptide Ac-Ala-Thr-Glu-Phe(p-
CH2SO3-)-Glu-Phe(p-CH2SO3-)-Leu-Asp-NH2 (3.60, tR  = 15.7 min) prepared from TCE 





Figure 3.10.  Analytical HPLC chromatogram of purified peptide Ac-Ala-Thr-Glu-Phe(p-
CH2SO3-)-Glu-Phe(p-CH2SO3-)-Leu-Asp-NH2 (3.60, tR  = 15.88 min) prepared using TCE 
protected amino acid 3.56.   
 
To compare our methodology to the previously reported methodology in which Smp 
is incorporated unprotected we also prepared peptide 3.60 using the identical procedure 
except sulfonate-unprotected amino acid 3.6 was used as a building block.  We found that 
amino acid 3.16 could be prepared in 94% yield from compound 3.56 by subjecting 3.56 to 
Zn/ammonium formate in MeOH (Scheme 3.9).  HPLC analysis of the crude peptide showed 
many peaks (Figure 3.10) and after purification using semi-preparative RP-HPLC pure 









6 equiv ammonium formate







3.16, 94%  




Scheme 3.10.  Analytical HPLC chromatogram of the crude peptideAc-Ala-Thr-Glu-Phe(p-
CH2SO3-)-Glu-Phe(p-CH2SO3-)-Leu-Asp-NH2 (3.60, tR=15.76 min) prepared from 
unprotected amino acid 3.16. 
 
3.4  Summary 
We have shown that TCE-protected sulfonates are stable to a variety of conditions 
such as strong acid, mild bases and reducing agents but are not stable to an excess of organic 
bases such as piperidine.  We demonstrated that amino acid 3.56 is an effective building 
block for the solid phase synthesis of Smp-bearing peptides when using 2-MP as base and 
that this approach provided the targeted peptide in higher yield compared to when sulfonate-
unprotected amino acid 3.16 was used.  We expect that the TCE group will be useful as a 
protecting group for sulfonates in general and will be especially effective in situations where 
stability to strongly acidic conditions is required.  Future studies will involve the preparation 
of other Smp-bearing peptides such as those corresponding the N-terminus of the DARC 
protein (see chapter 1, section 1.2.2.2) and then examine them for their ability to prevent 
DBL binding to Duffy positive red blood cells.  
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3.5  Experimental 
Synthesis of FmocPhe(p-CH2SO3H)OH (3.16).   
 
To a solution of amino acid 3.56 (1.0 g, 1.63 mmol) in HPLC grade methanol (3 mL) 
was added ammonium formate (0.61 g, 9.78 mmol) followed by Zn dust (0.64 g, 9.78 mmol).  
After stirring overnight, the reaction mixture was filtered through Celite® and concentrated 
by rotary evaporation. Compound 3.16 was purified by flash chromatography using 
CH2Cl2/MeOH/AcOH/H2O (50:8:1:1), and the solvent system was shifted to 
(CH2Cl2/MeOH/ AcOH /H2O 7:3:0.3:0.6) when compound 3.16 started to  elute from the 
column.  This gave pure 3.16 as a white solid (0.73 g, 94%).  Mp =  182-185 oC; 1H NMR 
(300 MHz, CD3OD): δ 7.76 (2H, d, J = 7.5 Hz); 7.59 (2H, d, J = 7.2 Hz), 7.38-7.25 (6H, m), 
7.15 (2H, d, J = 7.8 Hz), 4.35-4.27 (2H, m), 4.24-4.18 (1H, m), 4.15-4.11 (1H, m), 3.97 (2H, 
s), 3.14 (1H, dd, J1 = 9.3 Hz & J2 = 4.8 Hz), 2.94 (1H, dd, J1 = 8.4 Hz & J2 = 5.4 Hz); 13C 
NMR (75 MHz, DMSO-d6): δ 174.1, 156.1, 144.3, 144.2, 141.1, 136.6, 133.6, 130.3, 128.8, 
128.0, 127.5, 125.8, 125.7, 120.5, 65.98, 57.6, 56.5, 47.0, 36.9; LR-ESIMS m⁄z (relative 
intensity): 480 ([M-H]-, 100), 481 (M, 32); HR-ESIMS calculated for C25H22NO7S (M-H)- 





Determination of the enantiopurity of amino acid 3.56.   
The enantiopurity of the building block 3.56 was determined by synthesizing 
dipeptides Ac-Phe(p-SO3TCE)-A(L)-NH2 (3.59LL) and Ac-Phe(p-SO3TCE)-A(DL)-NH2 
(3.59LL/3.59DL)  and analyzing them by HPLC and 1H NMR.  The synthesis of the 
dipeptides was done in the same way as described for hexapeptide 2.16 and dipeptides 2.28 
and 2.29 using Rink amide as solid support, HBTU/HOBt as coupling agent and 2-MP for 
Fmoc removal (chapter 2, section 2.5.4). After coupling of the last amino acid and Fmoc 
removal, an acetylation step was conducted using acetic anhydride/pyridine/DMF mixture. 
The cleavage from the resin and post cleavage manipulations were performed in the same 
way as described before for 2.28 and 2.29. The crudes products after removal of the cleavage 
cocktail were purified by flash chromatography to yield the pure dipeptide products. The 
resulting dipeptides were analyzed using analytical C-18 RP-HPLC eluting with CH3CN/20 
mM ammonium acetate (pH = 6.8) employing a linear gradient of 20% to 35% CH3CN over 
40 min with the detector set to 220 nm (see Figures 3.4 and 3.6). 
Ac-Phe(p-CH2SO3TCE)-A(L)-NH2 (3.59LL)  
1H NMR (300 MHz, CD3OD): δ 7.42-7.39 (4H, m), 7.32-7.26 (4H, m), 4.71 (2H, s), 
4.68 (2H, s), 4.66 (4H, s), 4.59 (1H, dd, J1  = 5.9 Hz & J2  = 2.8 Hz), 4.40 (1H, t, J  = 7.7 Hz), 
4.28 (1H, dd, J 1 = 7.3 Hz & J2  = 7.1 Hz), 4.16 (1H, dd, J1  = 7.2 Hz & J2 = 7.0 Hz), 3.14 
(1H, dd, J1  = 8.0 Hz & J2  = 5.8 Hz), 3.0-2.8 (3H, m), 1.91 (3H, s), 1.88 (3H, s), 1.31 (3H, d, 
J  = 7.1 Hz),  1.12 (3H, d, J  = 7.3 Hz). HRMS (ESI+): calculated for C17H23Cl3N3O6S 





  1H NMR (300 MHz, CD3OD): δ 7.40 (2H, d, J  = 8.1 Hz), 7.30 (2H, d, J  = 8.1 Hz), 
4.68 (2H, s), 4.66 (2H, s), 4.59 (1H, dd, J1  = 5.9 Hz & J2  = 2.9 Hz), 4.28 (1H, dd, J1  = J2  = 
7.1 Hz), 3.14 (1H, dd, J1  = 8.0 Hz & J2  = 5.8 Hz), 2.95-2.87 (1H, m), 1.88 (3H, s), 1.31 (3H, 
d, J  = 7.1 Hz),; HRMS (ESI+): calculated for C17H23Cl3N3O6S (M+H)+ 502.0373, found 
502.0385.  The 1H NMR spectrum is shown in Figure 3.5.   
Synthesis of crude peptides AcATEPF(p-CH2SO3TCE)EF(p-CH2SO3TCE)LDNH2 
(3.61),  and AcATEPF(p-CH2SO3H)EF(p-CH2SO3H)LDNH2 (3.60 using amino acid 3.16 
as building block). 
The synthesis of these peptides was done automatically using a Quartet automated 
peptide synthesizer at 25 μM scale employing the same protocols as shown in the synthesis 
of peptides 2.34 and 2.37 (chapter 2, section 2.5.7) where the first amino acid is coupled as 
pentafluorophenyl activated ester using 4 equivalents excess. Coupling cycle for the 
remaining amino acids composed of a DMF wash, deprotection of Fmoc using 2-MP (3 x 10 
min), coupling of the amino acid using HBTU/HOBt/DIPEA and finally a DMF wash. The 
coupling of the last amino acid involved an extra step of acetylation after removal of the 
Fmoc group.  Cleavage from the resin using TFA:TIPS 95:5 followed by precipitation of the 
peptide using tert-butyl methyl ether was also performed as described before ((chapter 2, 
section 2.5.4).  The peptide pellet that remained after centrifugation was suspended in water 





Synthesis of peptide 3.60 from peptide 3.61.   
To a solution of crude peptide 3.61 (30 mg) in HPLC grade methanol (3 mL) was 
added ammonium formate (19.4 mg, 15 equiv), followed by 10% Pd/C (9 mg, 30% wt.).  The 
reaction was fitted with a balloon filled with H2, stirred at rt and the reaction was monitored 
by HPLC for the disappearance of peptide 3.61 (CH3CN/H2O 0.1% TFA) as eluent, linear 
gradient from 5 to 95 CH3CN in 60 min).  After 6 h, the reaction mixture was transferred into 
an Eppendorf tube and centrifuged to pellet the Pd/C.  The supernatant was removed and the 
pellet was washed two more times with 3 mL of methanol.  The combined supernatants were 
concentrated under reduced pressure.  Peptide 3.60 was purified using semipreparative RP-
HPLC with a UV detector set at 220 nm.  A linear gradient of 1% CH3CN/99% 100 mM 
ammonium acetate (pH = 9) to 10% CH3CN/90 % 100 mM ammonium acetate over 60 min 
was used as eluent (tR = 39.3 min).  Fractions containing peptide 3.60 were pooled, 
concentrated by high vacuum rotary evaporation and the residue was dissolved in water and 
repeatedly lyophilized until a constant weight was obtained.  Peptide 3.60 was obtained as 
flocculent white powder (16.7 mg, 60% yield based on resin loading).  Peptide 3.60 was 95% 
pure as determined by analytical RP-HPLC, tR= 15.8 min, 1% to 40% CH3CN in 0.1 M 
ammonium acetate (pH = 9) over 60 min, λ = 220 nm (Figure 3.10). HRMS (-ESI): 





Sulfotyrosine containing peptides as inhibitors of PTP1B.  
4.1   Introduction 
The signalling process mediated by protein phosphorylation is controlled by the 
opposing but complementary actions of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs).164  While PTKs catalyze the transfer of the phosphate moiety from ATP 
to the phenolic group of the tyrosine residue(s), PTPs catalyze the hydrolysis of the formed 
phosphate bond to yield the reverse of the aforementioned reaction.164 It is well accepted now 
that kinases are involved in controlling the amplitude of a signalling response, whereas 
phosphatases control its rate and duration.165,166 On the other hand, the imbalance in between 
PTKs and PTPs is linked to many disease states including cancer, diabetes, obesity and 
inflammation and autoimmunity.167-169  
Among the 107 members of the PTP family170, protein tyrosine phosphatase 1B 
(PTP1B) has garnered the most attention as far as inhibitor design is concerned.171, 172 PTP1B 
is known for its negative regulatory role in both insulin and leptin signalling. PTP1B 
dephosphorylates activated insulin receptor (IR), insulin receptor substrates (IRS) and the 
downstream result is the inhibition of glucose uptake.173-175 This is supported by the fact that 
overexpression of PTP1B in cell culture resulted in decreased insulin-stimulated IR 
phosphorylation.176-178 Diabetic mice showed a decrease in fat, plasma and blood glucose 
level upon treatment with PTP1B antisense oligonucleotides.179  Most significantly, PTP1B 
double-knockout mice showed an enhanced sensitivity to insulin, have improved glycemic 
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control and are more resistance to weight gain when fed with high-diet compared to wild-
type. Such effects most likely occurred because the increased energy expenditure resulted 
from enhanced leptin sensitivity.180, 181  Altogether these data suggesting that inhibitors to 
PTP1B could be developed into drugs for the treatment of metabolic diseases such as type-2 
diabetes and obesity.  
Free phosphotyrosine (pTyr) is a relatively poor PTP1B substrate (4.1, Km = 5 mM) 
in comparison to peptides bearing pTyr such as DADEpYL, a hexapeptide corresponding to a 
region in the epidermal growth factor receptor (Km = 3.6 μM).182  Peptides that do not bear a 
phosphate group do not bind to PTP1B.  These studies underscore the importance of both the 
phosphate group and residues in addition to the pTyr residue to substrate binding.  Phosphate 
esters are not considered to be suitable as drug candidates due to their hydrolytic liability and 
poor cell permeability.  Hence, the search for a suitable pTyr mimic for drug design has been 
a major part of PTP1B research.183  The phosphate group and numerous phosphate mimics 
have been incorporated into peptide and non-peptidyl platforms and tested as inhibitors for 
PTP1B.183  Numerous pTyr mimics have been evaluated in the context of the DADEXL 
hexapeptide (X = pTyr mimic).183   
X
H2N COOH
4.1, X = OP(O)2OH (pTyr or pY)
4.2, X = CH2P(O)2OH (Pmp)
4.3, X = CF2P(O)2OH (F2Pmp)
4.4, X = OS(O)2OH (sTyr or sY)
4.5, X = CH2S(O)2OH (Smp)




The most straightforward approach to preparing a stable pTyr mimic is to replace the 
bridging oxygen by a methylene group to give phosphonomethyl phenylalanine (4.2, Pmp). 
Insertion of amino acid 4.2 into the DADEXL hexapeptide template yielded peptide (4.8) 
resulted in a 25-fold lower affinity for PTP1B (IC50= 200 μM) compared to its parent peptide 
bearing 4.7. The loss of affinity was suggested to be due to the increase in pKa of the 
phosphonate group and a net reduction in formal charge of the phosphonate. In addition, the 
decrease in the affinity of the phosphonate may be reasoned by the loss of hydrogen bonding 

























4.7, X = OP(O)2OH 4.10, X = CH2S(O)2OH
4.8, X = CH2P(O)2OH 4.11, X = CF2S(O)2OH
4.9, X = CF2P(O)2OH
 
 In attempt to enhance the affinity of the phosphonate towards PTP1B, two α-fluorines 
were incorporated into Pmp to give the corresponding difluorphosphonomethylphenylalanine 
(4.3, F2Pmp) bearing a difluoromethylenephosphonyl (DFMP) group.  Upon insertion of 
F2Pmp into the hexapeptide platform (4.9) it showed an IC50 = 100 nM.  F2Pmp is one of the 
most effective phosphate mimics ever obtained, showing an approximate 1000-fold 
enhancement in affinity relative to the analogous peptides bearing Pmp (peptide 4.8).184   
This difference in affinity may be due to the possibility that the enzyme prefers to bind the 
dianionic form of the  phosphonate inhibitor as opposed to the monoanionic form.  At the pH 
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under which the inhibitor studies were performed (pH 6.5-7), the fluorinated phosphonate 4.9 
exists almost entirely in the dianionic form while the phosphonate group in the non-
fluorinated inhibitor 4.8 would exist mainly in the monoanionic form.  However, kinetic 
studies performed with these inhibitors over a broad pH range spanning the phosphonate and 
phosphate pKa’s revealed that the monoanionic and dianionic forms bind with equal affinity 
suggesting that the large difference in affinity between 4.8 and 4.9 is not due to the lower pKa 
of the fluorinated phosphonate moiety.  X-ray crystallographic studies of a small molecule 
inhibitor bearing a DFMP group bound to PTP1B suggest that the fluorines contribute to 
binding mainly by H-bonding with specific residues in the active site.185  
Inhibitors bearing the DFMP group are not highly cell permeable which limits their 
use in drug development.  Consequently, numerous less ionic phosphate mimics have been 
investigated.183  Among these mimics is sTyr (4.4) which was examined by Desmarais and 
coworkers as a substitute for pTyr.186  Surprisingly, the tetrapeptide (4.12) containing sTyr 
acted as good competitive inhibitor with an IC50 value in the low μM range which is in the 

























   The Taylor group developed sulfonomethylphenylalanine (4.5, Smp) and 
difluorosulfonomethylphenylalanine (4.6, F2Smp) as hydrolytically stable pTyr mimics and 
incorporated them into the hexapeptide platform to give peptides 4.10 and 4.11 respectively 
and tested them against PTP1B.187,188  Surprisingly, substitution of the methylene group in 
4.10 with a difluoromethylene group (4.11) did not have the significant effect on binding as 
found with the phosphonates  (IC50’s = 24 μM for 4.11 versus 44 μM for 4.10).  It has been 
hypothesized that with the sulfonates the larger sulfur atom (compared to phosphorus) 
somehow restricts movement of the mimic in the active site which prevents the fluorine 
atoms from attaining beneficial interactions within the active site.  The potency of peptides 
4.10 and 4.11 have never been compared to the corresponding sTyr peptide DADEsYLNH2 
(2.30), since 2.30 has never been prepared until very recently (see chapter 2). 
There are two objectives to the work in this chapter.  One is to determine how sTyr 
compares to Smp and F2Smp as a pTyr mimic in the context of PTP1B inhibition.  This will 
be done by determining the IC50 of peptide 2.30 whose synthesis was described in chapter 2. 
Another objective of this work is to determine if the Km’s or some other parameter (kcat, or 
kcat/Km) of phosphorylated peptide substrates can be used as a guide for developing peptide-
based PTP1B inhibitors.  If a peptide substrate exhibits a low Km then will its sTyr analog 
exhibit a good affinity or should other kinetic parameters of the substrate (such as kcat and 
kcat/Km) also be scrutinized?  In an attempt to answer this question we will construct a series 
of sTyr peptides that are based on some recently reported pTyr-bearing peptidyl PTP1B 
substrates.  The IC50’s will be determined for these sTyr peptides and compared to the 
reported Km’s  and other parameters of the corresponding pTyr substrates.    
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4.2   Results and discussion 
 To determine if the Km’s of pTyr substrates can be used as a guideline for preparing 
peptide-based inhibitors bearing pTyr mimics we chose a series of known pTyr peptide 
substrates that differed in their sequence, number of residues, Km’s and kcat values.  We wish 
to prepare the sTyr analogs of these peptides and determine their IC50’s and then compare the 
IC50’s to the Km’s ((and kcat/Km’s) of the pTyr peptidyl substrates.  Very recently, the groups 
of Barrios189 and Pei190 have reported several novel peptide substrates for PTP1B.  Among 
them are peptides 4.13 and 4.14 (Table 4.1).189  These peptides contain a phosphorylated 
coumarin-bearing amino acid in place of pTyr.  We specifically chose these two peptides for 
our studies since they have very similar Km’s but very different kcat’s and consequently 
different kcat/Km values.  The similar Km values would suggest that they bind to the enzyme 
with equal affinity but the much higher kcat value of peptide 4.13 suggests that the phosphate 
group in 4.13 is capable of obtaining an orientation in the active site that is more conducive 
to catalysis than that of peptide 4.14.  Peptide 4.15 (Table 4.1) was recently reported by Pei 
and coworkers.190  It has a sequence that is very different from that of peptides 4.13 and 4.14 
and also contains pTyr and not a phosphorylated coumarin residue.  Its Km is very similar to 
that of peptides 4.13 and 4.14 and has a kcat that is similar to peptide 4.14.  Peptide 4.16 
(Table 4.1) corresponds to residues 1159-1171 of the insulin receptor kinase.183  Its sequence 
and number of residues is quite different from the other peptides mentioned above.  It has 
two pTyr residues one which binds in the catalytic site and the other which binds in a second, 
non-catalytic pTyr binding site.  It has a Km (7.9 μM) (kcat was not reported) that is much 
lower than peptides 4.13-4.15.  It’s EC50 has been determined, using a substrate trapping 
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mutant of PTP1B, to be 210 nM.  The monophosphorylated forms of peptide 4.16 exhibit 
Km’s that are more than 10-fold higher than that of peptide 4.16.    
Table 4.1.  Kinetic parameters of compounds 4.13-4.16. 
Entry Sequence kcat (s-1) KM (μM) kcat/KM (M-1 s-1) 
1 Ac-FnGA-X-QLEENH2 (4.13)a 160 270 6.0 x 105 
2 Ac-VFDQ-X-HESPNH2 (4.14)a 11.5 280 4.1 x 104 
3 EHTGHpYAA (4.15)b 14 290 4.7 x 104 
4 ETDpYpYRKGGKGLL (4.16)c NRd 7.9 NRd 











 The synthesis of peptide 2.30 was reported in chapter 2 (section 2.3.7).  The sTyr 
analogues of peptide 4.13-4.16 (peptides 4.17-4.20) were prepared using the optimized 
procedure described for the synthesis of residue 1-20 of N-terminal of CXCR6 (Chapter 2) 
applying HCTU/HOCt/DIPEA (5 equiv) for amino acid coupling, 2-MP (3 x 10 min) for 
Fmoc deprotection and TFA:TIPS:H2O:EDT (92.5:2.5:2.5:2.5) for side chains protecting 
groups deprotection and cleavage from resin. Removal of the DCV groups was achieved 
using 50% w/w Pd(OH)2 under H2 atmosphere (balloon pressure) in water/methanol (1:1) 
containing  Et3N (one equiv of Et3N per acidic amino acid and two equiv per DCV group).  
IC50 determinations were carried out under conditions similar to those reported by 
MerckFrosst applying 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as substrate 
at Km concentration (5μM).191,192   The IC50 curves for peptide 2.30 and 4.17-4.20 are shown 




Figure 4.1.  IC50 plot for peptide 2.30.  Inhibitor concentrations range from 0.39-800 μM.  
IC50 = 9.4 ± 0.6 μM. 
 
Figure 4.2.  IC50 plot for peptide 4.17.  Inhibitor concentrations range from 0.19-400 μM.  
IC50 = 28.0  ± 1.4 μM. 
μM Inhibitor




























Figure 4.3.  IC50 plot for peptide 4.18.  Inhibitor concentrations range from 0.39-800 μM.    
IC50 = 61.0 ± 2.4 μM. 
 
Figure 4.4.  IC50 plot for peptide 4.19.  Inhibitor concentrations range from 0.39-800 μM.  
IC50 = 168 ± 5.4 μM. 
μM Inhibitor




























Figure 4.5.  IC50 plot for peptide 4.20.  Inhibitor concentrations range from 0.39-800 μM.   
IC50 = 121.2  ± 5 μM. 
 
 Among the peptides examined, hexapeptide 2.30 (DADEsYLNH2) was the most 
potent inhibitor of PTP1B with an IC50 = 9.4 μM.  This IC50 is similar to the Km values that 
have been reported for the analogous pTyr peptide 4.7 (5-20 μM).182  Although 2.30 is not as 
potent as its diflouromethylenephosphonate analogue (about 100 times less potent than 
peptide 4.9), it is slightly more potent than Smp (4.10) and F2Smp (4.11).  This confirms the 
results from our previous studies that the sulfur-containing inhibitors appear to be relatively 




















Table 4.2.  IC50`s of peptides 2.30 and 4.17-4.20. 
Entry Sequence IC50 (μM) 
1 DADEsYLNH2 (2.30) 9.4 
2 Ac-FnGA-sY-QLEENH2 (4.17) 28 
3 Ac-VFDQ-sY-HESPNH2 (4.18) 61 
4 EHTGHsYAANH2 (4.19) 168 
5 ETDsYsYRKGGKGLLNH2 (4.20) 121 
 
 The IC50 of peptide 4.19 is only 1.7 times less than that of its analogous pTyr peptide 
4.15.  However, it should be pointed out that the IC50 curve for this peptide was unusually 
steep (Figure 4.4) suggesting that inhibition could in part be due to inhibitor aggregation.193  
The IC50`s for peptides 4.17 and 4.18 are 5-10-fold less than the Km`s reported for the 
analogous phosphoryl coumarin-bearing peptides 4.13 and 4.14.  This suggests that the 
coumarin ring has a detrimental effect on substrate binding which makes it difficult to 
compare the effect of the sulfur versus phosphorus substitution (IC50 values of the sTyr 
peptides to the Km values of the coumarin-bearing peptides).  The kcat value for peptide 4.13 
is 14-fold greater than that of peptide 4.14.  Thus, at the very least, it appears that kcat values 
of these coumarin-bearing peptide substrates should not be used as a guideline for preparing 
the analogous peptide inhibitors bearing a pTyr mimic.  Also, once again it should pointed 
out that the IC50 curve for peptide 4.18 is unusually steep (Figure 4.3) suggesting that 
inhibition could in part be due to inhibitor aggregation.193  
 Surprisingly bis-sulfated peptide 4.20 exhibited a much higher IC50 compared to the 
Km of its pTyr analog 4.16.  Since our studies with peptide 2.30 and those of Desmarais et al. 
186 suggest that the sulfate group in sTyr peptides bind in the active site almost as well as the 
phosphate group in pTyr peptides (based on comparing IC50’s to Km’s) then the difference 
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between the IC50 of peptide 4.20 and the Km of peptide 4.16 could very likely be due to the 
presence of the extra sTyr residue in 4.20  As mentioned above, in peptide 4.16 one pTyr 
residue (pTyr1162) binds in the catalytic site and the other (pTyr 1163) binds in a second, 
non-catalytic pTyr binding site.  The monophosphorylated forms of peptide 4.16 exhibit Km’s 
that are more than 10-fold higher (> 80 μM) than that of peptide 4.16.  The IC50 found for 
peptide 4.20 (121 μM) is closer to that of the Km’s found for the monophosphorylated 
versions of peptide 4.16 suggesting that the binding synergism found with the two pTyr 
residues in peptide 4.16 does not occur with the corresponding sulfated peptide.  It is possible 
that the sTyr residue in peptide 4.20 that corresponds to pTyr residue 1163 in peptide 4.16 is 
not accommodated in the second, non-catalytic phosphate binding site very well.  
Determination of the IC50 values of the monosulfated versions of peptide 4.20 will help shed 
some light on this matter.  
4.3   Experimental 
4.3.1   General. 
See section 2.5.1 for general information concerning syntheses.  All reagents and 
buffers for for enzyme assays were obtained form Sigma unless stated otherwise.  DiFMUP 
was obtained from Molecular Probes.  PTP1B was obtained from (PROSPEC (Protein-
Specialists), Rehovot, Israel).  Enzyme assays were performed at 25 oC on a Molecular 
Devices Gemini microplate reader.   
4.3.2   Synthesis of sulfotyrosine bearing peptides. 
General procedure for the synthesis of peptides 4.17-4.20 
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Automated SPPS was used as described in chapter 2.  The general protocol used for 
peptide 2.48 (section 2.5.9) was used for all peptides. The last amino acids in peptides 4.17 
and 4.18 were incorporated applying the procedure described for insertion of the last amino 
acid in 2.39 (section 2.5.8).  The peptide was cleaved from the support using the same 
procedure described for peptide 2.48 (section 2.5.9).  The resulting crude peptides were 
analyzed by analytical RP-HPLC eluting with a linear gradient of 5:95 CH3CN:H2O (0.1% 
TFA) to 95:5 CH3CN:H2O (0.1% TFA) over 60 min, λ = 220 nm. The analytical HPLC 
chromatogram of crude DCV protected peptides showed mainly one major peak. The 
removal of the DCV groups from DCV protected intermediates was achieved applying the 
same procedure described for peptide 2.49 (section 2.5.9) except one equiv of Et3N per acidic 
amino acid and two equiv per DCV group were applied.   
Ac-FnGAsYQLEENH2 (4.17), Peptide 4.17 was purified using preparative HPLC 
(CH3CN/20 mm ammonium acetate as eluent, linear gradient from 15%  to 25% CH3CN over 
30 min, tR= 20.0 min) which gave  26.4 mg of pure 4.17 (82% yield). The analytical HPLC 
chromatogram (linear gradient of 15:85 CH3CN:20 mM ammonium acetate to 25:75 
CH3CN:20 mM ammonium acetate over 30 min) showed a single peak at tR= 21.2 min. 
HRMS (ESI-): calculated for C52H74N11O19S (M-H)-1 1188.4883, found 1188.4883. 
Ac-VFDQsYHESPNH2 (4.18), Peptide 4.18 was purified using preparative HPLC 
(CH3CN/20 mm ammonium acetate as eluent, linear gradient from 10%  to 25% CH3CN over 
30 min, tR= 16.5 min) which gave  27.2 mg of pure 4.18 (86% yield). The analytical HPLC 
chromatogram (linear gradient of 10:90 CH3CN:20 mM ammonium acetate to 30:70 
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CH3CN:20 mM ammonium acetate over 30 min) showed a single peak at tR= 14.7 min. 
HRMS (ESI-): calculated for C50H65N12O19S (M-H)-1 1169.4210, found 1169.4209. 
EHTGHsYAANH2 (4.19), Peptide 4.19 was purified using preparative HPLC (CH3CN/20 
mm ammonium acetate as eluent, linear gradient from 5% to 15% CH3CN over 30 min, tR= 
18.4 min) which gave 19.7 mg of pure 4.19 (82% yield). The analytical HPLC chromatogram 
(linear gradient of 5:95 CH3CN:20 mM ammonium acetate to 15:85 CH3CN:20 mM 
ammonium acetate over 30 min) showed a single peak at tR= 13.5 min. HRMS (ESI-): 
calculated for C38H53N13O15S (M-H)-1 963.3505, found 963.3505. 
ETDsY1152sY1153RKGGKGLLNH2 (4.20).  Peptide 4.20 was purified using semi-
preparative HPLC (CH3CN/20 mm ammonium acetate as eluent, linear gradient from 15%  
to 25% CH3CN over 30 min, tR= 15.5 min) which gave 30.5 mg of pure 4.20 (73% yield). 
The analytical HPLC chromatogram (linear gradient of 15:85 CH3CN:20 mM ammonium 
acetate to 25:75 CH3CN:20 mM ammonium acetate over 30 min) showed a single peak at tR= 
11.3 min. LRMS (ESI-): calculated for C67H105N19O26S (M-2H)2- 827.84655, found 
827.7619. 
4.3.3   IC50 and Ki determinations of peptides 2.30 and 4.17-4.20. 
Stock solutions of the inhibitors were prepared in 50 mM Bis–Tris HCl, pH 6.3, 5 
mM DTT, and 2 mM EDTA.  10 μL of each inhibitor stock solution was added to the wells 
of a 96-well microtiter plate containing 90 μL of 5.5 μM diFMUP in 50 mM Bis–Tris HCl, 
pH 6.3, 5 mM DTT, and 2 mM EDTA. The reactions were initiated at 25°C with 10 μL of a 
33 nM solution of PTP1B in a buffer containing 50 mM Bis–Tris HCl, pH 6.3, 20% glycerol, 
5 mM DTT, 2 mM EDTA, and 0.1% Triton X-100. The production of fluorescent product 
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diFMU was monitored for 10 min using a spectrofluorimeter platereader with excitation and 
emission at 360 nm and 460 nm, respectively. The initial rates of enzyme activity in relative 
fluorescence units per second (RFU/s) were used to determine the IC50. The ratio of the 
initial rate in the presence of inhibitor (Vi) to that in the absence of inhibitor (Vo) was 
calculated and plotted as a semi-log curve in Grafit, from which the IC50 value was calculated 
based on the following equation: Vi = Vo/[1 + ([I]/IC50)S] + B, where Vi is the initial rate of 
reaction at an inhibitor concentration of [I]; Vo is the velocity in the absence of inhibitor; B is 
background and s is the slope factor equal to Vo - B.  The IC50 curves for compounds 2.30 
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